SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES

Abstract

Pharmaceutical compositions comprising them, a method and intermediates for their preparation and their use in the preparation of medicines for the treatment of hyperproliferative diseases such as cancer and leukemia.

Description

DESCRIPTIVE MEMORY BACKGROUND OF THE INVENTION The present invention encompasses macrocyclic indole derivatives of the general formula (I) that inhibit the antiapoptotic activity of MCL-1 by inhibiting its interaction with proapoptotic proteins. Apoptosis, also called programmed cell death, is a natural process that allows a damaged or unwanted cell to die in a controlled manner. Dysregulation of this process leads to uncontrolled cell proliferation and is therefore a hallmark of cancer (Hanahan and Weinberg, 2011). Apoptosis is highly controlled by B-cell lymphoma 2 (BCL-2) family proteins. These proteins are characterized by their conserved regions known as BCL-2 homology (BH1-BH4) (BH1-BH4) domains (Korsmeyer, 1999) through which they interact with each other. The BCL-2 family can be divided into pro-apoptotic members, including BAX, BAK, BAD, BID, BIM, BMF, NOXA and PUMA, which induce cell death, and anti-apoptotic members such as BCL-2, BCL-XL, BCL -w, Bfl1 Al and myeloid cell leukemia-1 (MCL-1) block apoptosis (Adams and Cory, 2007). The relative expression level of these two opposing groups of the BCL2 family will decide whether a cell will enter apoptosis or not. MCL-1 has been identified as an important therapeutic target in cancer. MCL-1 is highly expressed in various human cancers and amplification of the MCL-1 locus is one of the most frequent somatic genetic events in human cancer, which further indicates its centrality in the pathogenesis of malignant neoplasia (Beroukhim et al., 2010). Its expression has been linked to deregulated anti-apoptotic pathways in cancer, leading to increased cancer cell survival, tumor development (Zhou et al., 2001) and resistance to anti-cancer therapies (Wertz et al., 2011). The MCL-1 protein has been shown to mediate survival in models of acute myeloid leukemia (Glaser et al., 2012), lymphomas (Kelly et al., 2014), and multiple myeloma (Zhang et al., 2002). Many chemotherapeutics, as well as radiation, aim to induce apoptosis in cancer cells. However, in malignant cells, apoptotic signaling is often deregulated, leading to a IF-2019-16843 747-APN-ANP#INPI Page 1 of 720 uncontrolled growth and therapeutic resistance. A key mechanism of resistance to apoptosis is to upregulate or genetically amplify MCL-1. MCI-1 is an important inhibitor of apoptosis in cancer. MCL-1 is the largest member of the antiapoptotic BCI-2 proteins. Its expression is tightly controlled with a half-life of only 1-4 hours. With its BH-3 domain, MCL-1 binds strongly to BH-3 containing only proapoptotic proteins such as BAK or BAX and prevents them from inducing pores in the mitochondrial membrane, thus blocking the intrinsic apoptotic pathway. Therefore, specific inhibition of the interaction of MCL-1 with BH-3 containing only proapoptotic proteins such as BAK or BAX represents a very attractive therapeutic principle to induce apoptosis in cancer cells and to treat resistance against chemotherapeutic agents, radiation and new target agents. However, from WO 2015 / 148854, US 2016 / 0106731, WO 2008 / 130970, some indole derivatives are known as MCL-1 inhibitors. As no inhibitor has demonstrated clinical efficacy, there is still a need to provide more MCL-1 inhibitors. SUMMARY The compounds of the present invention have now been found to effectively inhibit the activity of the antiapoptotic BCL-2 family member myeloid cell leukemia-1 (MCL-1) protein for which data are provided in the biological experimental section. and therefore can be used for the treatment or prophylaxis of hyperproliferative disorders, such as cancer-related disorders. According to a first aspect, the present invention provides compounds of the general formula (I): (YO), IF-2019-16843 747-APN-ANP#INPI Page 2 of 720 where A is where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9-membered to 16-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; A is (A3) where optionally one or two of the groups selected from CR11, CR12 and CR13 are replaced by a nitrogen atom, wherein R6 and R10, together with three carbon atoms of the phenyl ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9-membered to 16-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 each are independently selected from a hydrogen atom, a halogen atom, a cyano group, a C-i-Cs alkyl group and a Ci-Cs alkoxy group; R3 is selected from a hydrogen atom, a halogen atom, a cyano group, an alkyl-Ci-Cs group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-Cs group, an alkylthio-Ci-Cs group, a group -S(O)-(alkyl-Ci-C3), a group -S(O)2-(alkyl-Ci-C3), a haloalkoxy-Ci-C3 group, a haloalkylthio-Ci-C3 group and a cycloalkyl-C3-C5 group; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three, four or five substituents and each substituent is independently selected from a halogen atom, a group IF-2019-16843 747-APN-ANP#INPI Page 3 of 720 cyano, an alkyl-Ci-Cs group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-Ca group, a thioalkyl-Ci-Cs group, a haloalkoxy-C-i-Cs group, a (Ci -C3)-haloalkyl-S- and a cycloalkyl-Cs-Cs group; L is a -(CH2)m-E- group wherein any CH2 group is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, a Ci-alkyl group -Cs and an alkoxy-Ci-Cs group, or two substituents are optionally taken together with their intermediate atoms to form a saturated or partially unsaturated 3-6 membered cycloalkyl ring, or a saturated or partially saturated 3-8 membered heterocyclic ring unsaturated having 1-2 heteroatoms independently selected from an oxygen atom, a sulfur atom, an —S(O)- group, a -S(O)2- group and a -NR14- group; E is a bond, an oxygen atom, a sulfur atom, an -S(O)- group, an S(O)2- group or a -NR14- group and constitutes the connecting element to R4; m is 2, 3, or 4; N N \ / / N-N |_| R5 is selected from a COOH group, a -C(O)NHS(O)2(Ci-C6alkyl) group, a -C(O)-NHS(O)2(C3-C6cycloalkyl) group. , a -C(O)NHS(O)2(aryl) group, a -C(O)-NHS(O)2(CH2)sNHCO(alkyl-Ci-C6) group, a -C(O)NHS group (O)2(CH2)sNHCO(cycloalkyl-C3-C6) and a group -C(O)NHS(O)2(CH2)sNHCO(aryl); s is 0, 1 or 2; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or#-(C2-C9-alkenylene)-(B)t-CR22R23-##, where#is the point of bonding with the indole nitrogen atom and ** is the point of bonding with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-Cs alkyl group, a Ci-haloalkyl group -Cs, an alkoxy-Ci-Cs group, a haloalkoxy-Ci-Cs group, a cycloalkyl-Cs-Ce group and a (heterocycloalkyl)-(alkylene-Ci-C3)- group; IF-2019-16843 747-APN-ANP#INPI Page 4 of 720 -R6-R10- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenylene-C2-C9)-(B)t-CR22R23-##, where one or more -CH2 groups - are substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3 alkyl group, a Ci-C3 haloalkyl group, a Ci-Cs alkoxy group and a haloalkoxy group -Ci-C3, where * is the point of attachment to the indole nitrogen atom and ##is the point of attachment to the carbon atom of the phenyl residue carrying the R10 substituent; n is 2, 3, 4, 5, 6, 7, 8, or 9, if B is selected from -O-, -S-, -S(O)-, -S(O)2- and -N( R15)-, and n is 1,2, 3, 4, 5,6,7 or 8, if B is selected from a group -C(O)NR15- and a group NR15C(O)-, and n is O, 1 ,2, 3, 4, 5, 6 or 7, if B is selected from a group -N(R15)-C(=O)-N(R15)-, a group -O-C(=O)-N(R15 )- and a group -N(R15)-C(=O)-O-; t is 1; where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of a 9-membered to 16-membered ring regardless of the selection of the variable A1 , A2 or A3; B is independently selected from a group -C(O)NR15-, a group -NR15C(O)-, a group -N(R15)-, a group -N(R15)-C(=O)-N(R15 )-, a group -O-C(=O)-N(R15)-, a group -N(R15)-C(=O)-O-, -O-, -S-, -S(0)- and -S(0)2-; R8 is selected from a hydrogen atom, a Ci-Ce alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-C3 alkoxy group, a haloalkoxy-Ci-C3, a cycloalkyl-C3-C6 group, a heterocycloalkyl group and an NR21R22 group; a Ci-C3 haloalkyl group, a C3-C6 cycloalkyl group, and a Ci-C6 alkyl group in which one or two non-directly adjacent carbon atoms are independently replaced by a heteroatom IF-2019-16843 747-APN-ANP#INPI Page 5 of 720 selected from -O- and -NH-; R9 is selected from a hydrogen atom, a Ci-C4 alkyl group, a Ci-Cs hydroxyalkyl group, a Ci-C4 haloalkyl group, a Ci-C4 haloalkyl group-NH-C(O)-O-( alkylene-Ci-C3)-, a haloalkenyl-C2-C6 group, a group Ci-Ce-alkyl-O-, a haloalkoxy-Ci-C4 group, a group Ci-C6-alkyl-O-(alkylene-Ci- C3)-, a (C3-C7)-cycloalkyl group, a (C3-C7)-cycloalkyl-O-(Ci-C3-alkylene)- group, a phenyl-O-(Ci-C3-alkylene)- group, a phenyl group-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R18)- (heterocycloalkylene)-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (heterocycloalkenyl)-(phenylene)- O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene)-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group (R18)- (heteroarylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-NH-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-NH-(phenylene)-O-(alkylene- Ci-C3)-, a group (R19)-S(O)2-N(alkyl-Ci-C6)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19 )-S(O)2-(heterocycloalkylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(heteroarylene)-O-(alkylene-Ci- C3)-, a group (Rt9)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R19 )-S(O)2-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(heterocycloalkylene)-(heteroarylene)-O-(alkylene-Ci- C3)-, a group NR20R21-(alkylene-Ci-C3)-, IF-2019-16843 747-APN-ANP#INPI Page 6 of 720 a group (alkylene-Ci-C3)-NH-(alkylene-Ci-C3)-, a group (haloalkyl-Ci-C3)-(alkylene-Ci-C3)-NH-(alkylene-Ci-C3) -, a group (haloalkyl-Ci-C3)-NH-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-NH-C(O)-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-NR15-C(O)-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-C(O)-NH-(alkylene-Ci-C3 )-, a group (alkyl-Ci-C3)-C(O)-NR15-(alkylene-Ci-C3)-, F / ^X^N~(alkylene-Ci-C3)a group and a group O^X^N— (alkylene-Ci-Cs), where the phenyl ring is unsubstituted or substituted with a halogen atom, a hydroxy group or an alkoxy-Ci-Cs group and the heterocycloalkyl group is unsubstituted or is substituted with an oxo group (=0) or is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a C-i-Cs group and an alkoxy-Ci-Cs group, or R8 and R9 together form a 5-membered or 6-membered ring optionally comprising one or two heteroatoms independently selected from -O- and NR14-; R11 and R13 each are independently selected from a hydrogen atom, a halogen atom, a Ci-Cs alkyl group and a C-i-Cs alkoxy group; R12 is selected from a hydrogen atom, an alkoxy-Ci-Cs group, an alkyl-CiC3 group, a haloalkyl-Ci-C3 group, a haloalkoxy-Ci-Cs group and an NR16R17 group; R14 is a hydrogen atom or an alkyl-Ci-Cs group; R15 is independently selected from a hydrogen atom, a Ci-Ce-alkyl group that is unsubstituted or substituted with one or more substituents selected from a halogen atom, a Ci-Cs-alkyl group, a CiC3-haloalkyl group, a hydroxyalkyl-Ci-C3, an alkoxy-Ci-C3 group, a haloalkoxy7 group IF-2019-16843 747-APN-ANP#INPI Page 7 of 720 C1-C3, a heterocycloalkyl group, an aryl group, a (R18)(heterocycloalkylene)-(arylene)-O- group, a (heterocycloalkyl)-(arylene)-O- group, an aryl-O- group, a aryl-(alkylene-Ci-C3)-O- group, a (R19)-S(O)2arylene-O- group, a (R19)S(O)2-heterocycloalkylene-arylene-O- group, an arylene group -heteroarylene-O-, an aryl-heteroarylene-O-(alkylene-Ci-C3)- group, a heterocycloalkyl group-(alkylene-Ci-C3)-C(O)-, a heterocycloalkyl group-NH-C(O) )-, an aryl group-(alkylene-Ci-C3)-NH-C(O)-, a heterocycloalkylene group-(alkylene-Ci-C3)-S(O)2- and a heterocycloalkylene-heteroarylene- group S(O)2-; a Ci-C3-alkylene-C(O)- group, a heterocycloalkyl-(Ci-C3-alkylene)-C(O)- group, a heterocycloalkyl-(Ci-C3-alkylene)- group S(O)2-, a heterocyclyl group-NH-C(O)-, a heterocycloalkyl group-(alkylene-Ci-C3)-NH-C(O)-, an aryl group-(alkylene-Ci-C3) -NH-C(O)-, which is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from a halogen atom, a Ci-Cs alkyl group, and a Ci-Cs alkoxy group; a heterocycloalkyl-heteroarylene-S(O)2- group, a phenyl group, a group,—, and—alkyl-(Ci-C3) $. / Y-N N-S(Ofe.N' xi—¡z \—J alkyl-fCj-Ca) a group and where $ is the point of attachment to the nitrogen atom, to which R15 is attached; IF-2019-16843 747-APN-ANP#INPI Page 8 of 720 or R15 and R22 together, including the atoms to which they are attached, may form a 5-membered or 6-membered ring, both optionally comprising one or two additional heteroatoms independently selected from -O- and -NR14-; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C6 alkyl group, a Ci-Ce haloalkyl group, a Ci-C6 alkoxy group, a Ca-Cs cycloalkyl group, a Ci-C3 group. alkyl-C(O)-, a group-Ci-C3-alkylS(O)2- and a group Ci-C3-alkyl-O-C(=O)-; R18 is selected from a hydrogen atom, a hydroxy group, a cyano group, an alkyl-Ci-Cs group, a hydroxyalkyl-Ci-Ce group, an alkoxy-Ci-Cs group, a R21OC(O)-(alkylene- Ci-C3-)-, a group -C(O)OR21, a group -C(O)NR20R21, a group (alkyl-Ci-C3)-O-(alkylene-Ci-C3)-C(O)- , a (Ci-Ce-alkyl)-C(O)- group and a C3-C6-cycloalkyl-C(O)- group; R19 is selected from a C-i-Cs alkyl group, a Cs-Ce cycloalkyl group and an NR20R21 group; R20 and R21 are each independently selected from a hydrogen atom and a Ci-Ce alkyl group; R22 is independently selected from a halogen atom, a Ci-Ce-alkyl group that is unsubstituted or substituted with one or more substituents selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-Cs-alkyl group , a haloCi-C3alkyl group, a hydroxyC1-C3alkyl group, a Ci-C3alkoxy group, a haloCi-C3alkoxy group, a C3-C6cycloalkyl group, a heterocycloalkyl group, an aryl group, a group (R18)(heterocycloalkylene)-(arylene)-O-, a group (heterocycloalkyl)-(arylene)-O, an aryl group-O-, an aryl group-(alkylene-Ci-C3)-O- , a (R19)-S(O)2arylene-O- group, a (R19)S(O)2-heterocycloalkylene-arylene-O- group, an aryl-heteroarylene-O- group, an aryl-heteroar group ¡lene-O-(alkylene-Ci-C3)-, a heterocycloalkyl group-(alkylene-Ci-C3)-C(O)-, a heterocycloalkyl group-NH-C(O)-, an aryl group- (alkylene-Ci-C3)-NH-C(O)-, a heterocycloalkylene group-(alkylene-Ci-C3)-S(O)2- and a heterocycloalkylene-heteroarylene-S(O)2 group -; IF-2019-16843 747-APN-ANP#INPI Page 9 of 720 a Ci-C3-alkyl-C(O)- group, a cycloalkyl-Cs-Ce group, an aryl group, a heterocycloalkyl group, and a heteroaryl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group, a Ci-Cs alkyl group and a Ci-Ce haloalkyl group, or R22 and R23 together with the carbon atom to which they are attached form a 3-membered to 6-membered carbocyclic ring or a 3-membered to 6-membered heterocyclic ring comprising one or two heteroatoms selected from nitrogen, oxygen and sulfur; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 (Fig. 1): shows a comparison of tumor growth of AMO-1 multiple myeloma cells growing subcutaneously in immunocompromised mice with untreated animals (Vehicle) and groups treated with different concentrations of compound 47 example (n=10 animals / group). Figure 2 (Fig. 2): shows a comparison of tumor growth of MOLP-8 multiple myeloma cells growing subcutaneously in immunocompromised mice with untreated animals (Vehicle) and groups treated with different concentrations of compound 47 example (n=10 animals / group). Figure 3 (Fiq. 3): shows a comparison of tumor growth of SU-DHL 10 GC-DLBCL cells growing subcutaneously in immunocompromised mice with IF-2019-16843 747-APN-ANP#INPI Page 10 of 720 untreated animals (Vehicle) and groups treated with different concentrations of the example of compound 47 (n=10 animals / group). Figure 4 (Fiq. 4): shows P2i2i2 crystals of MBP-MCL1 seeded in complex with Example 47. Figure 5 (Fiq. 5): shows the density of 2Fo-Fc from Example 47 in complex with MBPMCL1 with a curve at 1 sigma. Figure 6 (Fiq. 6): shows the structure of Example 47 in complex with MBP-MCL1. For clarity, only ligands that are not hydrogen atoms are shown. The C7 carbon atom unambiguously presents the ( / ?)- configuration and the bound atropisomer as defined by the C4-C38 axis is the (Ra)- configuration. DETAILED DESCRIPTION DEFINITIONS The term "substituted" means that one or more hydrogen atoms in the designated atom or group are replaced with a selection of the indicated group, provided that the normal valence of the designated atom is not exceeded under the existing circumstances. Combinations of substituents and / or variables are permissible. The term 'Optionally substituted' means that the number of substituents may be equal to or different from zero. Unless otherwise indicated, optionally substituted groups may be substituted with all optional substituents that can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Generally, the number of optional substituents, when present, is likely to be 1, 2, 3, 4 or 5, especially 1,2 or 3. When the groups in the compounds according to the invention are substituted, it is possible that said groups are monosubstituted or polysubstituted with substituents, unless otherwise specified. Within the scope of the present invention, the IF-2019-16843 747-APN-ANP#INPI Page 11 of 720 meanings of all groups that occur repeatedly are independent of each other. It is possible that the groups in the compounds according to the invention are substituted with one, two, three, four or five identical or different substituents, especially with one, two or three substituents. The terms "oxo", "an oxo group" or "an oxo substituent" mean a doubly bonded oxygen atom =0. Oxo may be bonded to atoms of suitable valency, for example to a saturated carbon atom or to a sulfur atom. For example, but not limited to, one oxo group can be attached to a carbon atom, resulting in the formation of a C(=0) carbonyl group, or two oxo groups can be attached to a sulfur atom, resulting in the formation of a C(=0) carbonyl group. results in the formation of a sulfonyl group -S(=0)2. The term "ring substituent" means a substituent attached to an aromatic or non-aromatic ring that replaces an available hydrogen atom on the ring. If a compound substituent is composed of more than one part, for example, (alkoxy-C-iC4)-(alkyl-Ci-C4), it is possible that the position of a given part is at any suitable position of said compound substituent, that is, the Ci-C4 alkoxy part can be bonded to any carbon atom of the Ci-C4 alkyl part of said group-(Ci-C4 alkoxy)-(Ci-C4 alkyl). A hyphen at the beginning or end of said compound substituent indicates the point of attachment of said compound substituent to the rest of the molecule. If a ring, comprising carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulfur atoms, for example, is substituted by a substituent, it is possible for said substituent to attach at any suitable position of said ring, whether be bonded to a suitable carbon atom and / or to a suitable heteroatom. The term “comprising” when used in the specification includes “consisting of” but need not be the scope indicated by “consisting of.” If any element is referred to within this text as such as mentioned herein, it means that it may be mentioned anywhere in this text. If within this text, any element is referred to as above within the description, it indicates any of the respective disclosures made within the specification on any of the preceding pages or on the same IF-2019-16843 747-APN-ANP#INPI Page 12 of 720 page. If, within this text, any item is referred to as below within the description, it indicates any of the respective disclosures made within the specification on any of the following pages, or further down the same page. The terms mentioned in this text have the following meanings: The term "halogen atom" means a fluorine, chlorine, bromine or iodine atom, particularly a fluorine, chlorine or bromine atom. The term "Ci-C8-alkyl" means a linear or branched saturated hydrocarbon group having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, for example, a methyl-, ethyl-group. , propyl-, / so-propyl-, n-butyl-, / so-butyl-, sec-butyl-, tere-butyl-, n-pentyl-, / so-pentyl-, 2-methylbutyl-, 1-methylbutyl -, 1-ethylpropyl-, 1,2-dimethylpropyl-, neo-pentyl-, 1,1dimethylpropyl-, n-hexyl-, 4-methylpentyl-, 3-methylpentyl-, 2-methylpentyl-, 1-methylpentyl-, 2ethylbutyl -, 1-ethylbutyl-, 3,3-dimethylbutyl-, 2,2-dimethylbutyl-, 1,1-dimethylbutyl-, 2,3dimethylbutyl-, 1,3-dimethylbutyl-, 1,2-dimethylbutyl-, n-heptyl -, 5-methylhexyl-, 4-methylhexyl-, 2-methylhexyl-, 1-methylhexyl-, 2-ethylpentyl-, -ethylpentyl-, 3,3-dimethylpentyl-, 2,2-dimethylpentyl-, 1,1-dimethylpentyl-, 2,3-dimethylpentyl-, 1,3-dimethylpentyl-, 1,2-dimethylpentyl-, n-octyl- , 6-methylheptyl-, 4-methylheptyl-, 2-methylheptyl-, 1-methylheptyl-, 2-ethylhexyl-, 1-ethylhexyl-, 3,3-dimethylhexyl-, 2,2-dimethylhexyl-, 1,1-dimethylhexyl-, 2, 3-dimethylhexyl-, 1,3-dimethylhexyl-, 1,2-dimethylhexyl-, or an isomer thereof. Preferably, said group has 1,2, 3, 4, 5 or 6 carbon atoms ("Ci-C6-alkyl"), for example, a methyl-, ethyl-, n-propyl-, / so-propyl group -, n-butyl-, / so-butyl-, sec-butyl-, tere-butyl-, n-pentyl-, / so-pentyl-, 2-methylbutyl-, 1-methylbutyl-, 1-ethylpropyl-, 1,2 -dimethylpropyl-, neo-pentyl-, 1,1 -dimethylpropyl-, n-hexyl-, 4-methylpentyl-, 3-methylpentyl-, 2-methylpentyl-, 1-methylpentyl-, 2-ethylbutyl-, 1-ethylbutyl- , 3,3-dimethylbutyl-, 2,2-dimethylbutyl-, 1,1-dimethylbutyl-, 2,3-dimethylbutyl-, 1,3-dimethylbutyl- or 1,2-dimethylbutyl, or an isomer thereof. More preferably, said group has 1, 2, 3 or 4 carbon atoms ("Ci-C4-alkyl"), for example, a methyl-, ethyl-, npropyl-, / so-propyl-, n-butyl group -, / so-butyl-, sec-butyl- or tere-butyl-, 1, 2 or 3 carbon atoms ("Ci-C3-alkyl"), for example, a methyl-, ethyl-, n- group propyl- or / so-propyl, or 1 or 2 carbon atoms (“Ci-C2-alkyl”), for example, a methyl group, an ethyl group. The same definitions can apply if the alkyl group is placed within a IF-2019-16843 747-APN-ANP#INPI Page 13 of 720 chain as a bivalent “alkylene-Ci-Ce-” moiety. All of the names mentioned above will have an ene added to the end, so, for example, a pentyl becomes a bivalent pentylene group. Furthermore, the term "heteroalkyl-Ci-Ce-" refers to an alkyl-Ci-Ce- group in which one or more of the carbon atoms have been replaced with an atom selected from N, O, S or P, which are substituted as mentioned herein to satisfy the atomic valency requirements. The term “C2-C6 alkylene” means a divalent, linear or branched, saturated (or “tied”) hydrocarbon chain having 2, 3, 4, 5 or 6 carbon atoms, for example, -CH2-CH2- ( “ethylene” or “C2-alkylene”), -CH2-CH2-CH2-, -C(H)(CH3)-CH2- or C(CH3)2- (“propylene” or “C3-alkylene”), or for example -CH2-C(H)(CH3)-CH2-, -CH2C(CH3)2-, -CH2-CH2-CH2-CH2- (“butylene” or “C4-alkylene”), “alkylene -C5”, for example, CH2-CH2-CH2-CH2-CH2- (“n-pentylene”), or “-C6-alkylene-”, for example, -CH2-CH2-CH2CH2-CH2-CH2- (“ n-hexylene”) or a group -C(CH3)2-C(CH3)2. The term "hydroxy-(Ci-C6 alkyl)-" means a linear or branched, saturated hydrocarbon group in which one or more hydrogen atoms of a "Ci-Ce-alkyl" as defined above each are replaced by a hydroxy group, for example, a hydroxymethyl-, 1-hydroxyethyl-, 2-hydroxyethyl-, 1,2-dihydroxyethyl-, 3-hydroxypropyl-, 2-hydroxypropyl, 2,3-dihydroxypropyl-, 1,3-group -dihydroxypropan-2-yl-, 3-hydroxy-2-methyl-propyl-, 2-hydroxy-2-methylpropyl-, or a 1-hydroxy-2-methyl-propyl- group. In particular, hydroxyalkyl group means that a saturated, linear or branched, monovalent hydrocarbon group has 1, 2 or 3 carbon atoms in which 1 hydrogen atom is replaced with a hydroxy group, for example a hydroxymethyl-, 1-hydroxyethyl-group. , 2-hydroxyethyl-, 3-hydroxypropyl-, 2-hydroxypropyl-, 1-hydroxypropyl-, 2-hydroxy-2-methyl-ethyl. The term haloalkyl-Ci-C6 means a monovalent, saturated, linear or branched hydrocarbon group in which the term Ci-Ce alkyl is as defined above, and in which one or more of the hydrogen atoms are replaced, identically or different, by a halogen atom. Preferably, said halogen atom is a fluorine atom. Said haloalkyl-Ci-C6-, especially a haloalkyl-Ci-C3- group is for example fluoromethyl-, difluoromethyl-, trifluoromethyl-, 2-fluoroethyl-, 2,2-difluoroethyl-, 2,2,2-trifluoroethyl- , pentafluoroethyl-, 3,3,3-trifluoropropyl- or a 1,3-difluoropropan-2-l group. The term "alkoxy-Ci-C6-" means a saturated, linear or branched monovalent group of IF-2019-16843 747-APN-ANP#INPI Page 14 of 720 formula (alkyl-Ci-Ce-)-0-, in which the term “alkyl-Ci-Ce-” group is as defined above, for example methoxy-, ethoxy-, n-propoxy-, isopropoxy-, n-butoxy-, sec-butoxy-, isobutoxy-, fert-butoxy-, pentyloxy-, isopentyloxy- or an n-hexyloxy group, or an isomer thereof. The term "Ci-C6-alkyl" or "Ci-C6-thioalkyl" means a linear or branched, saturated, monovalent group of formula (Ci-C6-alkyl)-S-, in which the term “alkyl-Ci-Ce-” is as defined above, for example a group methylthio-, ethylthio-, n-propylthio-, isopropylthio-, n-butylthio-, sec-butylthio-, isobutylthio-, tert-butylthio -, pentylthio-, isopentylthio- or n-hexylthio, or an isomer thereof. The term haloalkoxy-Ci-C6 means a monovalent, saturated, linear or branched alkoxy-Ci-Ce group as defined above, in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom . Preferably, said halogen atom in “haloalkoxy-Ci-Ce-” is fluorine, resulting in a group that is referred to herein as “fluoroalkoxy-C-i-Ce-”. Groups representing fluoroalkoxy-Ci-C6 include, for example, -OCF3, -OCHF2, -OCH2F, -OCF2CF3 and -OCH2CF3. The term haloalkylthio-Ci-C6-" or "halothioalkyl-Ci-C6- or "Ci-C6-haloalkyl-S-" means a monovalent, saturated, linear or branched alkylthio-Ci-Ce- group. , as defined above, in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Preferably, said halogen atom in “haloalkylthio-Ci-Ce-” is fluorine. The term alkenyl-C2-Ce- means a linear or branched monovalent hydrocarbon group, containing one or more double bonds and having 2, 3, 4, 5 or 6 carbon atoms, preferably 2, 3 or 4 carbon atoms ( alkenyl-C2-C4-) or 2 or 3 carbon atoms (“alkenyl-C2-C3-”), it being understood that in the case in which said alkenyl group contains more than one double bond, then said double bonds can be isolated or conjugated with each other. Representative alkenyl groups include, for example, an ethenyl-, prop-2-enyl-, (E)-prop-1-enyl-, (Z)-prop-1-enyl-, / so-propenyl-, but -3enyl-, (E)-but-2-enyl-, (Z)-but-2-enyl-, (E)-but-1-enyl-, (Z)-but-l-enyl-, 2- methylprop-2-enyl-, 1-methylprop-2-enyl-, 2-methylprop-1-enyl-, (E)-1-methylprop-1-enyl-, (Z)-1-methylprop-1-enyl- , buta-1,3-dienyl-, pent-4-enyl-, (E)-pent-3-enyl-, (Z)-pent-3-enyl-, (E)-pent-2-enyl-, (Z)-pent-2-enyl-, (E)-pent-1-enyl-, (Z)-pent-1-enyl-, IF-2019-16843 747-APN-ANP#INPI Page 15 of 720 3-methylbut-3-enyl-, (E)-2-methylbut-2-enyl-, (Z)-1-methylbut-2-enyl-, (E)-2-methylbut-1-enyl-, (Z )-1-methylbut-1-enyl-, 2-methylbut-3-enyl-, 1 -methylbut-3-enyl-, (Z)-2-methylbut-2-enyl-, (E)-3-methylbut-1-enyl-, (Z)-2- methylbut-1-enyl-, 3-methylbut-2-enyl-, (E)-1-methylbut-2-enyl-, (Z)-3-methylbut-1-enyl-, (E)-1-methylbut-1-enyl-, 1-isopropylvinyl-, penta-1,4-dienyl-, 1,1-dimethylprop-2-enyl-, 1-ethylprop-1-enyl-, 1 -propylvinyl-, (E)-3,3-dimethylprop-1-enyl-, (Z)-3,3-dimethylprop- 1 -enyl-, hex-5-enyl-, (E)-hex-4-enyl-, (Z)-hex-4-enyl-, (E)-hex-3-enyl-, (Z)-hex -3-enyl-, (E)-hex-2-enyl-, (Z)-hex-2-enyl-, (E)-hex-1-enyl-, (Z)-hex-1-enyl-, 4-methylpent-4-enyl-, 4-methylpent-3-enyl-, 3-methylpent-4-enyl-, 2-methylpent-4-enyl-, 1 -methylpent-4-enyl-, (E)-2-methylpent-3-enyl-, (Z)-1 -methylpent-3- enyl-, (E)-3-methylpent-2-enyl-, (Z)-2-methylpent-2-enyl-, (E)-4-methylpent-1-enyl-, (Z)-3-methylpent- 1-enyl-, (E)-1-methylpent-1-enyl-, (5)-3-methylpent-3-enyl-, (Z)-2-methylpent-3-enyl-, (E)-4- methylpent-2-enyl-, (Z)-3-methylpent-2-enyl-, (E)-1 -methylpent-2-enyl-, (Z)-4-methylpent-1-enyl-, (E)- 2-methylpent-1-enyl-, (Z)-3-methylpent-3-enyl-, (E)-1-methylpent-3-enyl-, (Z)-4-methylpent-2-enyl-, (E )-2-methylpent-2-enyl-, (Z)-1-methylpent-2-enyl-, (E)-3-methylpent-1-enyl-, (Z)-2-methylpent-1-enyl-, (Z)-1-methylpent-1-enyl-, 3-ethylbut-3-enyl-, 2-ethylbut-3-enyl-, -ethylbut-3-enyl-, (E)-3-ethylbut-2-enyl-, (Z)-2-ethylbut-2-enyl-, (Z)-3-ethylbut-1-enyl- , 2-propylprop-2-enyl-, (E)-1 -ethylbut-2-enyl-, 2-ethylbut-1-enyl-, (Z)-3-ethylbut-2-enyl-, (Z)-1 -ethylbut-2-enyl-, (E)-1-ethylbut-1-enyl-, (£z)-2-ethylbut-2-enyl-, (E)-3-ethylbut-1-enyl-, (Z )-1-ethylbut-1-enyl-, -isopropylprop-2-enyl-, (E)-1-propylprop-1-enyl-, (Z)-2-isopropylprop-1-enyl-, hexa-1,5-dienyl- and an ethenyl- or prop group -2-enyl. -propylprop-2-enyl-, (E)-2-propylprop-1-enyl-, (Z)-1-propylprop-1-enyl-, (E)-1-isopropylprop-1-enyl-, 2-isopropylprop-2-enyl-, (Z)-2-propylprop-1-enyl-, (E)-2-isopropylprop-1-enyl-, (Z)-1-isopropylprop-1-enyl-, -(1,1-dimethylethyl-)ethenyl. In particular, this group is a The same definitions can apply if the alkenyl group is placed within a chain as a bivalent “alkenylene-Ci-C6-” moiety. All of the names mentioned above will have an ene added to the end, so, for example, a pentenyl becomes a bivalent pentenylene group. The term “C2-C6-haloalkenyl” means a linear or branched hydrocarbon group in which one or more of the hydrogen atoms of a “C2-C6-alkenyl” as defined above are each replaced, so identical or different, by an atom of IF-2019-16843 747-APN-ANP#INPI Page 16 of 720 halogen. Preferably, said halogen atom is fluorine, which results in a group herein called “flouroalkenyl-C2-C6-”. Groups representing flouroalkenyl-C2-C6- include, for example, -CH=CF2, -CF=CH2, -CF=CF2, -C(CH3)=CF2, -CH=C(F)-CH3, -CH2-CF=CF2and -CF2-CH=CH2. The term -C2-C6-alkynyl- preferably means a linear or branched, monovalent hydrocarbon group containing one or more triple bonds, and containing 2, 3, 4, 5 or 6 carbon atoms, preferably 2, 3 or 4 carbon atoms. carbon (C2-C4-alkynyl) or 2 or 3 carbon atoms (“C2-C3-alkynyl”). Groups representing C2-C6-alkynyl include, for example, a group ethynyl-, prop-1-ynyl-, prop-2-ynyl-, but-1-ynyl-, but-2-ynyl-, but-3- inyl-, pent-1-ynyl-, pent-2-ynyl, pent-3-ynyl-, pent-4-ynyl-, hex-1-ynyl-, hex-2-ynyl-, hex-3-ynyl- , hex-4-ynyl-, hex-5-ynyl-, 1-methylprop-2-ynyl-, 2-methylbut-3-ynyl-, -methylbut-3-ynyl-, 3-methylpent-4-ynyl-, 1 -methylpent-3-ynyl-, 1-met¡lbut-2-yn¡lo-, 2-methylpent-4-ynyl-, 4-methylpent-2-ynyl-, 3-methylbut-1-ynyl-, -methylpent-4-ynyl-, -methylpent-2-ynyl-, 1-ethylprop-2-ynyl2-methylpent-3-nyl4-methylpent-1 -ynyl3-methylpent-1-ynyl-, 2-ethylbut-3-ynyl-, 1-ethylbut-3-ynyl-, 1- ethylbut-2-ynyl-, 1-propylpro-2-ynyl, 1-isopropylpro-2-ynyl-, 2,2-dimethylbut-3-ynyl-, 1,1-dimethylbut-3-ynyl- , 1,1-dimethylbut-2-ynyl and 3,3-dimethylbut-1 -ynyl-. In particular, said alkynyl group is an ethynyl-, prop-1-ynyl- or prop-2-ynyl group. The term “C3-Cio-cycloalkyl” means a saturated monocyclic or bicyclic hydrocarbon ring containing 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms (“C3-Ci0-cycloalkyl”). Said C3-Cw cycloalkyl group may be, for example, a monocyclic hydrocarbon ring, for example, cyclopropyl-, cyclobutyl-, cyclopentyl-, cyclohexyl- or cycloheptyl, or a bicyclic hydrocarbon ring, such as decalinyl-. Preferably, said hydrocarbon ring is monocyclic and contains 3, 4, 5, 6 or 7 carbon atoms ("C3-C7-cycloalkyl"), for example, a cyclopropyl-, cyclobutyl-, cyclopentyl-, cyclohexyl- or cycloheptyl-group, or said hydrocarbon ring is monocyclic and contains 3, 4, 5 or 6 carbon atoms ("cycloalkyl-C3-C6-"), for example, a cyclopropyl-, cyclobutyl-, cyclopentyl- or cyclohexyl group. A cycloalkyl group may be optionally substituted as defined in the respective part where said term is used. The term “(C4-C8)-cycloalkenyl” means a monovalent, mono- or bicyclic hydrocarbon ring containing 4, 5, 6, 7 or 8 carbon atoms and one double bond. In particular, said ring contains 4, 5 or 6 carbon atoms ("cycloalkenyl-C4-C6"). This group IF-2019-16843 747-APN-ANP#INPI Page 17 of 720 cycloalkenyl-C4-C8- is for example a monocyclic hydrocarbon ring, for example a cyclobutenyl-, cyclopentenyl-, cyclohexenyl-, cycloheptenyl- or cyclooctenyl- group, or a bicyclic hydrocarbon ring, for example a group bicyclo[2.2.1]hept-2-enyl- or bicyclo[2.2.2]oct-2-enyl. The term “4- to 10-membered heterocycloalkyl” means a mono- or bicyclic hydrocarbon ring containing 3, 4, 5, 6, 7, 8, or 9 carbon atoms and containing 1, 2, 3, or 4 heteroatoms. which may be identical or different, said heteroatoms are preferably selected from oxygen, nitrogen or sulfur and where the carbon atoms and heteroatoms add up to 4, 5, 6, 7, 8, 9 or 10 ring atoms in total, it is possible that said heterocycloalkyl group is linked to the rest of the molecule through any of the carbon atoms or, if present, a nitrogen atom. “Heterospirocycloalkyl-”, “heterobicycloalkyl-” and “bridged heterocycloalkyl-”, as defined below, are also included within the scope of this definition. Preferably, said “4- to 10-membered heterocycloalkyl” group is monocyclic and contains 3, 4, 5 or 6 carbon atoms and one or two of the heteroatoms mentioned above, which add up to 4, 5, 6 or 7 atoms. ring atoms in total (a “4- to 7-membered monocyclic heterocycloalkyl”), or contains 3, 4, or 5 carbon atoms and one or two of the heteroatoms mentioned above, adding up to 4, 5, or 6 ring atoms in total (a “4- to 6-membered monocyclic heterocycloalkyl”), or contains 3, 4, or 5 carbon atoms or one or two of the heteroatoms mentioned above, adding up to 5 or 6 ring atoms in total (a “heterocycloalkyl”). 5- to 6-membered monocyclic-”); It is possible that said heterocycloalkyl group is attached to the rest of the molecule through any of the carbon atoms or nitrogen atoms, if present. By way of example, but not limited thereto, said “4- to 7-membered monocyclic heterocycloalkyl” may be a 4-membered ring, a “4-membered heterocycloalkyl” group, such as an azetidinyl or oxetanyl group; or a 5-membered ring, a 5-membered heterocycloalkyl group, such as a tetrahydrofuranyl-, dioxolinyl-, pyrrolidinyl-, imidazolidinyl-, pyrazolidinyl- or pyrrolinyl group; or a 6-membered ring, a “6-membered heterocycloalkyl” group, such as a tetrahydropyranyl-, piperidinyl-, morpholinyl-, 3-oxomorpholinyl-4-yl, ditianyl-, thiomorpholinyl- or piperazinyl group; or a 7-membered ring, a 7-membered heterocycloalkyl group, such as a group IF-2019-16843 747-APN-ANP#INPI Page 18 of 720 azepanyl-, diazepanyl- or oxazepanil, for example. The heterocycloalkyl groups may be substituted one or more times with alkyl-Ci-Ca, alkoxy-Ci-Cs, hydroxy, halogen or a carbonyl group. The term "5- to 7-membered heterocycloalkenyl" means a non-aromatic, unsaturated, monocyclic heterocycle with 5, 6, or 7 ring atoms in total, containing one or two double bonds and one or two ring heteroatoms identical or different from the series: N, O, S; It is possible that said heterocycloalkenyl group is linked to the rest of the molecule through any carbon atom, or if present, a nitrogen atom. Said heterocycloalkenyl group is, for example, a 4 / - / -pyranyl-, 3,6-dihydro-2Hpyran-4-yl-, 2H-pyranyl-, dihydropyridinyl-, tetrahydropyridinyl-, 2-oxopyridin-1 (2H) group -yl-, 2,5-dihydro-1 / - / -pyrrolyl-, [1,3]dioxolyl-, 4H-[1,3,4]thiadiazinyl-, 2,5-dihydrofuranyl-, 2,3-dihydrofuranyl -, 2,5-dihydrothiophenyl-, 2,3-dihydrothiophenyl-, 4,5-dihydrooxazolyl- or 4 / - / -(1,4]thiazinyl. These heterocycloalkenyl groups may be substituted with a hydroxy group or a methoxy group. The term fused heterocycloalkyl or heterobicycloalkyl- means a saturated bicyclic heterocycle with 6, 7, 8, 9 or 10 ring atoms in total, in which the two rings share two adjacent ring atoms, which fused heterocycloalkyl contains one or two identical ring heteroatoms or different from the series: N, O, S; It is possible that said fused heterocycloalkyl group is linked to the rest of the molecule through any carbon atom, or if present, a nitrogen atom. Said fused heterocycloalkyl or “heterobicycloalkyl-” group is, for example, an azabicyclo[3.3.0]octyl-, azabicyclo[4.3.0]nonyl-, diazabicyclo[4.3.0]nonyl-, oxazabicyclo[4.3] group. .0]nonílo-, thiazabiciclo[4.3.0]nonílo-, or azabiciclo[4.4.0]decílo. The term "aryl" means a phenyl-, naphthyl-, 5,6-dihydronaphthyl-, 7,8-dihydronaphthyl-, 5,6,7,8-tetrahydronaphthyl-, indanyl- or indenyl group that is unsubstituted or substituted with one, two, three, four or five substituents, each substituent independently selected from halogen, cyano, alkyl-Ci-Cs, haloalkyl-Ci-Cs, alkoxy-Ci-Cs, thioalkyl-Ci-C3, haloalkoxy-Ci-C3, haloalkyl-Ci-C3, cycloalkyl-Cs-Cs, especially halogen, alkyl-Ci-Cs, haloalkyl-C-i-Cs, alkoxy-Ci-Cs, and haloalkoxy-Ci-Cs. The term heteroaryl- means a monocyclic, bicyclic or aromatic ring system. IF-2019-16843 747-APN-ANP#INPI Page 19 of 720 tricyclic having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms (a 5- to 14-membered heteroaryl group), preferably 5, 6, 9 or 10 atoms ring and containing 1, 2, 3 or 4 heteroatoms that may be identical or different, said heteroatoms being selected from oxygen, nitrogen and sulfur. Said heteroaryl group may be a 5-membered heteroaryl group, such as, for example, a thienyl-, furanyl-, pyrrolyl-, oxazolyl-, thiazolyl-, imidazolyl-, pyrazolyl-, isoxazolyl-, isothiazolyl-, oxadiazolyl-, triazolyl-, thiadiazolyl- or tetrazolyl; or a 6-membered heteroaryl group, such as, for example, a pyridyl-, pyridazinyl-, pyrimidyl-, pyrazinyl- or triazinyl group; or a benzo-fused 5-membered heteroaryl group, such as, for example, a benzofuranyl-, benzothienyl-, benzoxazolyl-, benzisoxazolyl-, benzimidazolyl-, benzothiazolyl-, benzotriazolyl-, indazolyl-, indolyl- or isoindyl group; or a benzo-fused 6-membered heteroaryl group, such as, for example, a quinolinyl-, quinazolinyl-, isoquinolinyl-, cinolinyl-, phthalazinyl- or quinoxalinyl group; or another bicyclic group, such as, for example, an indolizinyl-, purinyl- or pteridinyl group; or a tricyclic heteroaryl group, such as, for example, a carbazolyl-, acridinyl- or phenazinyl group. Preferably, heteroaryl is a monocyclic aromatic ring system having 5 or 6 ring atoms and containing at least one heteroatom, if there is more than one, they can be identical or different, said heteroatom is selected from oxygen, nitrogen and sulfur (monocyclic heteroaryl). 5 to 6 members-"), such as for example a thienyl-, furanyl-, pyrrolyl-, oxazolyl-, thiazolyl-, imidazolyl-, pyrazolyl-, isoxazolyl-, isothiazolyl-, oxadiazolyl-, triazolyl-, thiadiazolyl-, tetrazolyl group -, pyridyl-, pyridazinyl-, pyrimidyl-, pyrazinyl or triazinyl. In general, and unless otherwise mentioned, such heteroaryl groups include all possible isomeric forms thereof, for example, positional isomers thereof. Therefore, for some illustrative non-restrictive examples, the term pyridyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; The term thienyl- includes thien-2-yl and thien-3-yl. Furthermore, such heteroaryl groups can be attached to the rest of the molecule through any of the carbon atoms or, if applicable, a nitrogen atom, for example, pyrrol-1-yl-, pyrazol-1-yl- or imidazole- 1 -il. In general, and unless otherwise indicated, heteroaryl or heteroarylene groups include all possible isomeric forms, for example, tautomers and positional isomers with respect to the point of attachment to the rest of the molecule. Therefore, IF-2019-16843 747-APN-ANP#INPI Page 20 of 720 For some illustrative non-restrictive examples, the term pyridinyl- includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl- includes thien-2-yl and thien-3-yl. In particular, the heteroaryl group is a pyridyl group or a pyrimidyl group or an imidazolyl group, which includes a hydroxy substitution of the pyridyl group leading for example to a 2-hydroxy-pyridyl group which is the tautomeric form of a 2-oxo group. -2(1 Hj-pyridyl. The term Ci-Ce, as used throughout this text, for example, in the context of the definition of alkyl-Ci-Ce, haloalkyl-C-i-Ce, alkoxy-Ci-Ce or haloalkoxy-Ci-Ce means an alkyl group having an integer number of carbon atoms from 1 to 6, that is, 1.2, 3.4, 5 or 6 carbon atoms. Furthermore, it must be understood that said term “CiCe” must be interpreted as disclosing any subinterval included therein, for example Ci-C6, C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, Ci-C6; preferably Ci-C2, C1-C3 C1-C4 C1-C5, C-i-Ce; more preferably C1-C4; in the case of “haloalkyl-Ci-Ce” or “haloalkoxy-C-i-Ce-” even more preferably Ci-C2. Similarly, as used herein, the term C2-C6, as used throughout this text, for example, in the context of the definitions of C2-C6-alkenyl and C2-C6-alkynyl, means an alkenyl group or an alkynyl group having an integer number of carbon atoms from 2 to 6, that is, 2, 3, 4, 5 or 6 carbon atoms. It must also be understood that said term C2-C6 must be interpreted as disclosing any subinterval included therein, for example, C2-Ce, Cs-Cs, C3-C4, C2-Cs, C2-C4, C2-Cs; preferably C2-C3. Furthermore, as used herein, the term "C3-C7", as used throughout this text, for example, in the context of the definition of cycloalkyl-Cs-C?, means a cycloalkyl group having an integer number of carbon atoms from 3 to 7, that is, 3, 4, 5, 6 or 7 carbon atoms. It is further to be understood that said term C3-C7 should be interpreted as disclosing any subinterval included therein, for example, C3C6, C4-C5, C3-C5, C3-C4, C4-C6, C5-C7; preferably C3-C6. As used herein, the term "leaving group" refers to an atom or group of atoms that moves in a chemical reaction as a stable species carrying with it the bonding electrons, for example, typically forming an anion. Preferably, a leaving group is selected from the group comprising: halo, especially a chloro, bromo or iodo group, (methylsulfonyl)oxy-, [(4-methylphenyl)sulfonyl]oxy-, [(trifluoromethyl)sulfonyl]oxy-, [(nonafluorobutyl)sulfonyl]oxy-, [(4-bromophenyl)sulfonyl]oxy-, [(421 IF-2019-16843 747-APN-ANP#INPI Page 21 of 720 nitrophenyl)sulfonyl]ox¡-, [(2-nitrophenyl)sulfonyl]oxy-, [(4-isopropylphen¡l)sulfon¡l]ox¡-, [(2,4,6-triisoprop¡ lphenyl)sulfon¡l]oxy¡-, [(2,4,6-trimethylphenyl)sulfon¡l]oxy-, [(4-fert-butylphenyl)sulfonyl]oxy-, (phenylsulfonyl)oxy- and [(4-methoxyphenyl)sulfonyl]oxy. As used herein, the term protecting group is a protecting group attached to an oxygen or nitrogen atom in the intermediates that is used for the preparation of compounds of the general formula (I). Such groups are introduced, for example, by chemical modification of the respective hydroxy or amino group to obtain chemoselectivity in a subsequent chemical reaction. Protecting groups for hydroxy and amino groups are described, for example, in T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 4th edition, Wiley 2006; More specifically, protecting groups for amino groups may be selected from substituted sulfonyl groups, such as a mesyl-, tosyl-, or phenylsulfonyl group, acyl groups such as a benzoyl-, acetyl-, or tetrahydropyranoyl group, or carbamate-based groups, such as a tert-butoxycarbonyl group (Boc). Protecting groups for the hydroxy groups may be selected from acyl groups such as a benzoyl-, acetyl, pivaloyl- or tetrahydropyranoyl group, or may include silicon, such as, for example, a tert-butyldimethylsilyl-, tert-butyldiphenylsilyl-, triethylsilyl- or triisopropylsilyl group. The term substituent refers to a substituted group on, for example, an alkyl, haloalkyl, cycloalkyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl or heteroaryl group on any atom of that group, which replaces one or more hydrogen atoms therein. In one aspect, the substituent(s) in a group are independently single, or any combination of two or more of the permissible atoms or groups of atoms delineated for that substituent. In another aspect, a substituent may be substituted by any of the above substituents. Additionally, as used herein, the phrase optionally substituted means unsubstituted (e.g., substituted with an H) or substituted. It will be understood that the description of the compounds herein is limited by chemical bonding principles known to those skilled in the art. Accordingly, where a group may be substituted with one or more than a number of substituents, such substitutions are selected to comply with chemical bonding principles with respect to valences, etc., and to provide compounds that are not inherently unstable. For example, any carbon atom will be bonded to two, three, or four IF-2019-16843 747-APN-ANP#INPI Page 22 of 720 more atoms, consistent with the four valence electrons of carbon. Subject means a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, sheep, rodent or feline. It is possible that compounds of the general formula (I) exist as isotopic variants. Therefore, the invention includes one or more isotopic variants of the compounds of the general formula (I), especially deuterium-containing compounds of the general formula (I). The invention also includes all suitable isotopic variations of a compound of the invention. The term isotopic variant of a compound or a reagent is defined as a compound that exhibits an unnatural proportion of one or more of the isotopes that constitute said compound. The term unnatural ratio in relation to an isotope means a proportion of said isotope that is greater than its natural abundance. Natural isotope abundances that apply in this context are described in \sotopic Compositions of the Elements 1997, Pure Appl. Chern., 70(1), 217-235, 1998. An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom that has the same atomic number but an atomic mass different from the atomic mass usually found or predominantly found in the nature. Examples of isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2H (deuterium), 3H (tritium), 11C, 13C,14C,15N,17O,180,32P,33P,33S,34S,35S,36S,18F,36CI,82Br,123l,124l,129l and131l, respectively. Therefore, the term hydrogen or H should be understood to encompass 1H (protium), 2H (deuterium), and 3H (tritium) unless otherwise specified. Certain isotopic variations of a compound of the invention, for example, those in which one or more radioactive isotopes such as 3H or 14C are incorporated, are useful in tissue, substrate and / or drug distribution studies. Isotopes of tritium and carbon-14, i.e. 14C, are particularly preferred for their ease of preparation and detectability. Likewise, replacement with isotopes such as deuterium may provide certain therapeutic advantages. IF-2019-16843 747-APN-ANP#INPI Page 23 of 720 that result in better metabolic stability, for example, a longer in vivo half-life or reduced dosage requirements and may therefore be preferred in some circumstances. Isotopic variations of a compound of the invention can generally be prepared through conventional procedures known to one skilled in the art such as by the illustrative procedures or by the preparations described in the examples below using appropriate isotopic variations of suitable reagents. With respect to the treatment and / or prophylaxis of the disorders specified herein, the isotopic variant or variants of the compounds of the general formula (I) preferably contain deuterium ("deuterium-containing compounds of the general formula (I)"). ). Isotopic variants of the compounds of the general formula (I) in which one or more radioactive isotopes, such as 3H or 14C, are incorporated, are useful, for example in studies of tissue distribution of drugs and / or substrates. These isotopes are particularly preferred for their ease of incorporation and detectability. Positron-emitting isotopes such as 18F or 11C can be incorporated into a compound of the general formula (I). These isotopic variants of the compounds of the general formula (I) are useful for in vivo imaging applications. Deuterium-containing and 13C-containing compounds of the general formula (I) can be used in mass spectrometry analyzes in the context of preclinical or clinical studies. Isotopic variants of the compounds of the general formula (I) can generally be prepared by procedures known to a person skilled in the art, such as those described in the schemes and / or examples of the present invention, substituting a reagent for an isotopic variant. of said reagent, preferably by a reagent containing deuterium. Depending on the desired deuteration sites, in some cases deuterium can be incorporated from D2O directly into the compounds or into reagents that are useful for synthesizing such compounds. Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic bonds and acetylenic bonds is a rapid route for deuterium incorporation. Metal catalysts (i.e., Pd, Pt, and Rh) can be used in the presence of deuterium gas to directly exchange deuterium for hydrogen in hydrocarbon-containing functional groups. A variety of deuterated reagents and synthetic building blocks are commercially available from companies such as, for example, C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA and IF-2019-16843 747-APN-ANP#INPI Page 24 of 720 CombiPhos Catalysts, Inc., Princeton, NJ, USA. The term deuterium-containing compound of the general formula (1) is defined as a compound of the general formula (I), in which one or more hydrogen atom(s) is / are substituted by one or more deuterium atom(s). and in which the abundance of deuterium at each deuterated position of the compound of the general formula (I) is greater than the natural abundance of deuterium, which is approximately 0.015%. Especially, in a deuterium-containing compound of the general formula (I), the abundance of deuterium at each deuterated position of the compound of the general formula (I) is greater than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80%, preferably greater than 90%, 95%, 96% or 97%, and even more preferably greater than 98% or 99% in said positions. It is understood that the deuterium abundance at each deuterated position is independent of the deuterium abundance at other deuterated positions. The selective incorporation of one or more deuterium atoms into a compound of the general formula (I) can alter physicochemical properties (such as acidity [CL Perrin, et al., J. Am. Chem. Soc., 2007 , 129, 4490], basicity [CL Perrin et al., J. Am. Chem. Soc. 2005, 127, 9641], lipophilicity [B. Testa et al., Int. J, Pharm, 1984, 19 (3) , 271]) and / or the metabolic profile of the molecule and can lead to changes in the ratio of precursor compound to metabolites or in the amounts of metabolites formed. Such changes may give rise to certain therapeutic advantages and may therefore be preferred in some circumstances. Reduced rates of metabolism and metabolic change, where the proportion of metabolites changes, have been reported (AE Mutlib et al., Toxicol. Appl. Pharmacol., 2000, 169, 102). These changes in exposure to the parent drug and metabolites can have important consequences with respect to the pharmacodynamics, tolerability and efficacy of a deuterium-containing compound of the general formula (I). In some cases, deuterium substitution reduces or eliminates the formation of an unwanted or toxic metabolite and enhances the formation of a desired metabolite (for example Nevirapine: AM Sharma et al., Chem. Res. Toxicol., 2013, 26, 410 Efavirenz: AE Mutlib et al., Toxicol. Pharmacol., 2000, 169, 102). In other cases, the primary effect of deuteration is to reduce the rate of systemic elimination. As a result, the biological half-life of the compound increases. Potential clinical benefits would include the ability to maintain similar systemic exposure with reduced peak levels and increased trough levels. This could lead to fewer side effects and greater effectiveness, depending on the ratio IF-2019-16843 747-APN-ANP#INPI Page 25 of 720 pharmacokinetics / pharmacodynamics of the particular compound. ML-337 (C.J. Wenthur et al., J. Med. Chem., 2013, 56, 5208) and Odanacatib (K. Kassahun et al., WO2012 / 112363) are examples of this deuterium effect. Even other cases have been reported in which reduced rates of metabolism result in increased drug exposure without changing the rate of systemic elimination (e.g., Rofecoxib: F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295; Telaprevir: F. Maltais et al., J. Med. Chem., 2009, 52, 7993). Deuterated drugs that show this effect may have reduced dosage requirements (e.g., fewer doses or lower doses to achieve the desired effect) and / or may produce lower metabolite loads. A compound of the general formula (I) may have multiple potential sites of vulnerability to metabolism. To optimize the above-described effects on the physicochemical properties and metabolic profile, deuterium-containing compounds of the general formula (I) can be selected that have a certain pattern of one or more deuterium-hydrogen exchanges. In particular, the deuterium atoms of deuterium-containing compounds of the general formula (I) are bonded to a carbon atom and are located at those positions of the compound of the general formula (I), which are attack sites for metabolizing enzymes. such as for example cytochrome P450. For example, in some embodiments, the present invention relates to a deuterium-containing compound of the general formula (I), for example: R •íCH2)p Such deuterium-containing compounds can be prepared by methods well known to those skilled in the art. In particular, such deuterium-containing compounds can be prepared from the corresponding deffins, which are available by methods known to those skilled in the art, such as ring closure metathesis reactions, as discussed, for example, in the description IF-2019-16843 747-APN-ANP#INPI Page 26 of 720 general synthesis of compounds of the general formula (I), below, in the context of Schemes 2c and 2j, respectively. In cases where the plural form of the words compounds, salts, polymorphs, hydrates, solvates and the like is used herein, it must be taken to mean also the singular, compound, salt, polymorph, isomer, hydrate, solvate and similar. The terms “a” or “one” as used herein mean one or more. The term "stable compound" or "stable structure" means a compound robust enough to survive isolation at a useful degree of purity from a reaction and formulation mixture into an effective therapeutic agent. The compounds of the present invention, as well as the corresponding macrocyclic intermediates of formula (II), are generally chiral simply as a result of restricted rotation around at least one single bond, which is due to the limited conformational flexibility of their nucleus. macrocyclic as a whole or even open chain precursors. Therefore, the compounds of the present invention, as well as the corresponding macrocyclic intermediates, such as, for example, of formula (II), may exist as atropisomers. In the specific situation of the embodiments claimed and disclosed herein having a CR22R23 group present in the compounds of formula (I), as well as in various intermediates, atropisomerism can occur in different synthesis steps as soon as R22 and R23 have different meanings and are present in their claimed form or as suitable precursors, for example, already upon the Suzuki coupling of the starting materials of formulas (Vil) and (VI) to provide intermediates of formula (V). Atropisomers represent a subclass of conformers that arise from restricted rotation around a single bond. The conformers (called atropisomers) can be isolated as separate species (IUPAC Gold book, http: / / qoldbook.iupac.org / A00511 .html; Pure and Appl. Chem., 2009, 68, 21932222). This induced chirality belongs to the axial type of chirality. The compounds of the present invention, as well as the corresponding macrocyclic intermediates of formula (II), further optionally contain one or more asymmetric centers, depending on the location and nature of the various desired substituents. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can lead to racemic mixtures in the case of a single center IF-2019-16843 747-APN-ANP#INPI Page 27 of 720 asymmetric and in diastereomeric mixtures in the case of multiple asymmetric centers. Therefore, the compounds of the present invention, as well as the corresponding macrocyclic intermediates of formula (II), characterizing the above-mentioned atropisomerism and an additional asymmetric center can also exist as diasteromeric mixtures as described above. Those compounds that produce the most desirable biological activity are preferred. Also included within the scope of the present invention are separate, pure or partially purified isomers, stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention. Purification and separation of such materials can be achieved using conventional techniques known in the art. If only one isomer (enantiomer) shows the desired biological activity and the second isomer (enantiomer) is inactive, the preferred isomer is the one that produces the most desirable biological activity. If one isomer (enantiomer / diastereomer) shows better activity than the other isomer (enantiomer / diastereomer), the preferred isomer is the one that produces the best biological activity. These separate, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. Purification and separation of such materials can be achieved using conventional techniques known in the art. Optical isomers can be obtained by resolution of racemic mixtures according to conventional procedures, for example, by the formation of diastereoisomeric salts using an optically active acid or base or the formation of covalent diastereomers. Examples of suitable acids include tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers based on their physical and / or chemical differences by procedures known in the art, for example, by chromatography or fractional crystallization. The optically active bases or acids are then released from the separated diastereomeric salts. A different procedure for the separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatization, optimally chosen to maximize separation of the enantiomers. Suitable HPLC columns using a chiral phase are IF-2019-16843 747-APN-ANP#INPI Page 28 of 720 commercially available products, such as those manufactured by Daicel, for example, Chiracel OD and Chiracel OJ, for example, among many others, select them routinely. Enzymatic separations, with or without derivatization, are also useful. The optically active compounds of the present invention can further be obtained by chiral synthesis using optically active starting materials, enantioselective catalytic reactions and other suitable methods. In order to distinguish different types of isomers from each other, reference is made to Section E of the IUPAC Standards (Pure Appl Chem 45, 11-30, 1976). The present invention includes all possible stereoisomers of the compounds of the present invention as individual stereoisomers, or as any mixture of such stereoisomers, in any ratio. Isolation of a simple stereoisomer, for example of a simple enantiomer or diastereomer, of a compound of the present invention can be achieved by any suitable method, such as chromatography, especially chiral chromatography, for example. Furthermore, the compounds of the present invention may exist as tautomers. For example, any compound of the present invention containing a pyrazole moiety such as a heteroaryl group, for example, may exist as a 1H tautomer, or a 2H tautomer, or even a mixture in any amount of the two tautomers, namely: 1H tautomer 2H tautomer The present invention includes all possible tautomers of the compounds of the present invention as individual tautomers or as any mixture of such tautomers, in any ratio. Furthermore, the compounds of the present invention may exist as N-oxides, which are defined because at least one nitrogen of the compounds of the present invention is oxidized. The present invention includes all possible N-oxides. One embodiment of the invention is the compounds of formula (I) and a IF-2019-16843 747-APN-ANP#INPI Page 29 of 720 tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Another embodiment of the invention is the compounds of formula (l) and a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. Another embodiment of the invention is the compounds of formula (I) and a salt thereof, more specifically an amine salt, or an organic acid salt, more particularly a diethylamine salt, an acetic acid salt or a salt of citric acid. The present invention also includes useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs and salts, especially pharmaceutically acceptable salts and / or co-precipitates. The compounds of the present invention may exist as a hydrate, or as a solvate, where the compounds of the present invention form a crystal containing molecules of polar solvents, especially water, methanol or ethanol, for example, as a structural element of the crystal lattice of the compounds. Polar solvent molecules, especially water, may be present in a stoichiometric or nonstoichiometric relationship with the compound molecules. In the case of stoichiometric solvates, for example, a hydrate, hemihydrate, (semihydrate), monohydrate, sesquihydrate, dihydrate, trihydrate, tetrahydrate, pentahydrate, etc. are possible. solvates or hydrates, respectively. The present invention includes all of these hydrates or solvates. Furthermore, the compounds of the present invention may exist in free form, for example, in the form of a free base, or in the form of a free acid, or in the form of a zwitterion or may exist in the form of a salt. Said salt may be any salt, whether an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, commonly used in pharmacy, or used, for example, to isolate or purify the compounds of the present invention. The term "pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1-19. Includes any physiologically acceptable salts as mentioned below. Physiologically acceptable salts of the compounds according to the invention IF-2019-16843 747-APN-ANP#INPI Page 30 of 720 include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, disulfuric acid, phosphoric acid and nitric acid or with an organic acid, such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, tauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyljbenzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectinic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2hydroxyethanesulfonate acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfonic acid, ethanesulfonic acid, benzenesulfonic acid, paratoluenesulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, melic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerophosphoric acid, aspartic acid, sulfosalicylic acid, hemisulfuric and thiocyanic acid, for example. A pharmaceutically acceptable anion refers to the deprotonated form of a conventional acid, such as, for example, a hydroxide, a carboxylate, a sulfate, a halide, a phosphate or a nitrate. Physiologically acceptable salts of the compounds according to the invention also comprise salts of conventional bases, such as, by way of example and by preference, salts of alkali metals (for example, lithium, sodium and potassium salts), metal salts alkaline earth metals (for example, calcium, strontium and magnesium salts) and ammonium salts derived from ammonia or organic amines with 1 to 16 C atoms, such as, by way of example and by preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine , diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, / V-methylmorpholine, arginine, lysine, ethylenediamine, / V-methylpiperidine, / V-methylglucamine, dimethylglucamine, ethylglucamine, 1,6hexadiamine, glucosamine, sarcosine, serinol, tris( hydroxymethyl)aminomethane, aminopropanediol, Sovak's base and 1-amino-2,3,4-butanetriol. Furthermore, the compounds according to the invention can form salts with an ion of IF-2019-16843 747-APN-ANP#INPI Page 31 of 720 quaternary ammonium that can be obtained, for example, by quaternization of a nitrogen-containing basic group with agents such as lower alkylhalides, such as alkyl chlorides, for example, methyl chloride, ethyl chloride, propyl and butyl chloride; such as alkyl bromides, for example methyl bromide, ethyl bromide, propyl bromide and butyl bromide; and such as alkyliodides, for example methyl iodide, ethyl iodide, propyl iodide and butyl iodide; dialkyl sulfates such as dimethyl sulfate, diethyl sulfate, dibutyl sulfate and diamyl sulfates, long chain halides such as decyl chloride, lauryl chloride, myristyl chloride and stearyl chloride, decyl bromide, lauryl, myristyl bromide and stearyl bromide, decylium iodide, lauryl iodide, myristyl iodide and stearyl iodide, haralkyl halides such as benzyl chloride, benzyl bromide, benzyl iodide, phenethyl bromides and others. Examples of suitable quaternary ammonium ions are tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra(n-butylhammonium or / V-benzyl-A / ,A / , / V-trimethylammonium. The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of such salts, in any proportion. Unless otherwise specified, suffixes to chemical names or structural formulas relating to salts, such as hydrochloride, trifluoroacetate, sodium salt or x HCl, x CF3COOH, x Na+, for example, mean a form of salt, the stoichiometry of which is not specified. The solvates and hydrates of the disclosed intermediates or exemplary compounds, or salts thereof, which have been obtained by the preparation and / or purification processes described herein, can be formed in any ratio. Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, as an individual polymorph, or as a mixture of more than one polymorph, in any ratio. Furthermore, the present invention also includes prodrugs of the compounds according to the invention. The term "prodrugs" refers to compounds that may be biologically active or inactive, but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body. For example, a prodrug may be in the form of an ester IF-2019-16843 747-APN-ANP#INPI Page 32 of 720 in vivo hydrolyzable of the specified compound. Derivatives of the compounds of the formula (I) and salts thereof that are converted into a compound of the formula (I) or a salt thereof in a biological system (bioprecursors or prodrugs) are included in the invention. Said biological system may be, for example, a mammalian organism, especially a human subject. For example, the bioprecursor is converted to a compound of formula (I) or a salt thereof by metabolic processes. DESCRIPTION According to a first aspect, the present invention provides compounds of the formula (I) (I), where A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9- to 16-membered ring. members and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; IF-2019-16843 747-APN-ANP#INPI Page 33 of 720 A is (A3) where optionally one or two of the groups selected from CR11, CR12 and CR13 are replaced by a nitrogen atom, wherein R6 and R10, together with three carbon atoms of the phenyl ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9-membered to 16-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R3 is selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group, a Ci-C3 haloalkyl group, a Ci-C3 alkoxy group, a Ci-C3 alkylthio group, a -S(O)-(alkyl-Ci-C3) group, a -S(O)2-(alkyl-Ci-C3) group, a haloalkoxy-Ci-C3 group, a haloalkylthio-Ci-C3 group, and a cycloalkyl group -C3-Cs; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three, four or five substituents and each substituent is independently selected from a halogen atom, a cyano group, a alkyl-Ci-C3 group, a haloalkyl-Ci-C3 group, an alkoxy-Ci-C3 group, a thioalkyl-Ci-C3 group, a haloalkoxy-Ci-C3 group, a (C-i-C3)-haloalkyl-S group - and a cycloalkyl-Cs-Cs group; L is a -(CH2)m-E- group wherein any CH2 group is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, a Ci-alkyl group -C3y a Ci-C3 alkoxy group, or two substituents are optionally taken together with their intermediate atoms to form a saturated or partially unsaturated 3-membered to 6-membered cycloalkyl ring, or a saturated or 3-membered to 8-membered heterocyclic ring partially unsaturated having 1-2 heteroatoms independently selected from an oxygen atom, a sulfur atom, an —S(O)- group, a -S(O)2- group and a -NR14- group; IF-2019-16843 747-APN-ANP#INPI Page 34 of 720 E is a bond, an oxygen atom, a sulfur atom, an -S(O)- group, an S(O)2- group or a -NR14- group and constitutes the connecting element to R4; m is 2, 3, or 4; *N N\u N-N R5 is selected from a group COOH, a group, a group -C(O)NHS(O)2(alkyl-Ci-Ce), a group-C(O)-NHS(O)2(cycloalkyl-C3-C6) , a -C(O)NHS(O)2(aryl) group, a -C(O)-NHS(O)2(CH2)sNHCO(alkyl-Ci-C6) group, a -C(O)NHS group (O)2(CH2)sNHCO(C3-C6-cycloalkyl) and a -C(O)NHS(O)2(CH2)sNHCO(aryl) group; s is 0, 1 or 2; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##o «-(C^Cg-alkenyleneHBjt-CR^R23-##, where#is the point of attachment to the atom of indole nitrogen and##is the point of attachment to the pyrazole carbon atom bearing the R7 substituent and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from an atom; halogen, a hydroxy group, an NR16R17 group, an alkyl-Ci-Cs group, a haloalkyl-C-i-Cs group, an alkoxy-Ci-Cs group, a haloalkoxy-Ci-C3 group, a cycloalkyl-C3-C6 group and a (heterocycloalkyl)-(alkylene-Ci-C3)- group; -R6-R10- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenylene-C2-C9)-(B)t-CR22R23-##, where one or more -CH2 groups - are substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, an alkyl-Ci-Cs group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-Cs group and a haloalkoxy group -Ci-C3, where * is the point of attachment to the indole nitrogen atom and ## is the point of attachment to the carbon atom of the phenyl moiety bearing the R10 substituent; n is 2, 3, 4, 5, 6, 7, 8, or 9, if B is selected from -O-, -S-, -S(O)-, -S(O)2- and -N( R15)-, and n is 1.2, 3, 4, 5, 6, 7 or 8, if B is selected from a group -C(O)NR15- and a group NR15C(O)-, and n is 0, 1 ,2, 3, 4,5,6 or 7, if B is selected from a group -N(R15)-C(=O)-N(R15)-, a group -O-C(=O)-N(R15 )- and a group -N(R15)-C(=O)-O-; IF-2019-16843 747-APN-ANP#INPI Page 35 of 720 t is 1; where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of a 9 to 16 membered ring regardless of the selection of the variable A1, A2 or A3; B is independently selected from a group -C(O)NR15-, a group -NR15C(O)-, a group -N(R15)-, a group -N(R15)-C(=O)-N(R15 )-, a group -O-C(=O)-N(R15)-, a group -N(R15)-C(=O)-O-, -O-, -S-, -S(O)- and -S(O)2-; R8 is selected from a hydrogen atom, a Ci-Ce alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-Cs alkoxy group, a haloalkoxy-Ci-C3, a cycloalkyl-C3-C6 group, a heterocycloalkyl group and an NR21R22 group; a haloalkyl-Ci-Cs group, a cycloalkyl-Cs-Ce group, and an alkyl-Ci-C6 group in which one or two non-directly adjacent carbon atoms are independently replaced by a heteroatom selected from -O- and - NH-; R9 is selected from a hydrogen atom, a Ci-C4 alkyl group, a Ci-Cs hydroxyalkyl group, a Ci-C4 haloalkyl group, a Ci-C4 haloalkyl group-NH-C(O)-O-( alkylene-Ci-C3)-, a haloalkenyl-C2-C6 group, a group C-i-Ce-alkyl-O-, a haloalkoxy-Ci-C4 group, a group Ci-C6-alkyl-O-(alkylene-Ci- C3)-, a cycloalkyl-(C3-C7) group, a (C3-C7)-cycloalkyl-O-(alkylene-Ci-C3)- group, a phenyl-O-(alkylene-Ci-) group C3)-, IF-2019-16843 747-APN-ANP#INPI Page 36 of 720 a phenyl group-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)-(alkylene-Ci-C3)-O-(alkylene-Ci- C3)-, a group R18-(phenylene)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (heterocycloalkenyl )-(phenylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene)-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(phenylene)-O-(alkylene-Ci-C3) -, a group (R19)-S(O)2-NH-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-NH-(phenylene) -O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-N(alkylene-Ci-C6)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(heterocycloalkylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(heteroarylene)-O-(alkylene-Ci- C3)-, a group (R19)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R19 )-S(O)2-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(heterocycloalkylene)-(heteroarylene)-O-(alkylene- Ci-C3)-, a group NR20R21-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-NH-(alkylene-Ci-C3)-, a group (haloalkyl-Ci-C3)- (alkylene-Ci-C3)-NH-(alkylene-Ci-C3)-, a group (haloalkyl-Ci-C3)-NH-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)- NH-C(O)-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-NR15-C(O)-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3 )-C(O)-NH-(alkylene-Ci-C3)-, a group (alkylene-Ci-C3)-C(O)-NR15-(alkylene-Ci-C3)-, F J>x^N-(alkylene-Ci-C3)a group and a group O N— (alkylene-Ci-Cs), where the phenyl ring is unsubstituted or is IF-2019-16843 747-APN-ANP#INPI Page 37 of 720 substituted with a halogen atom, a hydroxy group or an alkoxy-Ci-C3 group and the heterocycloalkyl group is unsubstituted or substituted with an oxo group (=0) or is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a -Ci-C3 group and an alkoxy-Ci-C3 group, or R8 and R9 together form a 5-membered or 6-membered ring optionally comprising one or two heteroatoms independently selected from - O- and NR14-; R11 and R13 are each independently selected from a hydrogen atom, a halogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R12 is selected from a hydrogen atom, a Ci-C3 alkoxy group, a Ci-C3 alkyl group, a Ci-C3 haloalkyl group, a Ci-C3 haloalkoxy group and an NR18R17 group; R14 is a hydrogen atom or a Ci-C3 alkyl group; R15 is independently selected from a hydrogen atom, a Ci-Ce-alkyl group that is unsubstituted or substituted with one or more substituents selected from a halogen atom, a Ci-C3-alkyl group, a CiC3-haloalkyl group, a hydroxyalkyl-Ci-C3, a alkoxy-Ci-C3 group, a haloalkoxyCi-C3 group, a heterocycloalkyl group, an aryl group, a (R18)(heterocycloalkylene)-(arylene)-O- group, a (heterocycloalkyl) group )-(arylene)-O, an aryl-O- group, an aryl-(alkylene-Ci-C3)-O- group, a (R19)-S(O)2arylene-O- group, a ( R19)S(O)2-heterocycloalkylene-arylene-O-, an aryl-heteroarylene-O- group, an aryl-heteroarylene-O-(alkylene-Ci-C3)- group, a heterocycloalkyl group -(alkylene-Ci-C3)-C(O)-, a heterocycloalkyl group-NH-C(O)-, an aryl group-(alkylene-Ci-C3)-NH-C(O)-, a heterocycloalkylene group -(Ci-C3alkylene)-S(O)2- and a heterocycloalkylene-heteroarylene-S(O)2- group; a Ci-C3-alkylene-C(O)- group, a heterocycloalkyl-(Ci-C3-alkylene)-C(O)- group, a heterocycloalkyl-(Ci-C3-alkylene)-S(O) group 2-, IF-2019-16843 747-APN-ANP#INPI Page 38 of 720 a heterocyclyl-NH-C(O)- group, a heterocycloalkyl-(alkylene-Ci-C3)-NH-C(O)- group, an aryl-(alkylene-Ci) group -C3)-NH-C(O)-, which is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from a halogen atom, a Ci-C3 alkyl group, and a Ci-Cs alkoxy group; a heterocycloalkyl-heteroarylene-S(O)2- group, a phenyl group, $(><> a group ,—, y---alkyl-(Ci-C3) $Z Vn N-S(Ofe.N v—y X— / alkyl-(Ci-C3) a group y \j-S(O)2-alkyl-( Ci-C3) a group where $ is the point of attachment to the nitrogen atom, to which R15 is attached; or R15 and R22 together, including the atoms to which they are attached, may form a 5-membered or 6-membered ring, both optionally comprising one or two additional heteroatoms independently selected from -O- and -NR14-; R16 and R17 are each independently selected from a hydrogen atom, a C-i-Ce alkyl group, a Ci-Ce haloalkyl group, a Ci-Ce alkoxy group, a C3-C5 cycloalkyl group, a Ci-C3 group. alkyl-C(O)-, a group-Ci-C3-alkylS(O)2- and a group Ci-C3-alkyl-O-C(=O)-; R18 is selected from a hydrogen atom, a hydroxy group, a cyano group, an alkyl-Ci-Cs group, a hydroxyalkyl-Ci-Ce group, an alkoxy-Ci-C3 group, a group R21OC(O)-(alkylene- Ci-C3-)-, a group -C(O)OR21, a group -C(O)NR20R21, a group (alkyl-Ci-C3)-O-(alkylene-Ci-C3)-C(O )-, a (Ci-C6-alkyl)-C(O)- group and a C3-C6-cycloalkyl-C(O)- group; IF-2019-16843 747-APN-ANP#INPI Page 39 of 720 R19 is selected from a Ci-Cs alkyl group, a C3-C6 cycloalkyl group and an NR20R21 group; and R20 and R21 are each independently selected from a hydrogen atom and a C-i-Ce alkyl group; R22 is independently selected from a halogen atom, a Ci-C6 alkyl group that is unsubstituted or substituted with one or more substituents selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-alkyl group. C3, a haloalkyl-Ci-C3 group, a hydroxyalkylC1-C3 group, an alkoxy-Ci-Cs group, a haloalkoxy-Ci-Cs group, a cycloalkyl-C3-C6 group, a heterocycloalkyl group, an aryte group, a group (R18)(heterocycloalkylene)-(arylene)-O-, a group (heterocycloalkyl)-(arylene)-O, an aryl group-O-, an aryl group-(alkylene-Ci-C3)-O-, a group (R19)-S(O)zarylene-O-, a (R19)S(O)2-heterocycloalkylene-arylene-O- group, an aryl-heteroarylene-O- group, an aryl-heteroarylene-0-(alkylene) group -Ci-C3)-, a heterocycloalkyl group-(alkylene-Ci-C3)-C(O)-, a heterocycloalkyl group-NH-C(O)-, an aryl group-(alkylene-Ci-C3)-NH -C(O)-, a heterocycloalkylene-(alkylene-Ci-C3)-S(O)2- group and a heterocycloalkylene-heteroarylene-S(O)2- group; a Ci-C3-alkyl-C(O)- group, a cycloalkyl-Cs-Ce group, an aryl group, a heterocycloalkyl group, and a heteroaryl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group, a Ci-Ce alkyl group and a Ci-Ce haloalkyl group, IF-2019-16843 747-APN-ANP#INPI Page 40 of 720 R22 and R23 together with the carbon atom to which they are attached form a 3-membered to 6-membered carbocyclic ring or a 3-membered to 6-membered heterocyclic ring comprising one or two heteroatoms selected from nitrogen, oxygen and sulfur; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Other embodiments of the first aspect of the present invention According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9-membered to 13-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 and R2 each are independently selected from a hydrogen atom, a halogen atom, a cyano group, an alkyl-Ci-Cs group and an alkoxy-Ci-Cs group; R3 is selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group, a Ci-Cs haloalkyl group, a Ci-Cs alkoxy group and a Cs-Cs cycloalkyl group; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three, four or five substituents and each substituent is independently selected from a halogen atom, a cyano group, a alkyl-Ci-Cs group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-Cs group and a IF-2019-16843 747-APN-ANP#INPI Page 41 of 720 cycloalkyl-Cs-Cs group; L is a -(CH2)m-E- group wherein any CH2 group is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, a Ci-alkyl group -Cs and an alkoxy-Ci-C3 group; E is a bond, an oxygen atom, a sulfur atom, or a -NR14- group and constitutes the connecting element to R4; m is 2, 3, or 4; *N N\n N-N H R5 is selected from a group COOH and a group ; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenylene-C2-C6)-(B)t-CR22R23-##, where * is the point of union with the indole nitrogen atom and is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-Cs alkyl group, a Ci-haloalkyl group -Cs, a Ci-C3 alkoxy group, and a Ci-C3 haloalkoxy group; n is 2, 3, 4, 5 or 6 if B is selected from -O-, -S-, -S(O)-, -S(O)2- and -N(R15)-, and n is 1, 2, 3, 4, or 5, if B is selected from a group -C(O)NR15- and a group -NR15C(O)-, and n is 0, 1, 2, 3 or 4; if B is selected from a group -N(R15)-C(=O)-N(R15)-, a group -OC(=O)-N(R15)- and a group -N(R15)-C( =O)-O-; t is 1 where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of a 9-membered or 13-membered ring regardless of the selection of the variable A1 or A2; B is independently selected from a group -C(O)NR15-, a group -NR15C(O)-, a group -N(R15)-, a group N(R15)-C(=O)-N(R15) -, a group -O-C(=O)-N(R15)-, a group -N(R15)-C(=O)-O-, IF-2019-16843 747-APN-ANP#INPI Page 42 of 720 O-, -S-, -S(O)- and -S(O)2-; R8 is selected from a hydrogen atom, a Ci-Ce alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-Cs alkoxy group, a haloalkoxy-Ci-C3, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and an NR20R21 group; R9 is selected from a hydrogen atom, a Ci-C4 alkyl group, a Ci-Cs hydroxyalkyl group, a Ci-C4 haloalkyl group, a Ci-C4 haloalkyl group-NH-C(O)-O-( alkylene-Ci-C3)-, a haloalkenyl-C2-C6 group, a group Ci-Ce-alkyl-O-, a haloalkoxy-Ci-C4 group, a group Ci-C6-alkyl-O-(alkylene-Ci- C3)-, a (Ci-C3-alkyl)-NH-(Ci-C3-alkylene)- group, a (C3-C7)-cycloalkyl group and a (C3-C7)-cycloalkyl-O group -(alkylene-C-i-C3)-; R14 is a hydrogen atom or an alkyl-Ci-Cs group; R15 is independently selected from a hydrogen atom, an alkyl-Ci-Cs group that is optionally substituted with one or more substituents selected from a halogen atom, an alkyl-Ci-Cs group, a haloalkyl-C-i-Cs group, a hydroxyalkyl-Ci-Cs, an alkoxy-Ci-Cs group, a haloalkoxy-Ci-Cs group, a heterocycloalkyl group, an aryl group, a (R18)-(heterocycloalkylene)-(arylene)-O- group, an aryl group -O-, an aryl(Ci-C3alkylene)-O- group, a (R19)-S(O)2-arylene-O- group, a (R19)S(O)2heterocycloalkylene-arylene-O- group and an aryl-heteroarylene-O- group; a phenyl group, IF-2019-16843 747-APN-ANP#INPI Page 43 of 720 a groupt—,phalkyl-(Ci-C3) í<\ / A\ ,N-s(0lA, ,, , V—and \— / alkyl-iCj-Ca) a group and a group N N-YesOfe-alkyl-ÍCrCa) where $ is the point of attachment to the nitrogen atom, to which R15 is attached, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring , both optionally comprising one or two additional heteroatoms independently selected from -O- and -NR14-; R16 and R17 are each independently selected from a hydrogen atom, a Ci-Ce alkyl group, a Ci-C6 haloalkyl group, a Ci-Cs alkoxy group, a C3-C5 cycloalkyl group, a Ci-C3 group. alkyl-C(O)-, a group-Ci-C3-alkylS(O)2- and a group Ci-C3-alkyl-O-C(=O)-; R18 is selected from a hydrogen atom, a hydroxy group, a cyano group, a Ci-C3 alkyl group, a Ci-Ce hydroxyalkyl group, a Ci-C3 alkoxy group, a R21OC(O)-(alkylene- Ci-C3-)-, a group -C(O)OR21, a group -C(O)NR20R21, a group (alkyl-Ci-C3)-O-(alkylene-Ci-C3)-C(O)- , a (Ci-C6-alkyl)-C(O)- group and a C3-C6-cycloalkyl-C(O)- group; R19 is selected from a Ci-C3-alkyl group, a C3-Ce cycloalkyl group and an NR20R21 group; and R20 and R21 are each independently selected from a hydrogen atom and a C-i-Ce alkyl group; R22 is independently selected from a halogen atom a Ci-Ce-alkyl group that is unsubstituted substituted with one or more substituents selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3-alkyl group, a haloalkyl-Ci-C3, a hydroxyalkyl group IF-2019-16843 747-APN-ANP#INPI Page 44 of 720 C1-C3, an alkoxy-Ci-Cs group, a haloalkoxy-Ci-Cs group, a cycloalkyl-Ca-Ce group, a heterocycloalkyl group and a phenyl group, a cycloalkyl-Cs-Ce group, a phenyl group, a heterocycloalkyl and a heteroaryl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and a Ci-C4 alkyl group; either R22 and R23 together with the carbon atom to which they are attached form a 3-membered to 6-membered carbocyclic ring or a 3-membered to 6-membered heterocyclic ring comprising one or two heteroatoms selected from nitrogen, oxygen and sulfur; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 10-membered to 12-membered ring and * is the point of attachment of these residues to the atom of IF-2019-16843 747-APN-ANP#INPI Page 45 of 720 indole carbon bearing substituent A; R1 and R2 are each independently selected from a hydrogen atom and a halogen atom; R3 is a hydrogen atom; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two or three substituents and each substituent is independently selected from a halogen atom and a Ci-Cs alkyl group; L is a -(CH2)m-E- group; E is a bond or an oxygen atom and constitutes the connecting element to R4; m is 2, 3, or 4; R5 is a COOH group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##o#-(alkene-C3-C5)-(B)t-CR22R23-#*, where * is the attachment point with the indole nitrogen atom and ## is the attachment point with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-Cs alkyl group, a Ci-haloalkyl group -Cs, an alkoxy-C-i-Cs group, and a haloalkoxy-C-i-Cs group; n is 3, 4 or 5; t is 1; where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of a 10-membered to 12-membered ring regardless of the selection of the variable A1 or A2; B is independently selected from a group -N(R15)- and -O-; R8 is selected from a hydrogen atom, and a Ci-C4 alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Cs-Ce cycloalkyl group and a heterocycloalkyl; IF-2019-16843 747-APN-ANP#INPI Page 46 of 720 R9 is a Ci-C4-alkyl group, a Ci-Cs-hydroxyalkyl group, a Ci-C3-haloalkyl group, a Ci-Cs-O-alkyl group, a Ci-C3-haloalkoxy group, alkyl-O-(alkylene-Ci-C3)-, a cycloalkyl-(C3-C6) group, a group R19-(phenylene)-O-(alkylene-Ci-C3)-, a group NR20R21-(alkylene -Ci-C3)- and a group (alkyl-Ci-C3)-NH-(alkylene-Ci-C3)-; R15 is independently selected from a hydrogen atom and a Ci-Ce alkyl group that is unsubstituted or substituted with a substituent selected from a heterocycloalkyl group and an aryl group; either R15 and R22 together, including the atoms to which they are attached, may form a 5-membered or 6-membered ring, both optionally comprising one or two heteroatoms independently selected from -O- and -NR14-; R16 and R17 each are independently selected from a hydrogen atom, a Ci-C6 alkyl group, a Ci-C6 haloalkyl group and a Ci-C6 alkoxy group; R18 is selected from a hydrogen atom, a hydroxy group, a cyano group, an alkyl-Ci-Cs group, a hydroxyalkyl-C-i-Ce group, an alkoxy-Ci-Cs group, a C(O)OR21-(alkylene) group -Ci-C3-)-, a group -C(O)OR21, a group -C(O)NR20R21, a group (alkyl-Ci-C3)-O-(alkylene-Ci-C3)-C(O) -, a (Ci-C3-alkyl)-C(O)- group and a C3-C6-cycloalkyl-C(O)- group; R19 is selected from a C-t-Cs alkyl group, a Cs-Ce cycloalkyl group and an NR20R21 group; R20 and R21 are each independently selected from a hydrogen atom and an alkyl-Ci-Cs group; R22 is independently selected from a halogen atom an alkyl-Ci-Cs group that is unsubstituted or substituted with a selected group IF-2019-16843 747-APN-ANP#INPI Page 47 of 720 of a hydroxy group, an NR16R17 group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-C4 group, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group; a cycloalkyl-Cs-Ce group, a phenyl group, a heteroaryl group, a heterocycloalkyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a C-i-Cs alkyl group or one or two halogen atoms; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and a Ci-C4 alkyl group, or R22 and R23 together form a 3-membered to 6-membered carbocyclic ring; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom and a halogen atom; IF-2019-16843 747-APN-ANP#INPI Page 48 of 720 R3 is a hydrogen atom; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom and a Ci-C3 alkyl group; L is a -(CH2)m-E- group; E is an oxygen atom and constitutes the connecting element to R4; m is 3; R5 is a COOH group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or *-(alkenylene-C3-C4)-(B)t-CR22R23-##, where#is the point of bonding with the indole nitrogen atom and ** is the point of bonding with the pyrazole carbon atom carrying the R7 substituent; n is 4; t is 1; where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of an 11-membered ring regardless of the selection of the variable A1 or A2; B is independently selected from a group -N(R15)- and -O-; R8 is selected from a hydrogen atom and a Ci-C4 alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Cs-Ce cycloalkyl group and a heterocycloalkyl group. ; R9 is a Ci-C4 alkyl group; R15 is independently selected from a hydrogen atom and a Ci-Ce alkyl group that is unsubstituted or substituted with a heterocycloalkyl group; or R15 and R22 together, including the atoms to which they are attached, may form a 5-membered or 6-membered ring, both optionally comprising one or two heteroatoms independently selected from -O- and -NR14-; IF-2019-16843 747-APN-ANP#INPI Page 49 of 720 R16 and R17 each are independently selected from a hydrogen atom, an alkyl-Ci-Cs group, a haloalkyl-Ci-Ce group and an alkoxy-Ci-Cs group; R22 is independently selected from a halogen atom, a cycloalkyl-Cs-Ce group, a phenyl group and a alkyl-Ci-C5 group that is unsubstituted or substituted with one or more substituents selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl, a Ci-C3 alkoxy group, a Cs-Ce cycloalkyl group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and an alkyl-Ci-Cs group or R22 and R23 together form a 3-6 membered carbocyclic ring; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a IF-2019-16843 747-APN-ANP#INPI Page 50 of 720 11-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom and a halogen atom; R3 is a hydrogen atom; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom and a Ci-Cs alkyl group; L is a -(CH2)m-E- group; E is an oxygen atom and constitutes the connecting element to R4; m is 3; R5 is a COOH group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenelene-C2-C4)-(B)t-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and##is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; n is 4; t is 1 where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of an 11-membered ring regardless of the selection of the variable A1 or A2; B is independently selected from a group -N(R15)- and -O-; R8 is selected from a hydrogen atom and a Ci-C4 alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Cs-Ce cycloalkyl group and a heterocycloalkyl group. ; R9 is a Ci-C4 alkyl group; R15 is independently selected from a hydrogen atom and a Ci-Ce alkyl group. IF-2019-16843 747-APN-ANP#INPI Page 51 of 720 which is unsubstituted or substituted with a heterocycloalkyl group; either R15 and R22 together, including the atoms to which they are attached, may form a 5-membered or 6-membered ring, optionally comprising one or two heteroatoms independently selected from -O- and -NR14-; R16 and R17 each are independently selected from a hydrogen atom, an alkyl-Ci-Cs group, a haloalkyl-Ci-Ce group and an alkoxy-Ci-Cs group; R22 is independently selected from a halogen atom, a cycloalkyl-Cs-Ce group, a phenyl group, an alkyl-Ci-Cs group that is unsubstituted or substituted with one or more substituents selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl group, a Ci-C3 alkoxy group, a Cs-Ce cycloalkyl group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a C-i-Cs alkyl group or one or two halogen atoms; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and a Ci-C31o alkyl group. R22 and R23 together form a 3-membered to 6-membered carbocyclic ring; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where IF-2019-16843 747-APN-ANP#INPI Page 52 of 720 N-N .8' A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ##is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; R8 is a Ci-C3 alkyl group; R9 is a Ci-C3 alkyl group; R15 is a Ci-C3 alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a C3-C6 cycloalkyl group, a phenyl group and a Ci-Cs alkyl group that is unsubstituted or substituted with a substituent. IF-2019-16843 747-APN-ANP#INPI Page 53 of 720 selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl group, an alkoxy-Ci-Cs group, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom and a halogen atom; R3 is a hydrogen atom; R4 is an aryl group, which is unsubstituted or substituted with a halogen atom; L is a -(CH2)m-E- group; E is an oxygen atom and constitutes the connecting element to R4; m is 3; R5 is a COOH group; -R6-R7- es#-(CH2)n-(B)t-CR22R23-##, IF-2019-16843 747-APN-ANP#INPI Page 54 of 720 where # is the point of attachment with the indole nitrogen atom and ° is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; n is 4; t is 1; where the integers selected for the variables n and t, together with the methylene group CR22R23 and the other non-variable atoms of the pyrazole and the indole moiety result in the formation of an 11-membered ring regardless of the selection of the variable A1 or A2; B is independently selected from a group -N(R15)- and -O-; R8 is selected from a hydrogen atom and an alkyl-Ci-Cs group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a cycloalkyl-Cs-Ce group and a heterocycloalkyl group. ; R9 is an alkyl-Ci-Cs group; R15 is independently selected from a hydrogen atom and a C-i-Ce alkyl group that is unsubstituted or substituted with a heterocycloalkyl group; either R15 and R22 together, including the atoms to which they are attached, may form a 5-membered or 6-membered ring, optionally comprising one or two heteroatoms independently selected from -O- and -NR14-; R16 and R17 each are independently selected from a hydrogen atom, an alkyl-Ci-Cs group, a haloalkyl-Ci-Ce group and an alkoxy-Ci-Cs group; R22 is independently selected from a halogen atom, a Cs-Ce cycloalkyl group, a phenyl group, a Ci-C5 alkyl group that is unsubstituted or substituted with one or more substituents selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl group, an alkoxy-Ci-Cs group, a cycloalkyl-Cs-Ce group, a IF-2019-16843 747-APN-ANP#INPI Page 55 of 720 heterocycloalkyl and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-C3 alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein N-N ,8' A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ## is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; R8 is a Ci-C3 alkyl group; IF-2019-16843 747-APN-ANP#INPI Page 56 of 720 R9 is a Ci-C3 alkyl group; R15 is a Ci-C3 alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a C3-C6 cycloalkyl group, a phenyl group, a Ci-Cs alkyl group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a Ci-C3 haloalkyl group, a Ci-C3 alkoxy, a C3-C6 cycloalkyl group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-C3 alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a IF-2019-16843 747-APN-ANP#INPI Page 57 of 720 11-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a group -(Chkh-O-; R5 is a COOH group; -R6-R7- is -(ChU^-O-CR^R23-*#, or «-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ##is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; R8 is an alkyl-Ci-Cs group; R9 is an alkyl-Ci-Cs group; R15 is an alkyl-Ci-Cs group, or Ris and R22 together, including the atoms to which they are bonded, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a cycloalkyl-Cs-Ce group, a phenyl group, a alkyl-Ci-Cs group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a haloC1-C3 alkyl group, a alkoxy-Ci-C3, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is a hydrogen atom; IF-2019-16843 747-APN-ANP#INPI Page 58 of 720 or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ** is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; R8 is an alkyl-Ci-Cs group; R9 is a Ci-C3 alkyl group; R15 is an alkyl-Ci-Cs group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, an alkyl-Ci-Cs group and an alkoxy-Ci-Cs group; IF-2019-16843 747-APN-ANP#INPI Page 59 of 720 R22 is independently selected from a cycloalkyl-Cs-Ce group, a phenyl group, a alkyl-Ci-Cs group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a haloC1-C3 alkyl group, a alkoxy-Ci-Cs, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; IF-2019-16843 747-APN-ANP#INPI Page 60 of 720 -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, where * is the point of attachment to the indole nitrogen atom and ##is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; and R8 is a methyl group; R9 is a methyl group or an ethyl group; R15 is a methyl group; R22 is independently selected from a methyl group, an ethyl group, a hydroxyethyl group, a trifluoromethyl group, a cyclopropyl group, a methoxyethyl group, a 2-hydroxy-2-methyl-propyl group, a 3-hydroxy-3- methylbutyl, a (methoxymethylamino)ethyl group, a (dimethylamino)ethyl group, a (morpholin-4-yl)ethyl group, a 3-(morpholin-4yl)propyl group, a 2-(oxan-4-yl) group )ethyl, a 2-(4-methylpiperazin-1-yl)ethyl group, a 2-(3,3-difluoroazetidin-1 -yl)ethyl group, a 2-(3,3-difluoropyrrolidin-1-yl)ethyl group , a phenyl group, R15 and R22, together with the atoms to which they are attached, form a group, by which ##is the point of attachment with the pyrazole carbon atom that carries the substituent R7 and the nitrogen atom, which is the group -N(R15 ), is linked to the residue #-(CH2)4- of the R6-R7 chain, R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein IF-2019-16843 747-APN-ANP#INPI Page 61 of 720 A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and It is the point of attachment to the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more halogen atoms, R8 is a Ci-C3 alkyl group; R9 is an alkyl-Ci-Cs group; R15 is a Ci-Cs alkyl group,0 R15 and R22 together, including the atoms to which they are attached, can form a 5-membered ring or a 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a cycloalkyl-Cs-Ce group, IF-2019-16843 747-APN-ANP#INPI Page 62 of 720 a phenyl group, a Ci-Cs-alkyl group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl group, a Ci-C3 alkoxy group, a cycloalkyl-Cs-Cs, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a C-i-C3 alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is «-(CHs^-O-CR^R23-44, o#-(CH2)4-NR15-CR22R23-##, IF-2019-16843 747-APN-ANP#INPI Page 63 of 720 where # is the point of attachment with the indole nitrogen atom and ## is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms, R8 is a Ci-C3 alkyl group; R9 is an alkyl-Ci-Cs group; R15 is a Ci-C3 alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, an alkyl-Ci-Ca group and an alkoxy-Ci-Cs group; R22 is independently selected from a cycloalkyl-Cs-Ce group, a phenyl group, a alkyl-Ci-Cs group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a haloC1-C3 alkyl group, a alkoxy-Ci-C3, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a C-i-Cs alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein IF-2019-16843 747-APN-ANP#INPI Page 64 of 720 A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23·-*#, or#-(CH2)4-NR15-CR22R23-##, where#is the point of attachment to the indole nitrogen atom y##is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms, R8 is a Ci-C2 alkyl group; R9 is a Ci-C2 alkyl group; R15 is a Ci-Cs alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; One is independently selected from a hydrogen atom, a Ci-C3 alkyl group, and a Ci-C3 alkoxy group; R22 is independently selected from a cycloalkyl-Cs-Ce group, IF-2019-16843 747-APN-ANP#INPI Page 65 of 720 a phenyl group, a Ci-Cs-alkyl group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl group, a Ci-Cs-alkoxy group, a cycloalkyl-Cs-Ce, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-C3 alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the indole carbon atom bearing substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, IF-2019-16843 747-APN-ANP#INPI Page 66 of 720 where # is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; R8 is a Ci-C3 alkyl group; R9 is a Ci-C3 alkyl group; R15 is a Ci-C3 alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a C3-C6 cycloalkyl group, a phenyl group, a Ci-C5 alkyl group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a Ci-C3 haloalkyl group, an alkoxy group -Ci-C3, a C3-C6 cycloalkyl group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-C3 alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where IF-2019-16843 747-APN-ANP#INPI Page 67 of 720 A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group or a 6-fluoro-naphthyl group; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, or#-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ”* is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; R8 is a C-i-Cs alkyl group; R9 is a C-i-Cs alkyl group; R15 is a Ci-C3 alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a C3-Ce cycloalkyl group, a phenyl group, a Ci-C5 alkyl group that is unsubstituted or substituted with a substituent. IF-2019-16843 747-APN-ANP#INPI Page 68 of 720 selected from a hydroxy group, an NR16R17 group, a C1-C3 haloalkyl group, an alkoxy-Ci-Cs group, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-Cs alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is selected from **-(0142)4-0-014(043)-***,#-(CH2)4-O-CH(CH2CH3)-***, *-(CH2) 4-OΟΗ(ΟΡ3)-**; *-(ΟΗ2)4-Ο-ΟΗ[(ΟΗ2)2-ΟΗ]-##,#-(ΟΗ2)4-Ο-ΟΗ[ΟΗ2-Ο(ΟΗ3)2ΟΗ]-***, *-(CH2 )4-O69 IF-2019-16843 747-APN-ANP#INPI Page 69 of 720 CH[(CH2)2-C(CH3)2OH]-##,#-(CH2)4-O-CH[(CH2)2-OCH3]-##,#-(CH2)4-O-CH[ (CH2)2N(CH3)2]-**,#-(CH2)4-O-CH[(CH2)2-N(CH3)OCH3]-##,#-(CH2)4-O-CH( cyclopropyl)-##,#-(CH2)4-O-CH[(CH2)2-morpholino]-*#,#-(CH2)4-O-CH[(CH2)3-morpholino]-##, #-(CH2)4-OCH[(CH2)2-oxan-4-yl]-##,#-(CH2)4-O-CH[(CH2)2-4-methyl-piperazin-1 -¡I ]-**,#-(CH2)4-OCH[(CH2)2-(3,3-difluoropyrrolidin-1-yl)]-##,#-(CH2)4-O-CH[(CH2)2 -(3,3-difluoroazetidin-1¡I)].##, #-(CH2)4-O-CH-phenyl-##,#-(CH2)4-O-CH-benzyl-##,# -(CH2)2-CF2-CH2-O-CH[(CH2)2morpholino)]-*#,#-(CH2)4-N(CH3)-CH[(CH2)2-morpholino]-##,# -(CH2)4-N(CH3)-CH[(CH2)2- where * is the point of attachment with the indole nitrogen atom and is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; IF-2019-16843 747-APN-ANP#INPI Page 70 of 720 R5 is a COOH group; -R6-R7- is selected from#-(CH2)4-O-CH(CH3)-##,#-(CH2)4-O-CH(CH2CH3)-##,#-(CH2)4-OCH (CF3)-##;#-(CH2)4-O-CH[(CH2)2-OH]-##,#-(CH2)4-O-CH[CH2-C(CH3)2OH]-# #, *-(CH2)4-OCH[(CH2)2-C(CH3)2OH]-##,#-(CH2)4-O-CH[(CH2)2-OCH3]-##,#- (CH2)4-O-CH[(CH2)2- N(CH3)2]-*,#-(CH2)4-O-CH[(CH2)2-N(CH3)OCH3]-##,#-(CH2)4-O-CH(cycloprop¡l) -##,#-(CH2)4-O-CH[(CH2)2-morpholino]-##,#-(CH2)4-O-CH[(CH2)3-morpholino]-##,#- (CH2)4-OCH[(CH2)2-oxan-4-yl]-##,#-(CH2)4-O-CH[(CH2)2-4-methyl-piperazin-1 -yl]-* *,#-(CH2)4-OCH[(CH2)2-(3,3-difluoropyrrolidin-1-yl)]-##,#-(CH2)4-O-CH[(CH2)2-(3 ,3-difluoroazetidin-1¡I)].##,#-(CH2)4-O-CH-phenyl-##,#-(CH2)4-O-CH-benzyl-##,#- (CH2)2-CF2-CH2-O-CH[(CH2)2morpholino)]-#*,#-(CH2)4-N(CH3)-CH[(CH2)2-morpholino]-##,#- (CH2)4-N(CH3)-CH[(CH2)2- oxetan-4-yl]-**,#-(CH2)4-[1 -piperadin-2-yl]-**, and#- (CH2)4-[1 -pyrrolidin-2-yl]-**, where # is the point of attachment with the indole nitrogen atom and is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where A is (A1) or IF-2019-16843 747-APN-ANP#INPI Page 71 of 720 where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9 to 16 membered ring and * is the point of attachment of these residues to the indole carbon atom that carries the substituent A; either A is (A3) where optionally one or two of the groups selected from CR11, CR12 and CR13 are replaced by a nitrogen atom, wherein R6 and R10, together with three carbon atoms of the phenyl ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a ring of 9 to 16 members and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R3 is selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group, a Ci-C3 haloalkyl group, a Ci-C3 alkoxy group, a Ci-C3 alkylthio group, a -S(O)-(alkyl-Ci-C3) group, a -S(O)2-(alkyl-Ci-C3) group, a haloalkoxy-Ci-C3 group, a haloalkylthio-Ci-C3 group, and a cycloalkyl group -C3-Cs; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three, four or five substituents and each substituent is independently selected from a halogen atom, a cyano group, a alkyl-Ci-C3 group, a haloalkyl-Ci-C3 group, an alkoxy-Ci-C3 group, a thioalkyl-Ci-C3 group, a haloalkoxy-Ci-C3 group, a (Ci-C3)-haloalkyl-S group - and a cycloalkyl-C3-Cs group; L is a -(CH2)m-E- group wherein any CH2 group is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, a Ci-alkyl group -C3and an alkoxy group-Ci-C3, or two substituents are taken IF-2019-16843 747-APN-ANP#INPI Page 72 of 720 optionally together with their intermediate atoms to form a saturated or partially unsaturated 3-6 membered cycloalkyl ring, or a saturated or partially unsaturated 3-8 membered heterocyclic ring having 1-2 heteroatoms independently selected from one atom of oxygen, a sulfur atom, a -S(O)- group, a -S(O)2- group and a -NR14- group; E is a bond, an oxygen atom, a sulfur atom, an -S(O)- group, an S(O)2- group or a -NR14- group and constitutes the connecting element to R4, m is 2 , 3, or 4; ♦ N N \ / / N-N |_j R5 is selected from a COOH group, a -C(O)NHS(O)2(alkyl-Ci-C6) group, a -C(O)-NHS(O)2 group (C3-C6 cycloalkyl), a -C(O)NHS(O)2(aryl) group, a -C(O)-NHS(O)2(CH2)sNHCO(Ci-C6 alkyl) group, a -C(O)NHS(O)2(CH2)sNHCO(C3-C6-cycloalkyl) group and a -C(O)NHS(O)2(CH2)sNHCO(anlo) group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or#-(C2-C9-alkenylene)-(B)t-CR22R23-##, where#is the point of union with the indole nitrogen atom and is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-Cs-alkyl group, a C-i-haloalkyl group -Cs, an alkoxy-C-i-Cs group, a haloalkoxy-Ci-Cs group, a cycloalkyl-Cs-Cs group and a (heterocycloalkyl)-(alkylene-Ci-C3)- group; -R6-R10- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenylene-C2-C9)-(B)t-CR22R23-##, where one or more -CH2 groups - are substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, an alkyl-Ci-Cs group, a haloalkyl-C-i-Cs group, an alkoxy-C-i-Cs group and a haloalkoxy group -Ci-Cs, where # is the point of attachment to the indole nitrogen atom and ** is the point of attachment to the carbon atom of the phenyl residue carrying the R10 substituent; n is 2, 3, 4, 5, 6, 7, 8, or 9; IF-2019-16843 747-APN-ANP#INPI Page 73 of 720 t is 1; s is O, 1 or 2; where the integers selected for the variables n and t result in the formation of a ring of 9 to 16 members regardless of the selection of the variable A1, A2 or A3; B is independently selected from a group -C(O)NR15-, a group -NR15C(O)-, a group -N(R15)-, a group -N(R15)-C(=O)-N(R15 )-, a group -O-C(=O)-N(R15)-, a group -N(R15)-C(=O)-O-, -O-, -S-, -S(O)- and -S(O)2-; R8 is selected from a hydrogen atom, a Ci-Ce alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-C3 alkoxy group, a haloalkoxy-Ci-C3, a cycloalkyl-C3-C6 group, a heterocycloalkyl group and an NR21R22y group a haloalkyl-Ci-C3 group, a cycloalkyl-C3-C6 group, and a alkyl-Ci-Cs group in which one or two non-directly adjacent carbon atoms are independently replaced by a heteroatom selected from -O- and -NH-, R9 is selected from a hydrogen atom, a Ci-C4 alkyl group, a Ci-C3 hydroxyalkyl group, a Ci-C4 haloalkyl group, a Ci-C4 haloalkyl group-NH-C(O)-O-( alkylene-Ci-C3)-, a haloalkenyl-C2-Ce group, a group Ci-C6-alkyl-O-, a haloalkoxy-Ci-C4 group, a group Ci-C6-alkyl-O-(alkylene-Ci- C3)-, a (C3-C7)-cycloalkyl group, a (C3-C7)-cycloalkyl-O-(C3-C3alkylene)- group, IF-2019-16843 747-APN-ANP#INPI Page 74 of 720 a phenyl group-O-(alkylene-Ci-C3)-, a phenyl group-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group R18- (phenylene)-(alkylene-Ci-C3)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)-O-(alkylene-Ci-C3)-, a group R18-(phenylene)- (heteroarylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(alkylene-Ci-C3)-, a group (R18)-(heterocycloalkylene)-(phenylene)-O- (Ci-C3alkylene)-, a (heterocycloalkenyl)-(phenylene)-O-(Ci-C3alkylene)- group, a (R18)-(heteroarylene)-(Ci-C3alkylene) group )-O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2- (phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-NH-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)- S(O)2-NH-(phenylene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-N(alkyl-Ci-C6)-(phenylene)- O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(heterocycloalkylene)-(phenylene)-O-(alkylene-Ci-C3)-, a group (R18 )-(heterocycloalkylene)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R19)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group (R18)-(heteroarylene )-O-(alkylene-Ci-C3)-, a group (R19)-S(O)2-(heteroanlene)-O-(alkylene-Ci-C3)-, a group (R19)-S(O) 2-(heterocycloalkylene)-(heteroarylene)-O-(alkylene-Ci-C3)-, a group NR20R21-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-NH-(alkylene -Ci-C3)-, a group (haloalkyl-Ci-C3)-(alkylene-Ci-C3)-NH-(alkylene-Ci-C3)-, a group (haloalkyl-Ci-C3)-NH-(alkylene -Ci-C3)-, a group (alkyl-Ci-C3)-NH-C(O)-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-NR15-C(O)- (alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-C(O)-NH-(alkylene-Ci-C3)-, a group (alkyl-Ci-C3)-C(O)- NR15-(alkylene-Ci-C3)-, N“(alkylene-Ci-C3) a group a group IF-2019-16843 747-APN-ANP#INPI Page 75 of 720 N— (alkylene-Ci-Cs), where the phenyl ring is unsubstituted or substituted with a halogen atom, a hydroxy group or an alkoxy-Ci-Cs group and the heterocycloalkyl group is unsubstituted or substituted with a oxo group (=0) is either unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-Cs group and an alkoxy-Ci-Cs group, or R8 and R9 together form a 5-membered or 6-membered ring optionally comprising one or two heteroatoms independently selected from -O- and NR14-; R11 and R13 are each independently selected from a hydrogen atom, a halogen atom, a Ci-Cs alkyl group and a Ci-C3 alkoxy group; R12 is selected from a hydrogen atom, an alkoxy-Ci-Cs group, an alkyl-CiC3 group, a haloalkyl-C-i-Cs group, a haloalkoxy-Ci-Cs group and an NR16R17 group; R14 is a hydrogen atom or an alkyl-Ci-Cs group; R15 is independently selected from a hydrogen atom, a Ci-Ce-alkyl group that is unsubstituted or substituted with one or more substituents selected from a halogen atom, a Ci-C3-alkyl group, a CiC3-haloalkyl group, a hydroxyalkyl-C-i-Cs, an alkoxy-C-i-Cs group, a haloalkoxyC1-C3 group, a heterocycloalkyl group, an aryl group, a (R18)(heterocycloalkylene)-(arylene)-O- group, a (heterocycloalkyl)- group (arylene)-O, an aryl-O- group, an aryl-(alkylene-Ci-C3)-O- group, a (R19)-S(O)2arylene-O- group, a (R19) group S(O)2-heterocycloalkylene-arylene-O-, an aryl-heteroarylene-O- group, an anlo-heteroarylene-O-(alkylene-Ci-C3)- group, a heterocycloalkyl-(alkylene-O-) group Ci-C3)-C(O)-, a heterocycloalkyl-NH-C(O)- group, an anlo-(alkylene-Ci-C3)-NH-C(O)- group, a heterocycloalkylene-(alkylene- Ci-C3)-S(O)2- and a heterocycloalkylene-heteroarylene-S(O)2- group; a Ci-C3-alkylene-C(O)- group, IF-2019-16843 747-APN-ANP#INPI Page 76 of 720 a heterocycloalkyl group-(alkylene-Ci-C3)-C(O)-, a heterocycloalkyl group-(alkylene-Ci-C3)-S(O)2-, a heterocyclyl group-NH-C(O) )-, a heterocycloalkyl group-(alkylene-Ci-C3)-NH-C(O)-, an aryl group-(alkylene-Ci-C3)-NH-C(O)-, which is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from a halogen atom, an alkyl-Ci-Cs group and an alkoxy-Ci-C3 group, a heterocycloalkyl-heteroarylene-S(O)2- group, a phenyl group , alkyl-fCi-C)} -S(Oh-N alkyl-fCi-Cj) a group and a group N N— SjOfe-alkyl-ÍCi-Cj) where $ is the point of attachment to the nitrogen atom, to which R15 is attached; R16 and R17 are each independently selected from a hydrogen atom, a Ci-Ce-alkyl group, a C-i-Ce haloalkyl group, a Cs-Cs cycloalkyl group, a Ci-C3-C(O)-alkyl group, a Ci-C3-alkylS(O)2- group and a Ci-C3-alkyl-O-C(=O)R18 group is selected from a hydrogen atom, a hydroxy group, a cyano group, an alkyl-Ci-Cs group, a hydroxyalkyl-Ci-Ce group, an alkoxy-Ci-Cs group, a R21OC(O)-(alkylene-Ci-C3-)- group, a -C(O)OR21 group, a -C(O)NR20R21 group , a group (alkyl-Ci-C3)-O-(alkylene-Ci-C3)-C(O)-, a group (alkyl-Ci-Ce)-C(O)- and a group C3-C6-cycloalkyl crazy)-; R19 is selected from a C3-C3 alkyl group, a C3-C6 cycloalkyl group and a IF-2019-16843 747-APN-ANP#INPI Page 77 of 720 NR20R21; R20 and R21 are each independently selected from a hydrogen atom and a Ci-Ce alkyl group; R22 is independently selected from a halogen atom, a Ci-Ce-alkyl group that is unsubstituted or substituted with one or more substituents selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3-alkyl group , a Ci-C3 haloalkyl group, a Ci-C3 hydroxyalkyl group, a Ci-C3 alkoxy group, a Ci-C3 haloalkoxy group, a C3-C6 cycloalkyl group, a heterocycloalkyl group, an aryl group, a ( R18)(heterocycloalkylene)-(arylene)-O-, a group (heterocycloalkyl)-(arylene)-O, an aryl group-O-, an aryl group-(alkylene-Ci-C3)-O-, a group ( R19)-S(O)2arylene-O-, a group (R19)S(O)2-heterocycloalkylene-arylene-O-, an aryl-heteroarylene-O- group, an arylo-heteroarylene-O-( alkylene-Ci-C3)-, a heterocycloalkyl group-(alkylene-Ci-C3)-C(O)-, a heterocycloalkyl group-NH-C(O)-, an aryl group-(alkylene-Ci -C3)-NH-C(O)-, a heterocycloalkylene group-(alkylene-Ci-C3)-S(0)2- and a heterocycloalkylene-heteroarylene-S(O)2- group; and a Ci-C3-alkyl-C(O)- group; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group, a Ci-Ce alkyl group and a Ci-Ce haloalkyl group, or R22 and R23 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring or a 3-6 membered heterocyclic ring comprising one or two heteroatoms selected from nitrogen, oxygen or sulfur; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of IF-2019-16843 747-APN-ANP#INPI Page 78 of 720 the general formula (I): where A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 9 to 13 membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-Cs alkyl group and a Ci-C3 alkoxy group; R3 is selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group, a Ci-C3 haloalkyl group, a Ci-C3 alkoxy group and a C3-Cs cycloalkyl group; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three, four or five substituents and each substituent is independently selected from a halogen atom, a cyano group, a alkyl-Ci-C3 group, a haloalkyl-Ci-C3 group, an alkoxy-C-i-C3 group and a cycloalkyl-Cs-Cs group; L is a -(CH2)m-E- group wherein any CH2 group is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, a Ci-alkyl group -C3 and an alkoxy-Ci-C3 group; E is a bond, an oxygen atom, a sulfur atom, or a -NR14- group and constitutes the connecting element to R4; m is 2, 3, or 4; IF-2019-16843 747-APN-ANP#INPI Page 79 of 720 * N ft' N \ u N-N R5 is selected from a COOH group and a H group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenylene-C2-C9)-(B)t-CR22R23-##, where#is the point of bonding with the indole nitrogen atom and ** is the point of bonding with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3 alkyl group, a Ci-haloalkyl group -C3, a Ci-C3 alkoxy group, and a Ci-C3 haloalkoxy group; n is 2, 3,4,5 or 6; t is 1 where the integers selected for variables n and t result in the formation of a 9- or 13-membered ring regardless of the selection of variable A1 or A2; B is independently selected from a group -C(O)NR15-, a group -NR15C(O)-, a group -N(R15)-, a group N(R15)-C(=O)-N(R15) -, a group -O-C(=O)-N(R15)-, a group -N(R15)-C(=0)-0-, O-, -S-, -S(0)- and -S(0)2-; R8 is selected from a hydrogen atom, and a C-i-Ce alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-C3 alkoxy group, a haloalkoxy-Ci-C3 group, a cycloalkyl-C3-C6 group, a heterocycloalkyl group and an NR20R21 group; R9 is selected from a hydrogen atom, a Ci-C4 alkyl group, a Ci-C3 hydroxyalkyl group, a Ci-C4 haloalkyl group, a Ci-C4 haloalkyl group-NH-C(O)-O-( alkylene-Ci-C3)-, a haloalkenyl-C2-Ce group, IF-2019-16843 747-APN-ANP#INPI Page 80 of 720 a group Ci-Ce-alkyl-O-, a group haloalkoxy-Ci-C4, a group Ci-C6-alkyl-O-(alkylene-Ci-C3)-, a group (alkyl-Ci -C3)-NH-(Ci-C3-alkylene)-, a (C3-C7)-cycloalkyl group and a (C3-C7)-cycloalkyl-O-(Ci-C3-alkylene)- group; R14 is a hydrogen atom or a Ci-C3 alkyl group; R15 is independently selected from a hydrogen atom, a Ci-C6 alkyl group which is optionally substituted with one or more substituents selected from a halogen atom, a Ci-C3 alkyl group, a Ci-C3 haloalkyl group, a hydroxyalkyl group -Ci-C3, an alkoxy-Ci-C3 group, a haloalkoxy-Ci-C3 group, a heterocycloalkyl group, an aryl group, a (R18)-(heterocycloalkylene)-(arylene)-O- group, an aryl group- O-, an aryl(Ci-C3alkylene)-O- group, a (R19)-S(O)2-arylene-O- group, a (R19)S(O)2heterocycloalkylene-arylene-O- group and an aryl-heteroarylene-O- group; a phenyl group, a group where $ is the point of attachment to the nitrogen atom, to which R15 is attached, R16 and R17 are each independently selected from a hydrogen atom, a Ci-C6 alkyl group, a Ci-C6 haloalkyl group, a C3-C5 cycloalkyl group, a Ci-C3-C alkyl group ( O)-, a Ci-C3-alkylS(O)2- group and a Ci-C3-alkyl-O-C(=O) group81 IF-2019-16843 747-APN-ANP#INPI Page 81 of 720 R18 is selected from a hydrogen atom, a hydroxy group, a cyano group, an alkyl-Ci-Cs group, a hydroxyalkyl-Ci-Ce group, an alkoxy-Ci-Cs group, a R21OC(O)-(alkyl) group leno-Ci-C3-)-, a group -C(O)OR21, a group -C(O)NR20R21, a group (alkyl-Ci-C3)-O-(alkylene-Ci-C3)-C(O )-, a (Ci-Ce-alkyl)-C(O)- group and a C3-C6-cycloalkyl-C(O)- group; R19 is selected from an alkyl-Ci-Cs group, a cycloalkyl-Cs-Ce group and an NR20R21 group; and R20 and R21 are each independently selected from a hydrogen atom and a Ci-Ce alkyl group; R22 is independently selected from a halogen atom a Ci-C6 alkyl group that is unsubstituted substituted with one or more substituents selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3 alkyl group, a haloalkyl group -Ci-C3, a hydroxyalkylC1-C3 group, an alkoxy-Ci-C3 group, a haloalkoxy-Ci-C3 group, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and a phenyl group, a cycloalkyl-Cs-Ce group , a heterocycloalkyl group, a phenyl group and a heteroaryl group; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and a Ci-C4 alkyl group; either R22 and R23 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring or a 3-6 membered heterocyclic ring comprising one or two heteroatoms selected from nitrogen, oxygen or sulfur; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of IF-2019-16843 747-APN-ANP#INPI Page 82 of 720 the general formula (I): where A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form a 10 to 12 membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 and R2 are each independently selected from a hydrogen atom and a halogen atom; R3 is a hydrogen atom; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two or three substituents and each substituent is independently selected from a halogen atom and a Ci-C3 alkyl group; L is a -(CH2)m-E- group; E is a bond or an oxygen atom and constitutes the connecting element to R4, m is 2, 3, or 4; R5 is a COOH group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##o#-(alkenylene-C2-C9)-(B)t-CR22R23-##, where * is the point of bonding with the indole nitrogen atom and *# is the point of bonding with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a C-i-Cs alkyl group, a Ci-haloalkyl group -Cs, an alkoxy-C-i-Cs group, and a haloalkoxy-C-i-Cs group; n is 3, 4 or 5; t is 1; IF-2019-16843 747-APN-ANP#INPI Page 83 of 720 where the integers selected for the variables n and t result in the formation of a 10- or 12-membered ring regardless of the selection of variable A1 or A2; B is independently selected from a group -N(R15)- and -O-; R8 is selected from a hydrogen atom, a Ci-C4 alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Cs-Ce cycloalkyl group and a heterocycloalkyl group. ; R9 is an alkyl-Ci-C4 group, a hydroxyalkyl-Ci-Cs group, a haloalkyl-Ci-Cs group, a Ci-Cs-alkyl-O- group, a haloalkoxy-Ci-Cs group, a Ci-C3- group alkyl-O-(alkylene-Ci-C3)-, a cycloalkyl-(C3-C6) group, a group R19-(phenylene)-O-(alkylene-Ci-C3)-, a group NR20R21-(alkylene -Ci-C3)- and a group (alkyl-Ci-C3)-NH-(alkylene-Ci-C3)-; R15 is independently selected from a hydrogen atom and a Ci-Ce alkyl group that is unsubstituted or substituted with a substituent selected from a heterocycloalkyl group and an aryl group; R16 and R17 are each independently selected from a hydrogen atom, a Ci-Ce alkyl group, a Ci-Ce haloalkyl group; R18 is selected from a hydrogen atom, a hydroxy group, a cyano group, a Ci-C3 alkyl group, a Ci-C6 hydroxyalkyl group, a Ci-C3 alkoxy group, a C(O)OR21 group. (alkylene-Ci-C3-)-, a group -C(O)OR21, a group -C(O)NR20R21, a group (alkylene-Ci-C3)-O-(alkylene-Ci-C3)-C( O)-, a (Ci-C3-alkyl)-C(O)- group and a C3-C6-cycloalkyl-C(O)- group; R19 is selected from a Ci-C3 alkyl group, a Cs-Ce cycloalkyl group and an NR20R21 group; IF-2019-16843 747-APN-ANP#INPI R2° and R21cac|a are independently selected from a hydrogen atom and a C-i-Cs alkyl group; and R22 is independently selected from a halogen atom, a Ci-C4 alkyl group that is unsubstituted or substituted with a group selected from a hydroxy group, an NR16R17 group, a Ci-C4 alkoxy group, a Cs-Ce cycloalkyl group , a heterocycloalkyl group and a phenyl group; a phenyl group, a heteroaryl group, a cycloalkyl-Cs-Ce group, and a heterocycloalkyl group, R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and a Ci-C4 alkyl group or R22 and R23 together form a 3-6 membered carbocyclic ring; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the carbon atom IF-2019-16843 747-APN-ANP#INPI Page 85 of 720 indole carrying substituent A; R1 and R2 are each independently selected from a hydrogen atom and a halogen atom; R3 is a hydrogen atom; R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom and a Ci-C3 alkyl group; L is a -(CH2)m-E- group; E is an oxygen atom and constitutes the connecting element to R4, m is 3; R5 is a COOH group; -R6-R7- is#-(CH2)n-(B)t-CR22R23-##or#-(alkenylene-C2-C9)-(B)t-CR22R23-##, where#is the point of bonding with the indole nitrogen atom and##is the point of bonding with the pyrazole carbon atom carrying the R7 substituent; n is 4 or 5; t is 1 where the integers selected for variables n and t result in the formation of an 11-membered ring regardless of the selection of variable A1 or A2; B is independently selected from a group -N(R15)- and -O-; R8 is selected from a hydrogen atom and a Ci-C4 alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a C3-C6 cycloalkyl group and a heterocycloalkyl; R9 is a Ci-C4 alkyl group; R15 is independently selected from a hydrogen atom and a Ci-Ce alkyl group that is unsubstituted or substituted with a heterocycloalkyl group; IF-2019-16843 747-APN-ANP#INPI Page 86 of 720 R22 is independently selected from a halogen atom, a phenyl group, a C3-C6 cycloalkyl group, a Ci-C3 alkyl group that is unsubstituted or substituted with one or more substituents selected from a hydroxy group, an NR17R18 group, a Ci-C3 haloalkyl, a Ci-C3 alkoxy group, a C3-C6 cycloalkyl group, a heterocycloalkyl group and a phenyl group; R23 is independently selected from a hydrogen atom, a halogen atom, a hydroxy group and a Ci-C3 alkyl group, or R22 and R23 together form a 3-6 membered carbocyclic ring; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the indole carbon atom bearing substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; IF-2019-16843 747-APN-ANP#INPI Page 87 of 720 R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and ## is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently of a halogen atom; R8 is a Ci-Cs alkyl group, which is unsubstituted or substituted with a heterocycloalkyl group; R9 is a C-i-Cs alkyl group; R22 is a Ci-C3 alkyl group, which is unsubstituted or substituted with a heterocycloalkyl group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R8 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the indole carbon atom bearing substituent A; R1 and R2 are each independently selected from a hydrogen atom, an atom IF-2019-16843 747-APN-ANP#INPI of fluorine and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R8-R7- is#-(CH2)4-O-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and is the point of attachment with the pyrazole carbon atom that carries the substituent R7; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-C3 alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C3 alkyl group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the carbon atom IF-2019-16843 747-APN-ANP#INPI Page 89 of 720 indole carrying substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is “-(CH^-O-CR^R23-*#, where #is the point of attachment with the indole nitrogen atom and ##is the point of attachment with the pyrazole carbon atom that carries the substituent R7; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-C2 alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C2 alkyl group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two atoms IF-2019-16843 747-APN-ANP#INPI Page 90 of 720 carbon of the indole residue and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries the substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group, substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, where#is the point of attachment with the indole nitrogen atom and##is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-C2 alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C2 alkyl group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein N-N N-N 'o8„8A is (A1) or (A2) IF-2019-16843 747-APN-ANP#INPI Page 91 of 720 where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment from these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a 6-fluoro-naphthyl group; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and ° is the point of attachment with the pyrazole carbon atom that carries the substituent R7; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-C2 alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C2 alkyl group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein IF-2019-16843 747-APN-ANP#INPI Page 92 of 720 where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment from these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a group -(CH2)3-NR15-; R5 is a COOH group; -R6-R7- is#-(CH2)4-N(R15)-CR22R23-##, where#is the point of attachment with the indole nitrogen atom and##is the point of attachment with the carbon atom pyrazole bearing the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom; R8 is a Ci-C3 alkyl group that is unsubstituted or substituted with a heterocycloalkyl group; R9 is a Ci-C3 alkyl group; R15 is independently selected from a hydrogen atom and a Ci-C3-alkyl group, which is unsubstituted or substituted with a heterocycloalkyl group or a Ci-C3-haloalkyl group; R22 is a Ci-C3 alkyl group, which is unsubstituted or substituted with a heterocycloalkyl group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of IF-2019-16843 747-APN-ANP#INPI Page 93 of 720 the general formula (I): where A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-N(R15)-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ** is the point of attachment to the carbon atom pyrazole bearing the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-Cs alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is an alkyl-Ci-Cs group; R15 is selected from a hydrogen atom, a methyl group, a CH2CF3 group and a CH2CHF2 group; R22 is selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; IF-2019-16843 747-APN-ANP#INPI Page 94 of 720 or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the indole carbon atom bearing substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is «-(CH^-NÍR^-CR^R23-##, where #is the point of attachment with the indole nitrogen atom and ##is the point of attachment with the pyrazole carbon atom carrying the substituent R7; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-C2 alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C2 alkyl group; IF-2019-16843 747-APN-ANP#INPI Page 95 of 720 R15 is independently selected from a hydrogen atom, a methyl group, a CH2CF3 group and a CH2CHF2 group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a naphthyl group that is unsubstituted with a fluorine atom; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-N(R15)-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and ## is the point of attachment to the carbon atom pyrazole bearing the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; IF-2019-16843 747-APN-ANP#INPI Page 96 of 720 R8 is a Ci-Ca alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C2 alkyl group; R15 is independently selected from a hydrogen atom, a methyl group, a CH2CF3 group and a CH2CHF2 group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is a 6-fluoro-naphthyl group; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- es#-(CH2)4-N(R15)-CR22R23-##, IF-2019-16843 747-APN-ANP#INPI Page 97 of 720 where # is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more fluorine atoms; R8 is a Ci-C2 alkyl group, which is unsubstituted or substituted with a morpholino group or a piperazine group; R9 is a Ci-C2 alkyl group; R15 is independently selected from a hydrogen atom, a methyl group, a CH2CF3 group and a CH2CHF2 group; R22 is independently selected from a methyl group and a -(CH2)2-morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where r9-^X_,r7\ / / N-N R8' A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is naphthyl which is unsubstituted or substituted with a fluorine atom; IF-2019-16843 747-APN-ANP#INPI Page 98 of 720 L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- es#-(CH2)4-O-CR22R23-##; R8 is an alkyl-Ci-Cs group; R9 is a Ci-C3 alkyl group; R22 is independently selected from a haloCi-C3alkyl group and a C1-C3alkyl group that is unsubstituted or substituted with a hydroxy group, a C3-Cs cycloalkyl group, or a heterocyclyl group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where N-N .8' A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is selected from naphthyl and 6-fluoro-naphth-1 -yl; L is a -(CH2)3-O- group; IF-2019-16843 747-APN-ANP#INPI Page 99 of 720 R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and ## is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; R8 is a Ci-C3 alkyl group; R9 is a Ci-C3 alkyl group; R22 is independently selected from a haloCi-C3alkyl group and a Ci-C3alkyl group that is unsubstituted or substituted with a hydroxy group, a C3-C5cycloalkyl group, or a heterocyclyl group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): wherein where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the indole carbon atom bearing substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R3 is a hydrogen atom; R4 is selected from naphthyl and 6-fluoro-naphth-1-yl; L is a -(CH2)3-O- group; 100 IF-2019-16843 747-APN-ANP#INPI Page 100 of 720 R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; R8 is a methyl group; R9 is selected from a methyl group and an ethyl group; R22 is independently selected from a methyl group, an ethyl group, a hydroxyethyl group, a -(CH2)2-morpholino group, a trifluoromethyl group and a cyclopropyl group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom; R? It is a hydrogen atom; R4 is selected from naphthyl and 6-fluoro-naphth-1-yl; 101 IF-2019-16843 747-APN-ANP#INPI Page 101 of 720 L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##, where# is the point of attachment with the indole nitrogen atom and ## is the point of attachment with the pyrazole carbon atom that carries the R7 substituent; R8 is a methyl group; R9 is selected from a methyl group and an ethyl group; R22 is independently selected from a methyl group, an ethyl group, a hydroxyethyl group, a trifluoromethyl group, a cyclopropyl group and a -(CH2)2morpholino group; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; 102 IF-2019-16843 747-APN-ANP#INPI Page 102 of 720 R4 is selected from naphthyl and 6-fluoro-naphth-1-íl; L is a group -(Chhh-O-; R5 is a COOH group; -R8-R7- is#-(CH2)4-O-CH(CH3)-##,#-(CH2)4-O-CH[(CH2)2-morpholino]-##,#-(CH2) 4-OCH[(CH2)2-N-methylp¡perazino]-##,#-(CH2)4-O-CH[(CH2)2-pyrrolidino]-##,#-(CH2)4-O- CHjcyclopropyl)-***,#-(CH2)4-O-CH[(CH2)2-cyclopropyl]-##,#-(CH2)4-O-CH[(CH2)2-OCH3]-** ,#-(CH2)4-O-CH[(CH2)2-OH]-##,#-(CH2)4-O-CH(CH2CH3)-##, o#-(CH2)4-OCHjCFs) -***; where # is the point of attachment with the indole nitrogen atom and #* is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; R8 is a methyl group; R9 is selected from a methyl group and an ethyl group; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where A is where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these moieties to the indole carbon atom bearing substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is selected from naphthyl and 6-fluoro-naphthalin-1-yl; 103 IF-2019-16843 747-APN-ANP#INPI Page 103 of 720 L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is selected from **-(0142)4-0-014(0143)-***, *-(CH2)4-O-CH[(CH2)2-morpholino]-***, **-(CH2)4-O-CH(c¡clopropyl)-****, *-(ΟΗ2)4-0-ΟΗ[(ΟΗ2)2-ΟΗ]-***, *-(CH2) 4-O-CH(CH2CH3)-** and *-(CH2)4-O-CH(CF3)-##; where * is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; R8 is a methyl group; R9 is selected from a methyl group and an ethyl group; or a tautomer, or a salt thereof, or a salt of a tautomer or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where A is (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom carrying substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is a naphthyl group that is unsubstituted or substituted with a fluorine atom; L is a group -(Chkjs-O-; R5 is a COOH group; 104 IF-2019-16843 747-APN-ANP#INPI Page 104 of 720 -R6-R7- is#-(CH2)4-O-CR22R23-##or#-(CH2)4-NR15-CR22R23-##, where# is the point of attachment to the indole nitrogen atom and * # is the point of attachment to the pyrazole carbon atom carrying the R7 substituent; R8 is a Ci-C3 alkyl group; R9 is a Ci-C3 alkyl group; R15 is a Ci-C3 alkyl group, or R15 and R22 together, including the atoms to which they are attached, can form a 5-membered or 6-membered ring; R16 and R17 are each independently selected from a hydrogen atom, a Ci-C3 alkyl group and a Ci-C3 alkoxy group; R22 is independently selected from a C3-C4 cycloalkyl group, a phenyl group, a C-i-Cs alkyl group that is unsubstituted or substituted with a substituent selected from a hydroxy group, an NR16R17 group, a Ci-C3 haloalkyl group, a alkoxy-Ci-C3, a heterocycloalkyl group and a phenyl group; whereby any heterocycloalkyl group of R22 may be optionally further substituted with a Ci-C3 alkyl group or one or two halogen atoms; R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where 105 IF-2019-16843 747-APN-ANP#INPI Page 105 of 720 A is N-N R8(A1) (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is selected from naphthyl and 6-fluoro-naphth-1 -yl; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is selected from#-(CH2)4-O-CH(CH3)-##, «-(CH^-O-CHKCHzXoxan^-il)]-^,#-(CH2)4-O -CH[(CH2)2-morpholino]-##,#-(CH2)4-O-CH[(CH2)2-(4-methylp¡peraz¡n-1-yl)]-##,#- (CH2)4-O-CH[(CH2)2-(3,3-difluoropyrrolidin-1-yl)]-##,#-(CH2)4-O-CH[(CH2)2-(3fluoroazetid ¡n-1 -yl)]-**,#-(CH2)4-O-CH[(CH2)2-(3,3-difluoroazetidin-1 -yl)]-**,#-(CH2)4 -OCH(cyclopropyl)-**,#-(CH2)4-O-CH(phenyl)-*#, *-(CH2)4-O-CH(CH2-phenyl)-**,#-( CH2)4-OCH[(CH2)3-morpholino]-##, #-(CH2)4-O-CH[(CH2)2-OH]-##,#-(CH2)4-OCH2C(CH3) 2(OH)-**,#-(CHz)4-O-(CH2)2C(CH3)2<OH)-##,#-(CH2)4-O-CH[(CHz)zOCH3]·* *,#-(CH2)4-O-CH[(CH2)2N(CH3)(OCH3)]-##,#-(CH2)4-OCH[(CH2)2N(CH3)2]-##, #-(CHZ)4-O-CH(CH2CH3)-##, from ''-(CH^-O-CHCCFs)-*4,#-(CH2)2CF2-CH2-CH[(CH2)2-morpholino ],#-(CH2)4-N(CH3)-CH[(CH2)2-morpholino]-##,#-(CH2)4# -(CH2)4 N(CH3)-CH[(CH2)2-(oxan-4-yl)]-##, where# is the point of attachment to the indole nitrogen atom and ## is the point of attachment to the pyrazole carbon bearing the R7 substituent; R8 is a methyl group; IF-2019-16843 747-APN-ANP#INPI Page 106 of 720 R9 is selected from a methyl group and an ethyl group; or a tautomer, or a salt thereof, or a salt of a tautomer or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where A is (A1), or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R9 are each a hydrogen atom; R4 is selected from naphth-1-yl and 6-fluoro-naphth-1-yl; L is a -(CH2)3-O- group; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CR22R23-##; where # is the point of attachment with the indole nitrogen atom and # # is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; R8 is a Ci-Ca alkyl group; R9 is a C-i-Cs alkyl group; R22 is independently selected from a -Ci-Ca alkyl group and a -(CH2)2heterocycloalkyl group; 107 IF-2019-16843 747-APN-ANP#INPI Page 107 of 720 R23 is a hydrogen atom; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. According to a further aspect, the present invention provides compounds of the general formula (I): where A is (A1) or (A2) where R6 and R7, together with two carbon atoms of the pyrazole ring, two carbon atoms of the indole moiety and the nitrogen atom to which R6 is attached, form an 11-membered ring and * It is the point of attachment of these residues to the indole carbon atom that carries substituent A; R1 is selected from a fluorine atom and a chlorine atom; R2 and R3 are each a hydrogen atom; R4 is selected from naphth-1-yl and 6-fluoro-naphth-1-yl; L is a group -(Chhh-O-; R5 is a COOH group; -R6-R7- is#-(CH2)4-O-CH[(CH2)2-morphol¡no]-##; where # is the point of attachment with the indole nitrogen atom and # # is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; R8 is a methyl group; R9 is selected from a methyl group and an ethyl group; or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. 108 IF-2019-16843 747-APN-ANP#INPI Page 108 of 720 In some embodiments, the present invention includes compounds of the general formula (I) selected from Acid (rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-¡loxy)prop¡l]-2,10,11,12,13,15hexah¡drop¡razolo[4', 3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (mixture of stereoisomers), 2,3,15-Trimethyl-7-[3-(naphthalen-1-yloxy)propyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9] acid trifluoroacetic acid salt 10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 1), 2,3,15-Trimethyl-7-[3-(naphthalen-1-yloxy)propyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9] acid trifluoroacetic acid salt 10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 2), (rac)-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]índole-8carboxylic acid (mixture of stereoisomers), 2,3-D I-15-[2-(morpholin-4-yl)ethyl]-7-[3-(n aphthalen-1-yloxy)propyl]-2,10,11,12 acid 13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (stereoisomer 1), 2,3-Dimethyl-15-[2-(morpholin-4-¡l)ethyl]-7-[3-(naphthalen-1-yloxy)propyl]-2,10,11,12,13,15hexahydropyrazolo[ acid 4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (stereoisomer 2), (rac)-4-fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-¡lox¡)propyl acid]2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1 -yl)oxy] propi acid I} 109 IF-2019-16843 747-APN-ANP#INPI Page 109 of 720 N-ethylethanamine salt (enantiomer 2) (rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 3-Ethyl-4-fluoro-2-methyl-15-[2-(morphol i n-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)ox¡]propi acid I} 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 3-Ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), Acid (rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1 -i l)oxy] propi I}2, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy] propyl}-2,3-d imethyl-15-[2-(morpholin-4yl)ethyl]-2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid 110 IF-2019-16843 747-APN-ANP#INPI Page 110 of 720 2,10,11,12,13,15-hexahid ropyrazolo[4', 3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), Acid (rac)-4-fluoro-7-{3-[(6-fluoronaphthalen-1 -i l)oxy] propyl}-2,3-d im ethyl-15-[2-(morpholin-4yl)ethyl] -2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid—N-ethylethanamine (enantiomer 1) , (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (2-enantiomer ), (rac)-4-chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-2,10,11,12,13,15hexahydropyrazolo acid[4 ',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, (rac)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13 acid 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl) acid2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8111 IF-2019-16843 747-APN-ANP#INPI Page 111 of 720 carboxylic, (rac)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13,15-hexahydropyrazolo[ acid 4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (+)-4-Chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-2,10,11,12,13,15hexahydro¡razole acid [4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8-carboxylic acid - Nethylethanamine salt (enantiomer 1), (-)-4-Chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1 -yl)oxy]propyl}-2,10,11,12,13,15hexahydropyrazolo[4] acid ',3':9,10][1,6]oxazac¡cloundec¡no[8,7,6-h¡]indole-8-carboxylic - Nethylethanamine salt (enantiomer 2), Acid (+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic acid (enantiomer 1), Acid (-)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1 -yl)oxy]propyl}2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (+)-4-Chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-¡l)oxy]propyl}-15-(trifluoromethyl) acid2,10,11, 12,13 ,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), Acid (-)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl)2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (+)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1||)oxy]propyl}-2,10,11,12 acid N-ethylethanamine salt ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazac¡cloundecino[8,7,6hi]indole-8-carboxylic acid (enantiomer 1), (-)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1||)oxy]prop¡l}-2,10,11 acid N-ethylethanamine salt ,12,13,15-hexahydrop¡razolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6 112 IF-2019-16843 747-APN-ANP#INPI Page 112 of 720 hi]indole-8-carboxylic acid (enantiomer 2), (rac)-4-chloro(15-rac)-(2-methoxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]prop¡l}-2-methyl acid2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indol-8carboxylic, Acid (+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1-¡l)oxy]propyl}-2-methyl¡l2,10,11,12, 13,15-hexahídropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]índole-8carboxylic - N-ethylethanamine salt (enantiomer 1), Acid (-)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fIuoronaphthalen-1 -iI)ox¡]propyl}-2-methiI2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(2-methoxyethyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-¡l)oxy]propyl}-15-(2-methoxyethyl)-2-methyl2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]ndole-8carboxylic - N-ethylethanamine salt (enantiomer ), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-methoxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-(15-rac)-(2-hydroxyethyl)-2methyl- 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-h¡]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8 113 IF-2019-16843 747-APN-ANP#INPI Page 113 of 720 carboxylic (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10 ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15R)-[2-(morpholin-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]índole8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholín-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic-N-ethylethanamine salt , (rac)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2-methyl-15-[2-(morphol¡n-4yl) acid ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1 -iI)oxy]propyl}-2-methi 1-15-[2-(morpholin-4yl)ethyl] acid -2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid (enantiomer 1), (-)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methiI-15-[2-(morpholin-4¡l)et acid ¡ l]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid (enantiomer 2) , (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(2-hydroxy-2methylpropyl) acid -2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxy-2-methylpropyl)-2methyl-2,10 acid N-ethylethanamine salt (enantiomer) 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxy-2-methylpropyl)-2methyl-2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indol114 IF-2019-16843 747-APN-ANP#INPI Page 114 of 720 8-carboxylic - N-ethylethanamine salt (2-enantiomer), (rac)-4-chloro(15-rac)-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy] acid propyl}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic - 2-hydroxypropane-1,2,3-tricarboxylic acid salt, 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1¡ I )ox i]propyl acid}-2-methylyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazac¡cloundec¡no[8,7,6-hi]indole- 8-Carboxylic - Nethylethanamine salt (enantiomer 1), 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6fluoronaphthalen-1-yl)oxy]propyl acid N-ethylethanamine salt}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (enantiomer 2), 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}-2- acid methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (enantiomer 1), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-phenyl acid2,10,11,12,13 ,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-¡l)oxy]propyl}-2-methyl-15-[2-(oxan-4- yl)ethyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl] acid2,10 ,11,12,13,15-hexahydro¡razolo[4',3';9,10][1,6]oxazacycloundecino[8,7,6-h¡]ndole-8carboxylic acid (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8115 IF-2019-16843 747-APN-ANP#INPI Page 115 of 720 carboxylic (enantiomer 2), Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]prop¡l}-2-methyl-15-[2-(oxan-4- yl)ethyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]índole-8carboxylic salt N-ethylethanamine (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl) acid )et¡l]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic salt N-ethylethanamine (enantiomer 2), Acid (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-2-methyl-(15-rac)-[3-(morphol ¡n4-yl)propyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic , (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[3-(morpholin-4yl)propyl] acid -2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic, Acid (-)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-2-methyl-15-[3-(morpholin-4yl)prop ¡ l]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 - ¡I )ox¡] propyl}-2-m ethyl-(15-rac)-[2-(4methylpiperazin-1) acid -yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-h¡]indole-8- carboxylic - Nethylenethanamine salt (mixture 1 of stereoisomers), Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-(2-(4methyl p¡ perazin-1 - i l)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-h¡]¡ndole-8- carboxylic - Nethylenethanamine salt (stereoisomer 1), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-(2-(4methylpiperazin-1 -yl)ethyl acid N-salt 116 IF-2019-16843 747-APN-ANP#INPI Page 116 of 720 ethylethanamine (stereoisomer 2), 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl )oxy]p ropy l}-2-m ethyl-(15-rac)-[2-(4methylpiperazin-1) acid -yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic salt of Nethylethanamine (mixture 2 of stereoisomers 2), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(4-methylpiperazin1-yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic- N-ethylethanamine salt (stereoisomer 3), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(4-methylpiperazin1-yl)ethyl acid l]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid (stereoisomer 4), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(3-hydroxy-3methylbutyl)-2-methyl acid -2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(3-hydroxy-3-methylbutyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(3-hydroxy-3-methylbutyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-(15-rac)-[2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy acid ]propyl}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic , (+)-4-Chloro-15-[2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1i I )oxy]propyl acid}-2-m et i I-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8- carboxylic - Nethylethanamine salt (enantiomer 1), 117 IF-2019-16843 747-APN-ANP#INPI Page 117 of 720 (-)-4-Chloro-15-(2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}- acid 2-methyl-2,10,11,12,13,15hexahydropyrazolo^'.S'O.IOHI.ejoxazacyclundecinotSJ.e-hiJindol-S-carboxylic - Nethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-{2[methoxy(methyl)amino]ethyl} acid -2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8-carboxylic acid , (rac)-4-chloro-(15-rac)-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]pro p acid!} -2-met¡ lo-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]indole-8- carboxylic, 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2-methyl acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic (stereoisomer 1), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox]propyl}-2-methyl acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic (stereoisomer 2), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 3), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 4), 4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholi n-4) acid -yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]indole-8-carboxylic , Acid (+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin- 4-yl)ethyl]-2,10,11,12,13,15118 IF-2019-16843 747-APN-ANP#INPI Page 118 of 720 h exahid ropyrazolo[4', 3': 9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (enantiomer 1), Acid (-)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morph oli n-4-yl )ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8- carboxylic (enantiomer 2), 4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-15-[2(morpholin-4-yl) acid ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic Acid (+)-4-chloro-3-ethyl-12,12-d if I uoro-7-{3-[(6-fl uoron aphthalen-1 -i l)ox i]propyl}-2-methyl-15 -[2(morpholin-4-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi] indole-8-carboxylic acid (3-enantiomer), Acid (-)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin- 4-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid ( enantiomer 4), (rac)-15-benzyl-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2-methyl acid2,10,11,12,13,15 -hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(morpholin-4j|) acid ethyl]-10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1hi]indole-8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,14-dimethyl-15-[2(morpholin-4-yl) acid ethyl]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,14-dimethyl-15-[2(morpholin-4-yl) acid ethyl]-10,11,12,13,14,15-hexahydro-2H119 IF-2019-16843 747-APN-ANP#INPI Page 119 of 720 pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1 -hi]indole-8-carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(morpholin-4yl)ethyl acid ]-10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1 hi]indole-8-carboxylic, (rac)-4-chloro-3-ethyl-2,14-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphtha!en-1-yl)oxy acid ]propyl}10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole8-carboxylic— N-ethylethanamine salt - Stereoisomer 3, (rac)-4-chloro-3-ethyl-2,14-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl acid}10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole8-carboxylic salt N-ethylethanamine - Stereoisomer 4, 4-Chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(tetrahydro-2Hpyran-4-yl )et acid ¡ I]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1 -hi]indole-8-carboxylic (mixture of 4 isomers), (rac)-18-chloro-1-ethyl-2-methyl-15-[3-(1-naphth (rac)-17-chloro-1-ethyl-14-{3-[ (6-fluoronaphthalen-1yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10,11 -octahydro-2HpyrazoloIS'^'^.gipyrroloIl'^'Ojni.eidiazacycloundecinoylO.H.I- hijindol-IS-carboxylic acidhyloxy)propyl]-2,3b,4,5,6,7,9,10,11,12decahydropyrazolo[3',4':8,9]pindo[1',2':6, 7][1,6]diazacycloundecino[10,11,1 -hi]indole-14carboxylic acid(lsomer 1), (rac)-18-chloro-1-ethyl-2-methyl-15-[3-(1-naphthyloxy)propyl]-2,3b,4,5,6,7,9,10,11,12decahydropyrazolo[ acid 3',4':8,9]pyrido[1',2':6,7][1,6]diazacycloundecino[10,11,1 -hi]indole-14carboxylic acid (Isomer 2), (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2HpyrazolotS'^^S.gjpyrrolotl'^^e^HI ,6]diazacycloundecino[10,11,1-hi]indole-13-carboxylic, Acid (+)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11octah id ro-2 H-pi razolo[3' ,4': 8,9] pyrro lo[1', 2': 6,7][1,6]diazacycloundecino[10,11,1 -hi]i ndol-13z120 IF-2019-16843 747-APN-ANP#INPI Page 120 of 720 carboxylic, Acid (-)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11 octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[T,2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic, (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-¡l)ox¡]propyl}-2-methyl acid3b,4,5,6,8,9,10 ,11-octahydro-2Hpyrazolo[3',4':8,9]pyrrolo[1',2':6,7][1,6]diazacycloundec¡no[10,11,1 -hi]indole-13- carboxylic (Isomer 1), Acid (-)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11 octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[1',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic enantiomer 2), (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2-methyl acid3b,4,5,6,8,9,10, 11-octahydro-2Hp irazolo[3',4': 8,9] pyrolo[ 1', 2':6,7][ 1,6]diazacycloundecino[10,11,1 -hi]indole-13- carboxylic (Isomer 1) and (rac)-4-chloro-3-ethyl-15-[2-(rac)-(3-fluoroazetidin-1-yl)ethyl]-7-{3-[(6-fluoronaphthalen-1i I)ox¡ acid ] propy l}-2-m et i I-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole -8-carboxylic acid or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of the general formula (I) selected from the following list of selected compounds (+)-4-Chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)ox¡]propyl}-2,10,11,12,13,15hexahydropyrazolo[ acid 4',3':9,10][1,6]oxazac¡cloundec¡no[8,7,6-h¡]indole-8-carboxylic - Nethylethanamine salt (enantiomer 1), Acid (-)-4-chloro-15-ethyl-2,3-d imethyl-7-{3-[(naphthalen-1 -yl)oxy]propíl}-2,10,11,12,13, fifteen 121 IF-2019-16843 747-APN-ANP#INPI Page 121 of 720 hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid - Nethylethanamine salt (enantiomer 2), Acid (+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), Acid (-)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13, 15-hexahydropyrazolo[4',3,:9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), Acid (+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl)2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), Acid (-)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl)2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (+)-4-Chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1yl)oxy]propyl}-2,10,11,12,13 Acid N-Ethylenethanamine salt ,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid (enantiomer 1), (-)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1yl)oxy]propyl}-2,10,11,12 acid N-ethylethanamine salt, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid (enantiomer 2), (rac)-4-chloro(15-rac)-(2-methoxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, Acid (+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -iI)oxy]propyl}-2-methiI122 IF-2019-16843 747-APN-ANP#INPI Page 122 of 720 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12,13,15 -hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(2-methoxyethyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-15-(2-methoxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-methoxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(2-hydroxyethyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15R)-[2-(morpholin-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4) acid 123 IF-2019-16843 747-APN-ANP#INPI Page 123 of 720 il)ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indol8- carboxylic salt of N-ethylethanolamine, (rac)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]-acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, Acid (+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1 -iI)ox¡]propyl}-2-methiI-15-[2-(morpholin-4yl)ethyl] -2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indo18-carboxylic acid (enantiomer 1), (-)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(2-hydroxy-2methylpropyl)-2 acid -methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8-carboxylic, Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxy-2-methylpropyl)-2methyl-2,10 N-ethylethanamine salt enantiomer 1), (-)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-i!)oxy]propyl}-15-(2-hydroxy-2-methylpropyl)-2methyl-2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 2) , Acid (rac)-4-chloro(15-rac)-[2-(3,3-difluorop¡rrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6- fluoronaphthalen-1yl)oxy]propyl}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6- h¡]indole-8-carboxylic acid - salt of 2-hydroxypropane-1,2,3-tricarboxylic acid, 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}-2-methyl acid 2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid salt 124 IF-2019-16843 747-APN-ANP#INPI Page 124 of 720 ethylethanamine (enantiomer 1), 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-¡l)ethyl]-3-ethyl-7-{3-[(6fluoronaphthalen-1-yl)oxy] acid N-ethylethanamine salt prop¡l}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]ndole -8-carboxylic acid (enantiomer 2), 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1i l)oxy] propy l}-2- acid methylyl-2,10,11,12,13,15hexahydro¡razolo[4',3':9,10][1,6]oxazac¡cloundecino[8,7,6-hi]ndole-8-carboxylic acid (enantiomer 1), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-phenyl acid2,10,11,12,13 ,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-¡l)ethyl]2 acid, (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic (enantiomer 2), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl) acid )ethyl]2,10,11,12,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic salt N-ethylethanamine (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethaneamine salt ( enantiomer 2), 125 IF-2019-16843 747-APN-ANP#INPI Page 125 of 720 (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15-rac)-[3-(morpholin4-¡) acid I) propy l]-2,10,11,12,13,15-hexahydro¡razolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid , (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-met¡I-15-[3-(morpholin-4yl)propyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic, (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[3-(morpholin-4yl)propyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15-rac)-[2-(4methylpiperazin-1-yl)ethyl acid ]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic - Nethylethanamine salt (mixture 1 of stereoisomers), Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-¡l)oxy]prop¡l}-2-methyl-15-[2-(4methylpiperazin- 1-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]ndole-8-carboxylic - Nethylethanamine salt (stereoisomer 1), Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-2-methyl-15-[2-(4methylpiperazin-1 -i I )et¡ l]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8- carboxylic - Nethylenethanamine salt (stereoisomer 2), 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15-rac)-[2-(4methylpiperazin-1-yl)ethyl acid ]-2,10,11,12,13,15hexahydrop¡razolo[4',3':9,10][1,6]oxazac¡cloundecino[8,7,6-h¡]indole-8-carboxylic - Nethylenethanamine salt (mixture 2 of stereoisomers 2), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(4-methylpiperazin1 -yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic- N-ethylethanamine salt (stereoisomer 3), 126 IF-2019-16843 747-APN-ANP#INPI Page 126 of 720 (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(4-methylpiperazin1 -yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid (stereoisomer 4), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(3-hydroxy-3methylbutyl)-2-methyl acid -2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-15-(3-hydroxy-3-methylbutyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(3-hydroxy-3-methylbutyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-(15-rac)-[2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1i l) acid oxy]propyl}-2-m ethyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole- 8-carboxylic, (+)-4-Chloro-15-[2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}- acid 2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid Nethylethanamine salt (enantiomer 1), (-)-4-Chloro-15-(2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}- acid 2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid Nethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-{2[methoxy(methyl)amino]ethyl} acid -2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, (rac)-4-chloro-(15-rac)-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1) acid 127 IF-2019-16843 747-APN-ANP#INPI Page 127 of 720 ,7,6-hi]indole-8-carboxylic, 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 1), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 2), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 3), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 4), 4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(m orf oli n-4) acid -i I )ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, Acid (+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphtha1en-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin- 4-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic ( enantiomer 1), (-)-4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-15-[2(morphol in -4-i l)eti l]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8- carboxylic (2-enantiomer), 4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin-4-yl) acid ethyl]-2,10,11,12,13,15128 IF-2019-16843 747-APN-ANP#INPI Page 128 of 720 hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, Acid (+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-(2(morpholin -4-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic (enantiomer 3), Acid (-)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-(2(morpholi n -4-yl )ethyl]-2,10,11,12,13,15hexahydropyrazolo(4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8- carboxylic (4-enantiomer), (rac)-15-benzyl-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2-methyl acid2,10,11,12,13,15 -hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(morpholin-4¡| )ethyl]-10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1hi]indole-8-carboxylic , (15R)-4-chloro-3-ethyl-7-{3-((6-fluoronaphthalen-1-yl)oxy]propyl}-2,14-dimethyl-15-(2(morpholin-4-i l) acid ethyl]-10,11,12,13,14,15-hexahydro-2HpyrazolotS'^S.gHI.ejdiazacycloundenotlO.II.I-hiJindol-S-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,14-dimethyl-15-[2(morpholin-4-yl) acid ethyl]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(morpholin-4¡OethylJ) acid -IO.H.^.lS.^.IS-hexahydro^H-pyrazololS'^'^.gKI.eidiazacycloundecinollO.H.Ihi]indole-8-carboxylic, (rac)-4-chloro-3-ethyl-2,14-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl acid}10,11,12,13,14,15-hexahydro-2H-pyrazolo[3\4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole8-carboxylic acid—N salt -ethylethanamine - Stereoisomer 3, 129 IF-2019-16843 747-APN-ANP#INPI Page 129 of 720 (rac)-4-chloro-3-ethyl-2,14-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl acid}10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole8-carboxylic salt N-ethylethanamine - Stereoisomer 4, 4-Chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(tetrahydro-2Hpyran-4-yl)ethyl acid ]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic acid (mixture of 4 isomers), (rac)-18-chloro-1-ethyl-2-methyl-15-[3-(1-naphth(rac)-17-chloro-1-ethyl-14-{3-[(6 -fluoronaphthalen-1yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10,11-octahydro-2Hpyrazolo[3',4': 8,9]pyrrolo[ 1', 2' :6,7][ 1,6]diazacycloundecino[10,11,1 -h i]indole-13-carboxylic acidhyloxy)propyl]-2,3b,4,5,6,7,9,10,11, 12decahydropyrazolo[3\4':8,9]pyrido[1\2L6,7][1,6]diazacycloundecino[10,11,1-hi]indole-14carboxylic acid(lsomer 1), (rac)-18-chloro-1-ethyl-2-methyl-15-[3-(1-naphthyloxy)propyl]-2,3b,4,5,6,7,9,10,11,12decahydropyrazolo[ acid 3',4':8,9]pyrido[T,2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-14carboxylic (Isomer 2), (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2Hp irazolo[3',4': 8,9] pyrrolo[ 11,2':6,7][ 1,6]diazacycloundecino[10,11,1 -h i]i ndole-13-carboxylic, Acid (+)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[1',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic, Acid (-)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[T,2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic, (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2Hpi razolo[3',4': 8,9] pyrrolo[ 1', 2':6,7][1,6]diazacycloundecino[10,11,1 -hi]indole-13-carboxylic acid 130 IF-2019-16843 747-APN-ANP#INPI Page 130 of 720 (Isomer 1), Acid (-)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[1 ',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic acid (2-enantiomer ), (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2Hpyrazolo[3',4':8,9]pyrrolo[1',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13-carboxylic acid (Isomer 1 ) and (rac)-4-chloro-3-ethyl-15-[2-(rac)-(3-fluoroazetidin-1 -yl)ethyl]-7-{3-[(6-fluoronaphthalen-1 i I )oxy acid ] propyl}-2-m eti I-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8 -carboxylic or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of the general formula (I) selected from the following list of selected compounds (rac)-2,3,15-trimethyl-7-[3-(naphthalen-1-yloxy)propyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10] acid [1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (mixture of stereoisomers), 2,3,15-Trimethyl-7-[3-(naphthalen-1-yloxy)propyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9] acid trifluoroacetic acid salt 10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 1), 2,3,15-Trimethyl-7-[3-(naphthalen-1-yloxy)propyl]2,10,11,12,13,15-hexahydro¡razole[4',3'] acid trifluoroacetic acid salt: 9,10][1,6]oxazac¡cloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 2), (rac)-2,3-dimethyl-15-[2-(morpholin-4-¡l)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10,11,12,13 ,15-hexahydropyrazolo[4', 3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8131 IF-2019-16843 747-APN-ANP#INPI Page 131 of 720 carboxylic (mixture of stereoisomers), 2,3-Dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl]-2,10,11,12,13,15hexahydropyrazolo[4] acid ',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (stereoisomer 1), 2,3-Dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl]-2,10,11,12,13 acid ,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (stereoisomer 2), (rac)-4-fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 3-Ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 3-Ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl}2 acid ,10,11,12,13,15-hexahydrop¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]¡ndole-8132 IF-2019-16843 747-APN-ANP#INPI Page 132 of 720 carboxylic, 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2,3-d imethyl-15-[2-(morpholin-4¡|)ethyl] acid -2,10,11,12,13,15-hexahydro¡razolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-h¡]¡ndole8-carboxylic, 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-¡l)ethyl]2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholín-4-yl)ethyl]2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]índole-8carboxylic acid (enantiomer 2), (rac)-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4yl)ethyl]-2 acid, 10,11,12,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]¡ndole8-carboxylic, 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholín-4yljetyl) acid ^.lOJI.^.IS.IS-hexahydropyrazolo^'.S'^.IOHI.ejoxazacicloundecinoiej.e-hOindol133 IF-2019-16843 747-APN-ANP#INPI Page 133 of 720 8-carboxylic, Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methi I-15-[2-(morpholin-4¡ I )ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-h¡]¡ndole8-carboxylic—N -ethylethanamine (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (2-enantiomer ), (rac)-4-chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propíl}-2,10,11,12,13,15hexahydropyrazolo acid [4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]indole-8-carboxylic, (rac)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)ox¡]propyl acid}2,10,11,12,13 ,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-h¡]ndole-8carboxylic, (rac)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl) acid2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13,15-hexahydropyrazolo[ acid 4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (+)-4-Chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1 -yl)oxy]propyl}-2,10,11,12,13,15hexahydropyrazolo[4] acid ',3':9,10][1,6]oxazac¡cloundec¡no[8,7,6-hi]indole-8-carboxylic - Nethylethanamine salt (enantiomer 1), (-)-4-Chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1 -yl)oxy]propyl}-2,10,11,12,13,15hexahydropyrazolo[4] acid ',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic - Nethylethanamine salt (enantiomer 2), Acid (+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]ndole-8carboxylic acid (enantiomer 1), 134 IF-2019-16843 747-APN-ANP#INPI Page 134 of 720 Acid (-)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), Acid (+)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl)2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]ndole-8carboxylic - N-ethylethanamine salt (enantiomer 1), Acid (-)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1 -iI)oxy]propyl}-15-(trifluoromethyl)2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (+)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1¡l)oxy]propyl}-2,10,11,12 acid N-ethylethanamine salt ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid (enantiomer 1), (-)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1¡|)oxy]propyl}-2,10,11,12 acid N-ethylethanamine salt ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazac¡cloundec¡no[8,7,6hiJindol-8-carboxylic acid (enantiomer 2), (rac)-4-chloro-(15-rac)-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11, 12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, Acid (+)-4-chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl2,10,11,12,13,15 -hexahydroprazol[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]ndole-8carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-15-cyclopropyl-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12,13,15 -hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic- N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-(15-rac)-(2-hydroxyethyl)-2methyl-2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, 135 IF-2019-16843 747-APN-ANP#INPI Page 135 of 720 (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexah¡drop¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-2-methyl-(15R)-[2-(morpholín) -4yl)ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-2-methyl-15-[2-(morpholin-4yl) acid )ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic-N salt -ethylethanamine, (rac)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, Acid (+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methiI-15-[2-(morpholin-4yl)ethyl]- and (-)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl) acid )ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid (2-enantiomer) or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of the formula 136 IF-2019-16843 747-APN-ANP#INPI Page 136 of 720 general (I) selected from the following list of selected compounds (rac)-4-fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]ndole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]prop¡l} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl acidJ2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indol-8carboxylic, 3-Ethi l-4-f luoro-2-methyl-15-[2-(morpholin-4-yl)et¡ l]-7-{3-[(naphthalen-1 -yl)oxy] propi I} acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic - N-ethylethanamine salt ( enantiomer 1), 3-Ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2.10 ,11,12,13,15-hexahydropyrazolo[4',3,:9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8 137 IF-2019-16843 747-APN-ANP#INPI Page 137 of 720 carboxylic (enantiomer 2), (rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4yl)ethyl]-acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4yl)ethyl]-2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4¡|)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole8-carboxylic—N-ethylethanamine ( enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8 138 IF-2019-16843 747-APN-ANP#INPI Page 138 of 720 carboxylic—N-ethylethanamine (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-(15-rac)-(2-methoxyethyl)-2methyl-2 acid ,10,11,12,13,15-hexahydro¡razolo[4',3':9,10] [1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-methoxyethyl)-2-methyl acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), Acid (-)-4-chloro-3-ethyl-7-{3-[(6-fl uoronaphthalen-1 -yl)oxylpropyl}-15-(2-methoxyethyl)-2-methyl2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15R)-[2-(morpholin-4¡OethylJ) acid ^.IO.H.^.IS.IS-hexahydropyrazoloK.S'O.IOJII.eioxazacicloundecinoiej.e-hylindole8-carboxylico, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4¡|)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic-N-ethylethanamine salt , (rac)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]prop¡l}-2-methyl-15-[2-(morpholin-4yl) acid )ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-3-ethyl-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4¡|)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid (enantiomer 1), Acid (-)-3-ethyl-4-fluoro-7-{3-[(6-fl uoronaphthalen-1 -yl)oxy]propíl}-2-methyl-15-[2-(morpholin- 4¡l)ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic ( enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-(15-rac)-(2-hydroxy¡-2methylpropyl)-2- acid methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-h¡]indole-8-carboxylic, 139 IF-2019-16843 747-APN-ANP#INPI Page 139 of 720 Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxy-2-methylpropyl)-2methyl-2,10 ,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxy-2-methylpropyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro(15-rac)-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy] acid propyl}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic - 2-hydroxypropane-1,2,3-tricarboxylic acid salt, Acid4-chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}-2-methyl-2 ,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic - Nethylethanamine salt (enantiomer 1), 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6fluoronaphthalen-1 -i I )oxy] acid N-ethylethanamine salt propy l}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (enantiomer 2), 4-Chloro-15-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}-2-methyl acid 2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (enantiomer 1), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy] p royl}-2-methi I-15-[2-(oxan-4-yl)ethyl]2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic (enantiomer 1), 140 IF-2019-16843 747-APN-ANP#INPI Page 140 of 720 (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(oxan-4-yl)ethyl acid ]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2-methyl-15-[2-(oxan-4-yl) acid N-salt -ethylethanamine (enantiomer 1) (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl!-15-[2-(oxan-4-yl) acid ethyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), Acid (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2-methyl-(15-rac)-[3-(morpholin4- ¡ I) propyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic¡ co, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2-methyl-15-[3-(morpholin-4yl) acid propyl]-2,10,11,12,13,15-hexah¡dropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6hi]indole-8-carboxylic, (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[3-(morpholín-4) acid ¡ I) propyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15-rac)-[2-(4methylpiperazin-1-yl)ethyl acid ]-2,10,11,12,13,15hexahydrop¡razolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]ndole-8-carboxylic¡ co - Nethylethanamine salt (mixture 1 of stereoisomers), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-¡l)oxy]propyl}-2-methyl-15-[2-(4methylpiperazin-1 -yl) acid ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazac¡cloundec¡no[8,7,6-hi]indole-8-carboxylic - Nethylenethanamine salt (stereoisomer 1), Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)ox¡]propyl}-2-methiI-15-[2-(4 141 IF-2019-16843 747-APN-ANP#INPI Page 141 of 720 methyl piperazi η-1 -yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6- hi]indole-8-carboxylic acid - Nethylethanamine salt (stereoisomer 2), 4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15-rac)-[2-(4methylpiperazin-1-yl)ethyl acid ]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid - Nethylethanamine salt (mixture 2 of stereoisomers 2), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(4-methylpiperazin1-yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4,,3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic- N-ethylethanamine salt (stereoisomer 3), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(4-methylpiperazin1-yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6hi]indole-8-carboxylic acid (stereoisomer 4), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-(15-rac)-(3-hydroxy-3methylbutyl)-2-methyl acid -2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(3-hydroxy-3-methylbutyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 1), (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(3-hydroxy-3-methylbutyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-4-chloro-(15-rac)-[2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy acid ]propyl}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic , (+)-4-Chloro-15-(2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)oxy]propyl}- acid 2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic salt 142 IF-2019-16843 747-APN-ANP#INPI Page 142 of 720 ethylethanamine (enantiomer 1), (-)-4-Chloro-15-[2-(3,3-difluoroazetidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1yl)ox¡]propyl acid} -2-metyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic salt of Nethylethanamine (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propíl}-(15-rac)-{2[methoxy(methyl)amino] acid ethyl}-2-methyl-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, 4-Chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin-4-yl) acid ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic, Acid (+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin- 4-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid ( enantiomer 1), Acid (-)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholi n -4-i l)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic (enantiomer 2), Acid4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholin-4) -yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic Acid (+)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methylI-15-[2(morpholin- 4-yl)ethyl]-2,10,11,12,13,15hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid ( enantiomer 3), Acid (-)-4-chloro-3-ethyl-12,12-difluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2(morpholi n -4-i l)ethyl]-2,10,11,12,13,15143 IF-2019-16843 747-APN-ANP#INPI Page 143 of 720 hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (enantiomer 4), (rac)-15-benzyl-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2-methyl acid2,10,11,12,13,15 -hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(morpholin-4yl)ethyl acid ]-10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1hi]indole-8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,14-dimethyl-15-[2(morpholin-4-yl) acid ethyl]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1 -hi]indole-8-carboxylic, (15R)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,14-dimethyl-15-[2(morpholin-4-yl) acid ethyl]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(morpholin-4yl)ethyl acid ]-10,11,12,13,14,15-hexahydro-2H-pyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1hi]indole-8-carboxylic, 4-Chloro-3-ethyl-7-{3-[(6-fluoro-1-naphthyl)oxy]propyl}-2,14-dimethyl-15-[2-(tetrahydro-2Hpi ran-4-i I acid )et¡ I]-10,11,12,13,14,15-hexahydro-2Hpyrazolo[3',4':8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8 -carboxylic (mixture of 4 isomers), (rac)-18-chloro-1-ethyl-2-methyl-15-[3-(1-naphth (rac)-17-chloro-1-ethyl-14-{3 -[(6-fluoronaphthalen-1yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10,11-octahydro-2Hpyrazolo[3',4':8,9]pyrrolo [ 1', 2':6,7][1,6]diazacycloundecino[10,11,1 -hi]i ndol-13-carboxylic acidhyloxy)propyl]-2,3b,4,5,6,7,9 ,10,11,12decahydropyrazolo[3',4':8,9]pyrido[1', 2': 6,7][1,6]diazacycloundecino[10,11,1 -hi]indole-14carboxylic acid(lsomer 1) and (rac)-18-chloro-1-ethyl-2-methyl-15-(3-(1-naphthyloxy)propyl]-2,3b,4,5,6,7,9,10,11,12 acid 144 IF-2019-16843 747-APN-ANP#INPI Page 144 of 720 decahydropyrazolo[3',4':8,9]pyrido[1 ',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-14carboxylic acid (Isomer 2) or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of the general formula (I) selected from the following list of selected compounds Acid (rac)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]prop¡l}2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]¡ndole-8carboxylic, Acid (+)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), Acid (-)-4-chloro-15-(2-hydroxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1 -yl)oxy]prop¡I}2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro(15-rac)-(2-methoxyethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic, (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-15-phenyl acid2,10,11,12,13,15 -hexah¡dropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic, (rac)-4-chloro-(15-rac)-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1¡ l)oxy] propyl acid}-2-m ethyl-2,10,11,12,13,15hexahydrop¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]¡ndole-8 -carboxylic, 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8145 IF-2019-16843 747-APN-ANP#INPI Page 145 of 720 carboxylic (stereoisomer 1), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]¡ndole-8carboxylic acid (stereoisomer 2), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10,11,12, 13,15-hexahydro¡razolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-h¡]¡ndole-8carboxylic acid (stereoisomer 3), 4-Chloro-15-[2-(dimethylamino)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 4), (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2Hpyrazolo[3',4':8,9]pyrrolo[T,2':6,7][1,6]diazac¡cloundecino[10,11,1-h¡]indole-13- carboxylic and Acid (+)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 ,11octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[T,2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of the general formula (I) selected from the following list of selected compounds (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-(15-rac)-(2-hydroxyethyl)-2methyl-2,10 acid ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), 146 IF-2019-16843 747-APN-ANP#INPI Page 146 of 720 (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-15-(2-hydroxyethyl)-2-methyl acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), Acid (-)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-¡l)oxy]propyl}-2-methyl-3b,4,5,6,8,9, 10,11octahydro-2H-pyrazolo[3',4':8,9]pyrrolo[1',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13carboxylic, (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2Hpyrazolo[3',4':8,9]pyrrolo[1 ',2':6,7][1,6]diazacycloundecino[10,11,1-hi]indole-13-carboxylic (Isomer 1 ), Acid (-)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-3b,4,5,6,8,9,10 .11 octah id ro-2 H-p irazolo[3', 4': 8.9] p irro lo[1', 2': 6.7][1.6]diazacycloundecino[10,11,1 -h ijindol- 13carboxylic (2-enantiomer) and (rac)-17-chloro-1-ethyl-14-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl acid3b,4,5,6,8,9,10,11 -octahydro-2Hpyrazolo[3',4':8,9]pyrrolo[1',2':6,7][1,6]diazacycloundecino[10,11,1 -hi]indole-13-carboxylic acid (Isomer 1 ) or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of the general formula (I) selected from the following list of selected compounds Acid (rac)-2,3,15-tñmet¡l-7-[3-(naphthalen-1-yloxy¡)propyl]-2,10,11,12,13,15hexahydro¡razolo[4',3' :9,10][1,6]oxazac¡cloundec¡no[8,7,6-hi]¡ndole-8-carboxylic acid (mixture of stereoisomers), 2,3,15-tnmethyl-7-[3-(naphthalen-1-¡loxy)prop¡l]2,10,11,12,13,15-hexahydropyrazolo[4',3'] acid trifluoroacetic acid salt :9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8147 IF-2019-16843 747-APN-ANP#INPI Page 147 of 720 carboxylic (stereoisomer 1), 2,3,15-Trimethyl-7-[3-(naphthalen-1-yloxy)propyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9] acid trifluoroacetic acid salt 10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (stereoisomer 2), Acid (rac)-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl]2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic acid (mixture of stereoisomers), 2,3-Dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl]-2,10,11,12,13,15hexahydropyrazolo[4] acid ',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid (stereoisomer 1), 2,3-d imethyl-15-[2-(m oryol i n-4-i l)ethyl]-7-[3-(n aphthalen-1 -yloxy) propi acid IJ-2,10,11,12, 13,15hexahydro¡razolo[4',3':9,10][1,6]oxazac¡cloundecino[8,7,6-h¡]¡ndole-8-carboxylic acid (stereoisomer 2), (rac)-4-fluoro-2,3-dimethyl-15-[2-(m oryol in-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl] acid2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic, 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2), (rac)-3-ethyl-4-fluoro-2-methyl-15-[2-(morpholín-4-yl)ethyl]-7-[3-(naphthalen-1-yloxy)propyl]2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indol-8carboxylic, 3-Ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8148 IF-2019-16843 747-APN-ANP#INPI Page 148 of 720 carboxylic - N-ethylethanamine salt (enantiomer 1), 3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)ox¡]propyl}2 acid, 10,11,12,13,15-hexahydropyrazolo[4,,3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 2) , (rac)-4-chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1 -yl)oxy]prop¡ I}2 acid ,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]¡ndole-8carboxylic, 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-¡l)ethyl]-7-{3-[(naphthalen-1-yl)ox¡]propyl acid}2.10 ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic acid (enantiomer 1), 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2,3-dimethyl-15-[2-(morphol¡n-4yl)ethyl] acid -2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]¡ndole8-carboxylic, 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-¡l)ethyl]2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]2 acid ,10,11,12,13,15-hexahydropyrazolo[4,,3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholín-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic, 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazac,cloundecino[8,7,6-hi]indole-8 149 IF-2019-16843 747-APN-ANP#INPI Page 149 of 720 carboxylic—N-ethylethanamine (enantiomer 1), 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholín-4-yl)ethyl] acid2.10 ,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 2), (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole8-carboxylic, (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10] [ 1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic—N-ethylethanamine (enantiomer 1) , (-)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4-yl) acid )ethyl]2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][ 1,6]oxazacycloundecino[8,7,6-hi]índole-8carboxylic—N-ethylethanamine (enantiomer 2), (rac)-4-chloro-15-ethyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-2,10,11,12,13,15hexahydropyrazolo[4]acid ',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]ndole-8-carboxylic, Acid(rac)-4-chloro-15-(2-hydroxy¡ethyl)-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic, (rac)-4-chloro-3-ethyl-2-methyl-7-{3-[(naphthalen-1-yl)oxy]propyl}-15-(trifluoromethyl) acid2,10,11,12,13, 15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic and (rac)-4-chloro-15-cyclopropyl-2,3-dimethyl-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10,11,12,13,15- acid hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture of them. 150 IF-2019-16843 747-APN-ANP#INPI Page 150 of 720 In some embodiments, the present invention includes compounds of general formula (I) selected from: 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1 -yl)ox¡]propyl acid}2,10,11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]ndole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 3-Ethyl-4-fluoro-2-methyl 1-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]prop acid ¡l}2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - salt of N- ethylethanamine (enantiomer 1), 4-Chloro-2,3-dimethyl-15-[2-(morpholín-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]prop¡l} acid2.10 ,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)ox¡]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1) and (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic—N-ethylethanamine (enantiomer 1) or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of general formula (I) selected from: 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 151 IF-2019-16843 747-APN-ANP#INPI Page 151 of 720 3-Ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1 - i l)ox¡]propyl acid}2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl} acid2,10,11,12 ,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]índole-8carboxylic—N-ethylethanamine (enantiomer 1), 4-fluoro-7-{3-[(6-fluoronaphthalen-1-¡l)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10, 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic—N-ethylethanamine (enantiomer 1) (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-15-[2-(morpholín-4yl) acid )ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundec¡no[8,7,6-hi]indole8-carboxylic—N -ethylethanamine (enantiomer 1) and Acid (+)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15R)-[2-(morpholin-4¡| )ethyl]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of general formula (I) selected from: 4-Chloro-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)ox¡]prop¡l acid}2,10, 11, 12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic acid (enantiomer 1), 4-Chloro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl] acid2,10,11 ,12,13,15-hexahydrop¡razolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]¡ndole-8152 IF-2019-16843 747-APN-ANP#INPI Page 152 of 720 carboxylic—N-ethylethanamine (enantiomer 1), (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1 -yl)oxy]propyl}-2-methyl-15-[2-(morpholin-4yl)ethyl]- acid 2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic—N-ethylethanamine (enantiomer 1) and (+)-4-Chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-(15R)-[2-(morpholin-4yl)ethyl acid ]-2,10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole8-carboxylic acid or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes compounds of general formula (I) selected from: 4-Fluoro-2,3-dimethyl-15-[2-(morpholin-4-¡l)ethyl]-7-{3-[(naphthalen-1-yl)oxy]propyl}2,10 acid 11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-h¡]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1), 3-ethyl-4-fluoro-2-methyl-15-[2-(morpholin-4-yl)ethyl]-7-{3-[(naphthalen-1-yl)ox¡]propyl}2 acid, 10,11,12,13,15-hexahydropyrazolo[4',3':9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8carboxylic - N-ethylethanamine salt (enantiomer 1) and 4-Fluoro-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2,3-dimethyl-15-[2-(morpholin-4-yl)ethyl]2 acid ,10,11,12,13,15-hexahydro¡razolo[4',3':9,10][1,6]oxazac¡cloundecino[8,7,6-h¡]indole-8carboxylic—N-ethylethanamine (enantiomer 1) or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In some embodiments, the present invention includes intermediates 1-208, as well as their use for the preparation of compounds of the general formula (I). In some embodiments, the present invention includes compounds 153 IF-2019-16843 747-APN-ANP#INPI Page 153 of 720 intermediates 1-74, as well as their use for the preparation of compounds of the general formula (I). In some embodiments, the present invention includes intermediates 74-208, as well as their use for the preparation of compounds of general formula (I). In some embodiments, the present invention includes all compounds of general formula (I) as disclosed in the examples section, starting with example 1 and ending with example 28, or a tautomer, an N-oxide or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes all compounds of general formula (I) as disclosed in the examples section, starting with example 1 and ending with example 108, or a tautomer, an N-oxide or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes all compounds of general formula (I) as disclosed in the examples section, starting with example 29 and ending with example 108, or a tautomer, an N-oxide or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, in which R1, R2 and R3 are each selected from a hydrogen atom, a halogen atom and a Ci-C3 alkyl group, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, in which R1 and R2 are each independently selected from a hydrogen atom, a halogen atom, a cyano group, an alkyl-Ci- group. Cs and an alkoxy-Ci-C3 group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, in which R1 and R2 are each independently selected from a hydrogen atom and a halogen atom or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 154 IF-2019-16843 747-APN-ANP#INPI Page 154 of 720 In some embodiments, the present invention includes compounds of formula (I), above, in which R1 and R2 are each independently selected from a hydrogen atom, a fluorine atom and a chlorine atom or a tautomer, an N -oxide, or a salt thereof, or a salt of a tautomer or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I) above, wherein R1 is selected from a hydrogen atom, a fluorine atom and a chlorine atom; and R2 and R3 are each a hydrogen atom; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, wherein R1 is a hydrogen atom or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer , or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, in which R1 is a chlorine atom or a fluorine atom or a tautomer, a Noxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, wherein R1 is a fluorine atom or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer , or a salt of an N-oxide, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I) above, wherein R3 is selected from a hydrogen atom, a halogen atom, a cyano group, a Ci-C3 alkyl group, a haloalkyl group -Ci-C3, an alkoxy-CiC3 group, an alkylthio-Ci-C3 group, a -S(O)-(alkyl-Ci-C3) group, a -S(O)2-(alkyl-CiC3) group ), a haloalkoxy-Ci-C3 group, a haloalkylthio-Ci-C3 group and a cycloalkyl-C3-C5 group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 155 IF-2019-16843 747-APN-ANP#INPI Page 155 of 720 In some embodiments, the present invention includes compounds of formula (I), above, in which R3 is selected from a hydrogen atom, a halogen atom, a cyano group, an alkyl-Ci-Cs group, a group haloalkyl-Ci-Cs, an alkoxy-Ci-Cs group and a cycloalkyl-Cs-Cs group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N -rust, or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I), above, wherein R3 is a hydrogen atom or a tautomer, an N-oxide, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I) above, wherein R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three , four or five substituents and each substituent is independently selected from a halogen atom, a cyano group, an alkyl-Ci-Cs group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-C3 group, a thioalkyl group -Ci-C3, a haloalkoxy-Ci-C3 group, a (C1-C3)haloalkyl-S- group and a cycloalkyl-Cs-Cs group; or a tautomer, an N-oxide, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. In some embodiments, the present invention includes compounds of formula (I) above, wherein R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two, three , four or five substituents and each substituent is independently selected from a halogen atom, a cyano group, an alkyl-C-i-Cs group, a haloalkyl-Ci-Cs group, an alkoxy-Ci-Cs group and a cycloalkyl-Cs group -Cs; or a tautomer, an N-oxide, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one, two or three substituents and each substituent is independently selected from a halogen atom and a Ci-C3 alkyl group; or a tautomer, an N-oxide, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. 156 IF-2019-16843 747-APN-ANP#INPI Page 156 of 720 In other embodiments, the present invention includes compounds of formula (I) above, wherein R4 is selected from an aryl group and a heteroaryl group, each of which is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom and a Ci-C3 alkyl group or a tautomer, an N-oxide, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. In other embodiments, the present invention provides compounds of formula (I), above, wherein R4 is selected from a naphthyl group that is unsubstituted or substituted with a fluorine atom or a chlorine atom or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention provides compounds of formula (I), above, wherein R4 is selected from a naphthyl group that is unsubstituted or substituted with a fluorine atom or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention provides compounds of formula (I), above, in which R4 is selected from a naphth-1-yl group and a 6-fluoronaphth-1-yl group or a tautomer, an N- oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention provides compounds of formula (I), above, in which R4 is a naphth-1-yl group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention provides compounds of formula (I), above, wherein R4 is a 6-fluoro-naphth-1-yl group or a tautomer, an N-oxide, or a salt thereof , or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is a -(CH2)m-E- group that is optionally substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, a Ci-C3 alkyl group and a 157 IF-2019-16843 747-APN-ANP#INPI Page 157 of 720 alkoxy-Ci-Cs, or two substituents are taken together with their intermediate atoms to form a saturated or partially unsaturated 3-membered to 6-membered cycloalkyl ring, or a saturated or partially saturated 3-membered to 8-membered heterocyclic ring unsaturated having 1-2 heteroatoms independently selected from an oxygen atom, a sulfur atom, an -S(O)- group, an -S(O)2- group and a -NR14- group or a tautomer, an N -oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is a -(CH2)m-E- group that is optionally substituted with one or two substituents and each substituent is independently selected from a halogen atom, a hydroxy group, an alkyl-Ci-Cs group and an alkoxy-C-i-Cs group, or two substituents are taken together with their intermediate atoms to form a saturated or partially unsaturated 3-6 membered cycloalkyl ring, or a saturated or partially unsaturated 3-8 membered heterocyclic ring having 1-2 heteroatoms independently selected from an oxygen atom, a sulfur atom, an -S(O)- group, a -S(O)2- group and a -NR14- group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is a -(CH2)m-E- group wherein any CH2 group is unsubstituted or substituted with one or two substituents and each substituent is independently selected from a halogen atom, a cyano group, a hydroxy group, an alkyl-Ci-Cs group and an alkoxy-Ci-Cs group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein L is a -(CH2)m-E- group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is a -(CH2)m-E- group and m is 2, 3 or 4 or a tautomer, a Noxide, or a salt of the same, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 158 IF-2019-16843 747-APN-ANP#INPI Page 158 of 720 In other embodiments, the present invention includes compounds of formula (I), above, in which L is a -(CH2)m-E- group and m is 3 or a tautomer, an N-oxide, or a salt of the themselves, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein L is an unsubstituted group -(CH2)m-E- or a tautomer, an N-oxide, or a salt thereof , or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is an unsubstituted group -(CH2)m-E-, E is oxygen or NR15 and m is 3 or a tautomer, an N -oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is an unsubstituted group -(CH2)m-E-, E is oxygen and m is 3, or a tautomer, an N- oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein L is a (CH2)3-O- group or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which E is an oxygen atom, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which L is an unsubstituted group -(CH2)m-E- and E is an oxygen atom or a tautomer, an N-oxide , or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Even in other embodiments, the present invention includes compounds of the 159 IF-2019-16843 747-APN-ANP#INPI Page 159 of 720 * N ~V N \ u N-N |_| formula (I) above, in which R5 is a COOH group, a group, a C(O)-NHS(O)2(alkyl-Ci-C6) group, a -C(O)-NHS(O)2 group (c¡cloalkyl-C3-C6), a group C(O)-NHS(O)2(aryl), a group -C(O)-NHS(O)2(CH2)2NHCO(alkyl-Ci- C6), a C(O)-NHS(O)2(CH2)2NHCO(C3-C6-cycloalkyl) group or a -C(O)NHS(O)2(CH2)2NHCO(aryl) group, or a tautomer , an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of the formula *N N\<1 N-N |_| (I), above, in which R5 is a COOH group, or a group, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which R5 is a COOH group, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer , or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene -C2-Cg)-(B)tCR22R23.##, where# is the point of attachment with the indole nitrogen atom and ° is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups are unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, an alkyl-Ci-Cs group, a haloalkyl-Ci- group Cs, a Ci-C3 alkoxy group, and a Ci-C3 haloalkoxy group, a C3-C6 cycloalkyl group, and a (heterocycloalkyl)-(Ci-C3 alkylene)- group, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of the formula 160 IF-2019-16843 747-APN-ANP#INPI Page 160 of 720 (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene-C2-Ce)-(B)tCR22R23 .##, where# is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups are unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a C-i-Cs-alkyl group, a Ci-haloalkyl group Cs, an alkoxy-Ci-C3 group, and a haloalkoxy-Ci-Cs group, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide , or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene -C3-Cs)-(B)tGR22R23.## where# is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups are unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3 alkyl group, a haloalkyl group Ci-C3, an alkoxy-Ci-C3 group, and a haloalkoxy-Ci-C3 group, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N -rust, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene -C3-C5)-(B)tCR22R23-## where# is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom or a tautomer, or a salt thereof, or a salt of a tautomer or a mixture thereof. themselves. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene -C3-C4)-(B)tCR22R23.##, where# is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and where one or more 161 IF-2019-16843 747-APN-ANP#INPI Page 161 of 720 -CH2- groups are unsubstituted or substituted with one or more substituents independently selected from a halogen atom or a tautomer, or a salt thereof, or a salt of a tautomer or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene -C3-C4)-(B)tCR22R23-##, where# is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent or a tautomer, or a salt thereof, or a salt of a tautomer or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- s#-(CH2)n-(B)t-CR22R23-##o#-(achenylene -C3-C4)-(B)r GR22R23-##, where #is the point of attachment with the indole nitrogen atom and ##is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or a tautomer, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, in which -R6-R7- is#-(CH2)n-(B)t-CR22R23-##o#-(alkenylene- C3-C4)-(B)tCr22r23-##, where# is the point of attachment with the indole nitrogen atom and is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups are substituted with one or more substituents independently selected from a halogen atom or a tautomer, or a salt thereof or a salt of a tautomer or a salt of an N-oxide or a mixture of them. In other embodiments, the present invention includes compounds of formula (I) above, wherein -R6-R7- is#-(CH2)4-O-CR22R23-##o#-(CH2)4-NR15 -CR22R23-##, or a tautomer, an N-oxide, or a salt thereof, a salt of an N-oxide, or a salt of a tautomer or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- is#-(CH2)4-O-CR22R23-##or a tautomer, an N-oxide , or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 162 IF-2019-16843 747-APN-ANP#INPI Page 162 of 720 In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- is#-(C2-C9 alkenylene)-(B)t-CR22R23-##, in where * is the point of attachment with the indole nitrogen atom and ## is the point of attachment with the pyrazole carbon atom bearing the R7 substituent or a tautomer, or a salt thereof, or a salt of a tautomer or a mixture of them. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- is#-(C2-C9 alkenylene)-(B)t-CR22R23-##, in where # is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the pyrazole carbon atom carrying the R7 substituent; and wherein one or more -CH2- groups may be unsubstituted or substituted with one or more substituents independently selected from a halogen atom or a tautomer, an N-oxide or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- is#-(CH2)4-N(R15)-CR22R23-##or a tautomer, a N-oxide or a salt thereof, or a salt of a tautomer, a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which -R6-R7- is#-(CH2)4-N(R15)-CR22R23-##or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, in which -R6-R7- is#-(CH2)4-N(R15)-CR22R23-##, where# is the point of attachment with the indole nitrogen atom y##is the point of attachment with the pyrazole carbon atom bearing the substituent R7y wherein one or more -CH2- groups may be unsubstituted or substituted with one or more independently selected substituents of a halogen atom or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein -R6-R7- is selected from#-(CH2)4-O-CH(CH3)-##,#-( ΟΗ2)4-Ο-ΟΗ[(ΟΗ2)2morpholino]-*#,#-(CH2)4-O-CH[(CH2)2-N-methylpiperazino]-##,#-(CH2)4-O- CH[(CH2)2pyrrolidino]-**,#-(CH2)4-O-CH[(CH2)2-cyclopropyl]-##,#-(CH2)4-O-CH(cyclopropyl)-##, #-(CH2)4-O-CH[(CH2)2-O-CH3]-##, *-(CH2)4-O-CH[(CH2)2-OH]-##, *-(CH2 )4-O 163 IF-2019-16843 747-APN-ANP#INPI Page 163 of 720 CHÍCHzCHs)-**, and#-(CH2)4-O-CH(CF3)-##, or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, in which -R6-R7- is selected from#-(CH2)4-O-CH(CH3)-^,#-(CH2 )4-O-CH[(CH2)2morpholino]-##,#-(CH2)4-O-CH(cyclopropyl)-##,#-(CH2)4-O-CH[(CH2)2-OH ]-##,#-(CH2)4-OCH(CH2CH3)-##, and#-(CH2)4-O-CH(CF3)-##, or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein -R6-R7- is selected from#-(CH2)4-O-CH[(CH2)2(oxan-4- il)]-**,#-(CH2)4-O-CH[(CH2)2-morpholino]-##,#-(CH2)4-O-CH[(CH2)2-(4methylpiperazin-1- il)]-##,#-(CH2)4-O-CH[(CH2)2-(3,3-difluoropyrrolidin-1-¡l)]-##,#-(CH2)4-OCH [(CH2)2-(3-fluoroazetidin-1-¡l)]-##,#-(CH2)4-O-CH[(CH2)2-(3,3-difluoroazetidin-1-yl) ]-##,#-(CH2)4-O-CH(cyclopropyl)-##,#-(CH2)4-O-CH(phenyl)-##,#-(CH2)4-O-CH( CH2-phenyl)-##,#-(CH2)4-O-CH[(CH2)3-morpholino]-##,#-(CH2)4-O-CH[(CH2)2-OH]-# #,#-(CH2)4-OCH2C(CH3)2(OH)-#*, **-(CH2)4-O-(CH2)2C(CH3)2(OH)-##,#-(CH2 )4-O-CH[(CH2)2-OCH3]-##,#-(CH2)4-O-CH[(CH2)2N(CH3)(OCH3)]-##,#-(CH2)4 -O-CH[(CH2)2N(CH3)2]-##,#-(CH2)4-OCH(CH2CH3)-##,#-(CH2)4-O-CH(CF3)-##, #-(CH2)2-CF2-CH2-CH[(CH2)2-morpholino],#-(CH2)4N(CH3)-CH[(CH2)2-morpholino]-##,#-(CH2)4 -N(CH3)-CH[(CH2)2-(oxan-4-yl)]-##, or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, in which -R6-R10es#-(CH2)n-(B)t-CR22R23-##o#-(alkenylene-C2- C9)-(B)tCr22r23-##i where one or more -CH2- groups are substituted with one more substituents independently selected from a halogen atom, a hydroxy group, an NR16R17 group, a Ci-C3 alkyl group, a haloalkyl-Ci-C3 group, an alkoxy-Ci-C3 group and a haloalkoxy-Ci-C3 group, where # is the point of attachment with the indole nitrogen atom and ** is the point of attachment with the carbon atom of the phenyl residue bearing the R10 substituent; 164 IF-2019-16843 747-APN-ANP#INPI Page 164 of 720 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which: n is 2, 3, 4, 5, 6, 7, 8, or 9, if B is selected from -O-, -S-, -S(O)- and -S(O)2-, NR15y n is 1, 2, 3, 4, 5, 6, 7, 8 if B is selected from a group -C(O)NR15-, and a group NR15C(O)- and n is 0, 1, 2, 3, 4, 5, 6 or 7 if B is selected from a group -N(R15)-C(=O)-N(R15)-, a group -O-C(=O)-N(R15)- and a group -N( R15)-C(=O)-O-; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein n is 2, 3, 4, 5 or 6 if B is selected from -O-, -S-, -S(O )-, -S(O)2- and N(R15)-and n is 1, 2, 3, 4, or 5, if B is selected from a group -C(O)NR15-, and a group -NR15C( O)- and n is 0, 1, 2, 3, or 4 if B is selected from a group -N(R15)-C(=O)-N(R15)-, a group -OC(=O)-N (R15)- and a group -N(R15)-C(=O)-O-; and t is 1 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein n is 2, 3, 4, 5, 6, 7, 8, or 9; and t is 1 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein n is 2, 3, 4, 5 or 6; and t is 1 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein n is 3, 4 or 5; and t is 1 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or 165 IF-2019-16843 747-APN-ANP#INPI Page 165 of 720 a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, wherein n is 4 or 5; and t is 1 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which n is 4 and t is 1 or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein B is independently selected from a group -C(O)NR15-, a group -NR15C(O)-, a group -N (R15)-, a group -N(R15)-C(=O)-N(R15)-, a group -O-C(=O)N(R15)-, a group -N(R15)-C(= O)-O-, -O-, -S-, -S(O)- and -S(O)2-, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above in which is independently selected from a group -N(R15)- and -O-, or a tautomer, or a salt thereof, or a Salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which B is an oxygen atom or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein B is an atom of the group -NR15- or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein A is A1, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 166 IF-2019-16843 747-APN-ANP#INPI Page 166 of 720 In other embodiments, the present invention includes compounds of formula (I) above, wherein A is A2, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In even other embodiments, the present invention includes compounds of formula (I) above, wherein A is A3, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Even in other embodiments, the present invention includes compounds of formula (I) above, wherein A is A3 and the macrocyclic ring is a 9-membered ring, a 10-membered ring, an 11-membered ring, a 12-membered ring, a 13-membered ring, a 14-membered ring, a 15-membered ring or a 16-membered ring, in particular a 9-membered ring, a 10-membered ring, an 11-membered ring or a 12-membered ring, more particularly a 12-membered ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof . In other embodiments, the present invention includes compounds of formula (I) above, wherein A is A1 or A2, or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer , or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein A is A1 or A2 and the macrocyclic ring is a 9-membered ring, a 10-membered ring, an 11-membered ring, a 12-membered ring, a 13-membered ring, a 14-membered ring, a 15-membered ring or a 16-membered ring, especially a 9-membered to 12-membered ring, or a 12-membered to 13-membered ring , more particularly a 10-membered to 11-membered ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which A is A1 or A2, which together with the indole moiety and R6-R7 form a 9-membered macrocyclic ring, a macrocyclic ring of 10-membered or an 11-membered macrocyclic ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of the formula 167 IF-2019-16843 747-APN-ANP#INPI Page 167 of 720 (I), above, in which A is Α1 or A2, which together with the indole moiety and R6-R7 form a 9-membered macrocyclic ring, a 10-membered macrocyclic ring, an 11-membered macrocyclic ring or a 12-membered macrocyclic ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which A is A1, which together with the indole moiety and R6-R7 form a 9-membered macrocyclic ring, a 10-membered macrocyclic ring or an 11-membered macrocyclic ring or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. Even in other embodiments, the present invention includes compounds of formula (I), above, in which A is A1, which together with the indole moiety and R6-R7 form a 9-membered macrocyclic ring, a 10-membered macrocyclic ring members, an 11-membered macrocyclic ring or a 12-membered macrocyclic ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Even in other embodiments, the present invention includes compounds of formula (I), above, in which A is A2, which together with the indole moiety and R6-R7 form a 9-membered macrocyclic ring, a 10-membered macrocyclic ring members or an 11-membered macrocyclic ring or a tautomer, or a salt thereof, or a salt of a tautomer, or a mixture thereof. Even in other embodiments, the present invention includes compounds of formula (I), above, in which A is A2, which together with the indole moiety and R6-R7 form a 9-membered macrocyclic ring, a 10-membered macrocyclic ring members, an 11-membered macrocyclic ring or a 12-membered macrocyclic ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In still other embodiments, the present invention includes compounds of formula (I), above, in which A is A1 or A2, which together with the indole moiety and R6-R7 form a 10-membered macrocyclic ring or a macrocyclic ring 11-membered or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 168 IF-2019-16843 747-APN-ANP#INPI Page 168 of 720 In even other embodiments, the present invention includes compounds of formula (I), above, in which A is A1 or A2, which together with the indole moiety and R6-R7 form an 11-membered macrocyclic ring or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In even other embodiments, the present invention includes compounds of the formula (!) above, in which A is A1 or A2, and R8 and R9 are independently selected from Ci-C3 alkyl, especially methyl or ethyl or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Even in other embodiments, the present invention includes compounds of the formula (I) above, in which A is A1, and R8 and R9 are independently selected from alkyl-Ci-C3, especially methyl or ethyl or a tautomer, an N -oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. Even in other embodiments, the present invention includes compounds of the formula (I) above, in which A is A2, and R8 and R9 are independently selected from alkyl-Ci-C3, especially from methyl or ethyl or a tautomer, a N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I), above, in which R8 is selected from a hydrogen atom, a Ci-C6 alkyl group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, a Ci-C3 alkoxy group, a Ci-C3 haloalkoxy group, a C3-C6 cycloalkyl group, a heterocycloalkyl group and an NR21R22 group; a Ci-C3 haloalkyl group, a C3-C6 cycloalkyl group and a Ci-C6 alkyl group in which one or two non-directly adjacent carbon atoms are independently replaced by a heteroatom selected from -O- and -NH -; or a tautomer, an N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. 169 IF-2019-16843 747-APN-ANP#INPI Page 169 of 720 In other embodiments, the present invention includes compounds of formula (I), above, in which R8 is selected from a hydrogen atom, an alkyl-Ci-Cs group, which is unsubstituted or substituted with one or more substituents independently selected from a halogen atom, a hydroxy group, an alkoxy-Ci-Cs group, a haloalkoxy-Ci-C3 group, a cycloalkyl-Cs-Ce group, a heterocycloalkyl group and an NR20R21 group, or a tautomer, a N-oxide, or a salt thereof, or a salt of a tautomer, or a salt of an N-oxide, or a mixture thereof. In other embodiments, the present invention includes compounds of formula (I) above, wherein R8 is selected from a hydrogen atom, a Ci-C4 alkyl group, which is unsubstituted or substituted with one or more selected substituents. independently of a halogen atom, ...

Claims

1. A compound, characterized in that it is selected from: (FORMULA) and a pharmaceutically acceptable salt thereof. Nine claims follow.